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Abstract 
Activation Induced Deaminase (AID) is a crucial protein in B cells, required for a 
functional humoral immune system. The regulation and the molecular mechanism of 
AID is the focus of my thesis. 
As an enzyme, AID induces mutations and recombination in immunoglobulin genes, 
leading to increased antibody affinity for antigen and alterations in antibody-effector 
function. Catalytically, AID deaminates cytosine to uracil in single-stranded DNA, a 
DNA lesion that leads to a mismatch in double-stranded DNA. AID can be controlled 
via multiple pathways, including: a) targeting AID to the correct locus and b) regulating 
the processing of the AID-induced lesion. Proteins proposed to be involved in targeting 
AID include members of the transcription and chromatin regulation machinery, whereas 
a variety of DNA repair and DNA metabolism proteins have been shown to be involved 
in AID-induced lesion-processing. The physical and functional interactions of AID with 
these co-factors are not well characterised. In this thesis I determined the molecular 
details and biology of candidates for AID interaction.  
First, I used a novel technique to uncover and characterise interacting partners of 
endogenous chromatin-bound AID from B cells. The presented work shows that the 
RNA polymerase II elongation associated protein PAF1 binds directly to AID, while 
knocking down members of the PAF complex in B cells inhibits AID-induced 
immunoglobulin diversification. 
Secondly, I was able to identify a novel interaction of the DNA repair regulator PCNA 
with AID, both in vitro and in vivo. Importantly, PCNA function was proven to be 
susceptible to interference by AID and thus influencing lesion resolution. 
Taken together, this thesis highlights the importance of cofactors for defining the AID 
molecular pathway, relevant to all known functions of AID within and possibly beyond 
the B cell reaction. 
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Chapter 1. Introduction 
1.1 Immunity through Antibody diversification 
1.1.1 B cells and the B cell reaction 
The mammal immune system is based on cellular and humoral components. Cellular 
components develop from myeloid or lymphoid precursors in the bone marrow 
(Janeway, 2001). Cells of myeloid origin, such as macrophages, make up the innate 
immune system, whereas specific cells of lymphoid origin mediate the adaptive immune 
response, which is unique to vertebrates. In the adaptive immune response, specialised 
lymphoid cells produce humoral components to defend against foreign agents such as 
pathogenic microorganisms. Immune cells circulate the body through the blood stream, 
tissues and the lymphatic system until they activate their respective defence 
mechanisms. Lymphocytes that are part of the adaptive immune system are B cells, 
which mature in the bone marrow and are named after the Bursa of Fabricius in birds 
where they were discovered, and T cells, which mature in the thymus. Cells from innate 
and adaptive system communicate with each other to function effectively. For example, 
T helper cells have the ability to activate B cells and macrophages (Viret and Janeway, 
1999). To this end, all lymphocytes express a large collection of receptors on their 
surface, which enable cell-cell communication and signal reception. The final stage of B 
cell maturation is aided by T cells and takes place in the germinal centres of lymphoid 
organs (Allen et al., 2007), where antigens are encountered. The antigen receptor of the 
B cells is one of the most important molecules of the adaptive immune system as it can 
recognise and bind an exceptionally broad variety of antigens, enabling the defence 
against an almost unlimited number of pathogens. The receptor, also called antibody or 
immunoglobulin, Ig, can be surface bound or secreted. Each B cell expresses one 
variety of antibody, and via clonal selection only those B cells that are useful to the 
immune system survive and proliferate (Burnet, 1957, Janeway, 2001).  
1.1.2 Antibody maturation in B cells 
Immunoglobulins are composed of four polypeptide chains, two disulphide linked 
heavy chains and two light chains that are attached to the heavy chains via further 
Chapter 1. Introduction 
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Figure 1. Organisation of the antibody molecules. 
 
A, The antibody is composed of two heavy chains (dark blue) and two light chains 
(light blue). Both have variable (V) and constant (C) regions. Black bars mark 
disulphide bridges. B, The Ig heavy chain locus can produce transcripts that comprise 
constant regions for the isotypes IgM (green), IgG (dark blue), IgA (pink) and IgE 
(purple). The Ig light chain can stem either from the IgLκ or the IgLλ locus.  
 
disulphide bridges (Figure 1 A). Although all vertebrates have immunoglobulins as part 
of their humoral defence, the mechanism of genetic maturation can vary between 
species. This description is restricted to the antibody maturation of mammals and, on 
occasion, of chickens (as indicated). While there are two genomic loci that can produce 
light chains (κ and λ), there is a single heavy chain locus (Figure 1 A). The heavy chain 
Chapter 1. Introduction 
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can undergo genetic recombination (see details below) that allows for the production of 
five different sub-classes of heavy chains (µ, δ, γ, α, ε, Figure 1 A). The B cell can 
express any of the sub-classes of heavy chains, and the resulting classes of Igs  [IgM, 
IgD, IgG, IgA and IgE (Figure 1 B)] define the Ig effector function (Janeway, 2001). A 
B cell always expresses membrane-bound IgM initially and can be induced to switch to 
any alternative secreted isotype. The predominant function of secreted IgM is to 
activate the complement system, a soluble component of the immune system to lyse 
bacteria. IgA is the main isoform secreted in body fluids, while IgG is the predominant 
form in the blood. IgG is primarily involved in opsonisation and inactivation of antigens 
and antigen carriers, as well as activating the complement system. IgE localises near 
epithelia and responds by sensitising mast cells, which can release proinflammatory 
signals.  
B cell development progresses through several stages comprising a number of 
rearrangements of the immunoglobulin loci (reviewed in Cunningham-Rundles and 
Ponda, 2005) in order to generate the maximal useful possible variability of Ig. The 
cells originate in the bone marrow where they undergo antigen-independent 
development. Here, as pro-B cells, the first genomic rearrangement takes place, VDJ 
recombination of the antibody heavy chain (Figure 2 A and reviewed in Schatz and Ji, 
2011). This process is dependent on the recombinases RAG1 and RAG2 that catalyse 
breakage and rejoining of DNA in a sequence specific way, whereby a variable (V) 
segment, a diversity (D) segment and a junction (J) segment are joint together to form a 
productive, recombined pre-B cell receptor (Figure 2 A). After an analogous VJ 
rearrangement of the κ or λ light chain in the pre-B cell, a complete IgM can be 
expressed on the surface. After clonal deletion of those B cells that recognise self 
antigens, the surviving immature B cells leave the bone marrow for the periphery, 
where upon antigen encounter, they undergo further steps of development and 
diversification. In the germinal centres of the lymphoid organs, (reviewed in Klein and 
Dalla-Favera, 2008) two reactions take place in order to optimise the properties of the 
antibody pool. Antigen contact induces somatic hypermutation (SHM) of Ig loci in the 
naïve B cells, introducing point mutations into the variable region of the Ig sequence to 
change the affinity for the antigen (Neuberger et al., 2003, Weigert et al., 1970). 
Through the process of antibody affinity maturation, only those B cell clones that have 
Chapter 1. Introduction 
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Figure 2. Diversification events at the Ig locus. 
 
A, the germline heavy chain locus (IgH) comprises variable (V) region segments (each 
with its own promoter), diversity (D) segments and junction (J) segments, followed by a 
matrix attachment region (MAR), the intronic enhancer (Eµ), and the switch region with 
several constant (C) genes. Each C region has a 5’ switch region (Sx) and an intronic 
promoter and enhancer for the production of a sterile transcript. VDJ recombination in 
early antigen-independent B cell development results in a rearranged variable region 
(preceded by a leader peptide, L). Transcription from the V promoter results in IgM 
heavy chain expression (pre-B cell receptor). B, B cell activation upon antigen contact 
results in sterile switch transcripts and activation of AID. Mutations are introduced in 
the VDJ and S regions in a distribution shown as frequency curves. At S regions, AID 
lesions can lead to double strand breaks (DSB) that are required for CSR. AID lesions 
(shown in asterisks) lead to SHM at VDJ and to CSR between switch donor (Sµ) and 
acceptor (here, Sγ1). The intervening sequence is excised as circular DNA (not shown). 
Transcription from the V gene promoter leads to the expression of IgG1. The light chain 
locus undergoes SHM in the same way and its product (here, Igκ) completes the IgH 
chain. 
 
(Modified from Pavri and Nussenzweig, 2011) 
 
acquired an increased affinity for the antigen are selected, and prompted to undergo 
Class Switch Recombination (CSR). These steps are antigen and T helper cell 
dependent, and require effector molecules such as cytokines. The process of CSR 
(reviewed in Chaudhuri and Alt, 2004) includes induction of double strand breaks into 
switch regions of the Ig gene (Figure 2 B) and joining of the variable region to one of 
the constant regions, according to the signals received by the cytokines. CSR observed 
in vivo can also be recapitulated in vitro, through addition of cytokines to isolated B 
cells or B cell lines (reviewed in Chaudhuri and Alt, 2004). 
1.2 The AID protein  
1.2.1 Role of AID in immunity 
Both SHM and CSR in the germinal centre are initiated by a small enzyme expressed 
upon activation of mature B cells, called Activation Induced Deaminase (AID) 
(reviewed in Petersen-Mahrt, 2005). This protein and its function will be the focus of 
this thesis. AID is also expressed in immature B cells of birds and some mammals when 
undergoing gene conversion of Ig genes (iGC), an alternative, templated sequence 
Chapter 1. Introduction 
 18 
diversification process (reviewed in Di Noia and Neuberger, 2007). AID is also 
expressed in non-immune tissues such as the germline and pluripotent tissues (Morgan 
et al., 2004). Individuals that lack AID or carry a mutated version of the gene develop a 
hyper IgM syndrome together with mild immunodeficiency (Revy et al., 2000), a 
phenotype recapitulated in knock-out mice (Muramatsu et al., 2000) and a consequence 
of the inability of activated B cells to undergo CSR and affinity maturation of Igs. The 
catalytic activity of AID to deaminate cytosines (dC) in DNA into uracils (dU) is 
necessary for these processes (Figure 3 A), and results in the controlled introduction of 
point mutations and other DNA rearrangements in the Ig locus. 
1.2.2 Biochemical Properties 
AID is a 24 kDa protein and founding member of the APOBEC family of nucleic acid 
deaminases. Although at the time of discovery AID was suggested to be an RNA 
editing enzyme based on sequence similarity to the related RNA deaminase APOBEC1, 
it was subsequently shown to deaminate DNA in vitro (Bransteitter et al., 2003, 
Chaudhuri et al., 2003, Dickerson et al., 2003) as well as in E. coli (Petersen-Mahrt et 
al., 2002). Enzymatic properties intrinsically restrict AID at the level of the number of 
lesions it can introduce and are thus an important point of regulation (reviewed in Peled 
et al., 2008). Catalytically, AID requires single stranded DNA (ssDNA) as a substrate, 
which in vivo can be provided by other DNA-associated enzymatic or metabolic 
processes (Odegard and Schatz, 2006). After deamination and reformation of the double 
stranded form, AID leaves a lesion in form of the DNA foreign base dU and a resulting 
mismatch, which can be further processed towards mutation or recombination. It was 
noticed that in hypermutated Ig genes, dC in the context of WRC (A/T-A/G-C) was 
more frequently targeted (Larijani et al., 2005, Rogozin and Kolchanov, 1992, Shapiro 
and Wysocki, 2002), and this was also found to be the preferred hot-spot motif for AID 
in vitro (Beale et al., 2004, Bransteitter et al., 2003, Yu et al., 2004). 
In contrast to the cytoplasmic DNA deaminase APOBEC3G, which stays associated 
with its substrate after a first deamination and moves processively along the DNA 
towards the next target (Chelico et al., 2006, Coker and Petersen-Mahrt, 2007), AID 
dissociates from its substrate between deaminations in vitro (Coker and Petersen-Mahrt, 
2007). Although the exact in vivo molecular mechanism at the target site still needs to 
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Figure 3. AID protein structure and properties. 
 
A, Reaction catalysed by AID. Deamination of cytosine in ssDNA leads to a uracil-
guanin basepair in dsDNA. B, The AID protein is depicted in light blue, with functional 
domains labelled and indicated in colours. Black bars indicate the SHM and CSR 
specific regions. Phosphorylated residues are drawn in orange, the active site in blue 
and the zinc co-ordinating residues in black. 
 
be determined, protection of the genome from an overactive AID is likely to account for 
a distributive mode of action. 
Structural models of AID are not available, although the crystal structure of APOBEC2, 
a related protein, has been solved and can at times be used comparatively. AID contains 
several functional domains (Figure 3 B). At the C-terminus, AID possesses a Nuclear 
Export Signal (NES). Also, the C-terminal portion of AID has been shown to be 
essential for CSR but not for SHM (Barreto et al., 2003, Shinkura et al., 2004, Ta et al., 
2003). A domain bearing resemblance to AID’s closely related proteins, APOBEC 
deaminases, stretches from amino acid (aa) 119 onwards. The cytosine deaminase 
domain lies between aa 55 and 94 and includes a zinc co-ordinating motif as well as the 
active site [histidine 56 (H56) and glutamic acid 58 (E58)]. Post-translational 
modifications of AID have been identified in primary B cells, including 
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phosphorylation at serine 38 (S38), S41, S43, (Pham et al., 2008) tyrosine 184 (Y184) 
(Basu et al., 2005), and threonine 140 (T140) (McBride et al., 2004).  
AID may also be regulated by interactions with potential cofactors. A number of AID 
associated proteins have a role in subcellular distribution (Hasler et al., 2011, Maeda et 
al., 2010, Patenaude et al., 2009, Uchimura et al., 2011, Wu et al., 2005), or substrate 
accessibility, such as the ssDNA binding protein RPA (Chaudhuri et al., 2004). 
Recently, a number of interacting proteins were reported that are directly linked to 
transcription and chromatin regulation (Jeevan-Raj et al., 2011, Nambu et al., 2003, 
Okazaki et al., 2011, Pavri et al., 2010) or related to RNA processing (Basu et al., 2011, 
Conticello et al., 2008). One example, MDM2, interacts with AID through the C-
terminal domain (MacDuff et al., 2006). However, interaction interfaces between AID 
and other proteins have only been mapped in a few cases (Conticello et al., 2008, 
Okazaki et al., 2011, Patenaude et al., 2009). 
1.2.3 AID outside of Immunity 
1.2.3.1 Anti-viral deaminases 
The AID/APOBEC family consists of several deaminase members within the vertebrate 
lineage. APOBEC1 has a role in editing apolipoprotein B mRNA for lipid metabolism 
(Navaratnam et al., 1993, Teng et al., 1993), while APOBEC2, which is muscle-
specific, and APOBEC4 do not seem to have catalytic activity (Liao et al., 1999, 
Rogozin et al., 2005, Sato et al., 2010). The APOBEC3 family of proteins have a role in 
innate immunity, as they are usually cytoplasmic anti-viral DNA targeting enzymes. 
Evolutionary, the AID/APOBEC protein family first emerged in vertebrates, with AID 
homologues found throughout bony fish, amphibians, birds and mammals (Conticello et 
al., 2005). Consequently, AID (together with APOBEC2) is thought to be the founding 
member of this family (Conticello et al., 2005), which has subsequently amplified and 
diversified further in mammals. In primates, the APOBEC3 family is the one with most 
numerous members. Mice have only one APOBEC3 protein, whereas humans possess 
at least eight APOBEC3 members (APOBEC3A-H). APOBEC3 proteins are able to 
restrict the propagation of retrotransposons and retroviruses (reviewed in Chiu and 
Greene, 2008). APOBEC3G is especially active against retroviruses such as the human 
immunodeficiency virus (HIV) through deamination, but also via a noncatalytic 
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function (Harris et al., 2003, Holmes et al., 2007, Newman et al., 2005). Briefly, 
APOBEC3G can be packaged into the viral particles of HIV, and mutate the viral 
single-stranded genome upon replication in the newly infected cell. That HIV has 
evolved a specific inhibitor peptide for APOBEC3G, Vif (Sheehy et al., 2002), 
emphasises the effectiveness of APOBEC3 proteins against retroviral proliferation. 
Mutation of foreign nucleic acids may be the ancestral role of the AID/APOBEC 
precursor, with the need of family re-expansion once AID had specialised in Ig 
diversification. AID’s cytoplasmic location and expression in the germline is 
reminiscent of this original purpose.  
1.2.3.2 AID in epigenetics  
Methylation of DNA has long been known to regulate chromatin state and accessibility. 
Inactive or silenced genes are associated with multiple methylation of cytosines (5meC) 
in the context of CpG, while in the surroundings of active promoters, CpG islands are 
kept methylation-free (Allis et al., 2006). Therefore, methylation of genes is a way for 
organisms to control gene expression, especially for embryonic development (Reik, 
2007) or oncogene repression. Wide-spread demethylation occurs in early development 
of mammals, when methylation patterns are erased (Reik, 2007), but also occurs in 
cancer cells, which frequently have deregulated methylation patterns (Ehrlich et al., 
1982, Feinberg and Vogelstein, 1983, Schar and Fritsch, 2011). However, an active 
demethylating enzyme has remained elusive (Fritz and Papavasiliou, 2010). On the 
other hand, the process of replacing methylated with non-methylated DNA is known to 
involve DNA repair related mechanisms (Gehring et al., 2009, Schar and Fritsch, 2011). 
Importantly, AID can deaminate 5meC in vitro (Bransteitter et al., 2003, Morgan et al., 
2004) resulting in a thymidine (dT) residue. AID is expressed in cells undergoing active 
demethylation, such as oocytes (Morgan et al., 2004), and recently, genetic links 
between AID and local and genome wide CpG demethylation have been discovered 
(Bhutani et al., 2010, Popp et al., 2010, Rai et al., 2008). AID is required for genome 
wide demethylation in primordial germ cells (Popp et al., 2010), as well as for DNA 
demethylation during the reprogramming of heterokaryons (Bhutani et al., 2010). In the 
zebrafish embryo, epigenetic changes during development were also shown to be 
dependent on AID cooperating with enzymes from the base excision repair (BER) 
pathway (Rai et al., 2008). 
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1.2.4 Regulation of AID 
1.2.4.1 Regulation of mRNA transcript levels 
When AID was originally discovered, it was expressed in germinal centre B cells 
induced by cytokine and ligand stimulation (Muramatsu et al., 1999), signals normally 
provided by T-cells. Signalling is mediated by both stimulatory and inhibitory factors. 
Various classical B cell specific transcription factors play a major role in transcriptional 
control of AID, amongst them PAX5, a master regulator and pluripotency factor for the 
B cell lineage (Cobaleda and Busslinger, 2008, Medvedovic et al., 2011), the nuclear 
factor-κB (NF-κB) cascade, a stress and inflammation associated pathway (reviewed in 
Marusawa et al., 2011) as well as E-box proteins (de Pooter and Kee, 2010). These 
regulators are complemented by additional positive and negative factors (Dedeoglu et 
al., 2004, Gonda et al., 2003, Lee et al., 2006, Sayegh et al., 2003, Shapiro-Shelef et al., 
2005, Xu et al., 2007). Furthermore, microRNAs affect AID expression. AID is 
negatively regulated by microRNA-155 as well as microRNA-181b (de Yebenes et al., 
2008, Dorsett et al., 2008, Teng et al., 2008). When microRNA repression of AID is de-
regulated, AID protein expression persists and increased Ig translocations are observed. 
Hormones can directly control AID expression (Pauklin and Petersen-Mahrt, 2009, 
Pauklin et al., 2009). Specifically, oestrogen activates the AID promoter via the 
oestrogen receptor without a need for co-stimulatory signals (Pauklin et al., 2009). This 
finding may be of importance for AID expression outside the immune system, e.g. in 
ovarian, breast or prostate tissue (Morgan et al., 2004). 
1.2.4.2 Regulation of protein  
1.2.4.2.1 Post-translational modifications 
Residues T140 and S38 on AID can be phosphorylated in vitro by serine/threonine 
kinases, PKA and various PKC isoforms (Basu et al., 2005, Chatterji et al., 2007, 
McBride et al., 2008, Pasqualucci et al., 2006). Phosphorylation of AID potentially 
contributes to regulation of localisation (Pasqualucci et al., 2006), activity (Pham et al., 
2008), function in SHM and CSR (McBride et al., 2008, Pasqualucci et al., 2006) and 
interactions (Chaudhuri et al., 2004). 
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Sites of ubiquitination in AID have been mapped poorly so far, but it has been found 
that the majority of the AID ubiquitination for proteasomal degradation takes place in 
the nucleus (Aoufouchi et al., 2008), regulating active AID levels by protein turnover.  
1.2.4.2.2 Subcellular localisation 
The access of the AID protein to DNA is restricted primarily by localising AID to the 
cytoplasm, regardless if AID is expressed ectopically (Rada et al., 2002) or 
endogenously (Cattoretti et al., 2006, Greiner et al., 2005, Pasqualucci et al., 2004). 
Only limited amounts can be identified within the nucleus. Recent work has revealed a 
complex system of localisation and retention signals that lead to AID 
nucleocytoplasmic shuttling, which includes N-terminal and C-terminal peptide signal 
elements, as well as turnover of AID. However, this field remains controversial with 
contradicting reports, possibly reflecting different experimental systems that were 
examined. Indications for a classic bipartite N-terminal nuclear localisation signal 
(NLS) were found (Ito et al., 2004), while others suggested passive nuclear localisation 
(Brar et al., 2004, McBride et al., 2004). Recently, (Patenaude et al., 2009) showed 
evidence that an active but non-linear NLS exists for AID, complemented by an 
independent cytoplasmic retention mechanism (Hasler et al., 2011, Patenaude et al., 
2009). The nuclear export of AID depends on the CRM1 export pathway (Brar et al., 
2004, Ito et al., 2004, McBride et al., 2004). The picture was further enhanced by 
reports of a differential lifespan of nuclear and cytoplasmic AID, as it was shown that 
AID stability is differentially regulated in these compartments (Aoufouchi et al., 2008, 
Uchimura et al., 2011). However, the C-terminal domain is consistently reported to be 
important for cytoplasmic localisation, as well as for CSR (Barreto et al., 2003, Ta et 
al., 2003), and deletion mutants of this part of the protein show a relocalisation to the 
nucleus when overexpressed in fibroblasts (Ito et al., 2004, McBride et al., 2004). Thus, 
it is emerging that a balance of signals and pathways determines the subcellular 
concentrations of AID. 
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1.3 Molecular mechanisms of AID 
1.3.1 Class Switch Recombination, Somatic Hypermutation and Gene 
Conversion 
AID introduces dU into ssDNA, a lesion that represents a foreign base in DNA as well 
as a mismatch when dsDNA is reformed. This lesion can be processed by error-free 
(repaired) or error-prone mechanisms. Ig diversification relies on error-prone processing 
of the dU, leading to mutation or recombination (reviewed in Neuberger et al., 2003). 
Deamination by AID is the initiating event and central requirement that allows Ig 
diversification processes to occur (Muramatsu et al., 2000).  
During SHM (reviewed in Di Noia and Neuberger, 2007), mostly un-templated point 
mutations are introduced into rearranged V regions, although insertions and deletions 
are occasionally observed (Goossens et al., 1998). Although deamination takes place at 
dC, mutations at C/G and A/T basepairs are observed with equal frequency. Transitions 
(interchange within purine or within pyrimidine bases, e.g. dC to dT) are slightly more 
frequent than transversions (interchange of a purine with a pyrimidine base, e.g. dC to 
dA) (reviewed in Di Noia and Neuberger, 2007). Various replication, DNA damage 
response and DNA repair pathways are known to be involved in generating different 
classes of mutations (Figure 4) (Neuberger et al., 2003, Odegard and Schatz, 2006). The 
most simple handling of the lesion that can occur is replication across the dU. Here, a 
dA nucleotide pairing with dU is inserted on the opposite strand by a replicative DNA 
polymerase, which has been termed phase Ia of SHM (reviewed in Neuberger et al., 
2003). If the dU nucleotide is removed by the enzyme uracil-DNA glycosylase (UNG), 
an abasic site is created, so that replication across the site (via error-prone translesion 
polymerases) can give rise to both transition and transversion mutations, termed phase 
Ib of SHM. In addition to activating base-excision repair (BER) via UNG, a U/G 
mismatch can also recruit the mismatch repair (MMR) machinery (Cascalho et al., 
1998, Rada et al., 2004, Wilson et al., 2005). This allows for mutations at A/T near the 
initiating U/G lesion, termed phase II, and is carried out through an error-prone patch 
repair process by DNA polymerase eta (Polη) (Delbos et al., 2007, Delbos et al., 2005) 
(Figure 4). 
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Figure 4. Model for AID-induced uracil lesion processing to SHM, iGC and CSR. 
 
After deamination of dC by AID, the U/G mismatches can be processed by UNG, MMR 
proteins MSH2/6, or/and replicative or translesion polymerases. These DNA repair 
pathways involve downstream DNA repair factors that further process the lesions into 
point mutations for SHM, iGC or DSB for CSR, using non-homologous end joining. 
SHM can be divided into phases Ia, Ib and II, according to the mechanism and 
mutational outcome (described in the text). 
 
(Modified from Neuberger et al., 2003) 
 
Cross-talk between BER and MMR pathways can exist if an additional nick or abasic 
site (provided by UNG) is needed for the functioning of long patch repair in MMR 
(Jiricny, 2006, Schanz et al., 2009). It still needs to be determined if this second lesion 
is required to induce the full AID dependent MMR processes, as MMR at the Ig locus 
differs from global MMR in its mutagenic outcome.  
Class Switch Recombination (reviewed in Chaudhuri and Alt, 2004) splits an expressed 
heavy chain variable region from a constant region and joins it to a different 
downstream constant region (Figure 2 B), deleting the interjacent DNA. As with SHM 
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(Yoshikawa et al., 2002), CSR can be induced on an artificial template by 
overexpressing AID in fibroblasts (Okazaki et al., 2002), indicating that it is executed 
by general cellular factors (Figure 4). Although CSR is not sequence specific, it is 
restricted to switch (S) regions that contain repetitive and guanine-rich regions and are 
of 2-10 kb in length.  
Mutations at S regions share key features of SHM, notably, point mutations, inversions 
and deletions (Dunnick et al., 1993, Dunnick et al., 1989, Nagaoka et al., 2002, Petersen 
et al., 2001). Disruption of Ung, Msh2, Msh6, and Exo1 in mice decrease CSR, 
indicating that these proteins process the dU lesion for double strand breaks in this 
process, too (Rada et al., 2004, Rada et al., 2002). CSR also depends on factors for 
nonhomologous end-joining, including Ku proteins and DNA-PKcs (Casellas et al., 
1998). Furthermore, CSR requires a number of factors involved in the DNA damage 
response: the cell cycle regulator ATM (Lumsden et al., 2004, Reina-San-Martin et al., 
2004), the phosphorylated histone variant γ-H2AX (Reina-San-Martin et al., 2003), 
NBS1, the regulatory component of the MRE11/RAD50/NBS1 (MRN) DNA damage 
response complex (Manis et al., 2004), and the p53-binding protein 1 (53BP1) (Reina-
San-Martin et al., 2004, Reina-San-Martin et al., 2003, Ward et al., 2004). The DNA 
damage response is an early sensor of AID-mediated DNA lesions and co-ordinates 
downstream DNA repair pathways that lead to CSR (reviewed in Harrison and Haber, 
2006). 
In avian species as well as rabbits, cattle and pigs (Butler, 1998), antibody diversity is 
mainly mediated through the process of Ig gene conversion (iGC) (Figure 4) (Arakawa 
and Buerstedde, 2004, Reynaud et al., 1985, Reynaud et al., 1987). Due to reduced 
germline diversity in the V, D and J gene segment recombination in these species, 
rearranged variable regions are identical or similar in all B cells prior to the iGC step 
(Reynaud et al., 1985, Reynaud et al., 1987). The diversification process is based on 
templated introduction of an alternative DNA sequence into variable regions using 
adjacent V pseudogenes (ψV).  
A chicken B cell lymphoma line that continuously undergoes iGC (Kim et al., 1990) has 
been used extensively to study this form of Ig diversification as well as the associated 
DNA repair processes. DT40 is a stable, bursal derived, fast proliferating, p53 null 
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lymphoma cell line carrying ALV deregulated c-myc (reviewed in Sale, 2004). In DT40, 
iGC is initiated by deamination of cytosines by AID (Arakawa et al., 2002, Harris et al., 
2002), followed by base removal by UNG, which creates an abasic site that can be a 
substrate for cleavage followed by homologous repair (Arakawa and Buerstedde, 2004). 
This recombination process is mediated by RAD51 paralogues XRCC2, XRCC3 or 
RAD51B and BRCA2 (Hatanaka et al., 2005, Sale et al., 2001). iGC promotes the 
copying of new sequence information from an upstream donor pseudogene (ψV) into V 
regions. Non-templated mutations are also found in chicken Ig genes, (McCormack and 
Thompson, 1990, Reynaud et al., 1987) representing a very limited form of SHM that 
lacks phase II, i.e. mutation at A/T (Sale, 2004). A similar form of limited SHM can 
also be found in some human lymphoma cell lines (Denepoux et al., 1997, Harris et al., 
2001, Poltoratsky et al., 2001). Although the basis of this finding is not well understood, 
it has been suggested that in DT40, translesion synthesis by Rev1 translesion 
polymerase across an AID-induced dU or abasic site would explain this reduced form of 
SHM (Simpson and Sale, 2003). 
1.3.2 Targeting of AID activity 
As described above, AID access to ssDNA is tightly restricted by a variety of 
mechanisms affecting expression levels, protein levels and AID activity. However, 
some loci are targeted by AID highly above background. This includes non-Ig as well 
as Ig loci. Although a variety of loci are targeted, Ig loci accumulate mutations at rates 
that are orders of magnitude (10-100 times) greater than non-Ig targets (Liu et al., 2008, 
Pasqualucci et al., 1998, Shen et al., 1998). Non Ig targets of AID in normal B cells 
include the genes Bcl-6, c-myc, Pim1 (Liu et al., 2008, Pasqualucci et al., 1998, Shen et 
al., 1998), Cd79a (Gordon et al., 2003), Cd79b (Gordon et al., 2003), Cd95 (Muschen et 
al., 2000), as well as a number of additional genes (Liu et al., 2008). Furthermore, 
genome-wide chromatin immunoprecipitation (ChIP) shows that AID can be detected 
occupying genes dispersed throughout the genome, in line with its promiscuous 
targeting (Yamane et al., 2011). Importantly, non Ig targets recapitulate the nature of 
mutations at Ig by carrying AID hotspot signatures (Storb et al., 2001) and localising to 
promoter proximal regions (Liu et al., 2008). The distribution of frequency of SHM in 
Ig genes resembles a bell shaped curve (depicted in Figure 2 B), with a peak closely 
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downstream of the promoter (Crews et al., 1981, Kim et al., 1981, Rada and Milstein, 
2001, Rada et al., 1997). The first ~150 bp downstream of the transcription start site 
(TSS) are devoid of mutation and mark the 5’ boundary (Rada et al., 1997). Mutation 
continues throughout a 1-1.5 kb region (Rada and Milstein, 2001 and references 
within), with a less sharp 3’ boundary but excluding C regions. These AID targeting 
boundaries are retained even in the absence of Ung (Longerich et al., 2005) and thus 
any error-free repair, indicating that it is AID access that is restricted to this domain. 
Similarly well defined mutation regions and a comparable distribution can be observed 
in S regions when Ung and Msh2 are absent (Xue et al., 2006). 
1.3.2.1 Transcription and AID targeting  
Transcription has long been associated with AID-induced immune diversification. The 
rate of transcription correlates with the rate of SHM (Peters and Storb, 1996), and 
germline transcription through the switch and the constant region precedes CSR 
(Stavnezer-Nordgren and Sirlin, 1986). In CSR, switch isotypes are chosen by 
transcriptionally activating the appropriate S regions through cytokines and other 
signals. Each S region responds to a specific cytokine combination (reviewed in 
Chaudhuri and Alt, 2004, Pavri and Nussenzweig, 2011). Thus, transcription has been 
recognised as a main signal for CSR (Shinkura et al., 2003). Antisense transcription has 
also been found in switch regions (Apel et al., 1992, Perlot et al., 2008), but it still 
needs to be determined if this contributes to DSB generation and/or CSR. It is not 
known if transcriptional targeting could be involved in AID dependent demethylation. 
Early transgenic work demonstrated that the Ig promoter or enhancer elements are 
necessary for SHM (Betz et al., 1994). Furthermore, when a 750 bp transgene is 
inserted directly downstream of the promoter in the IgH locus, mutations are shifted 
upstream accordingly, staying associated with the promoter (Tumas-Brundage and 
Manser, 1997). These and other studies establish that transcription of a gene is 
necessary, but not sufficient for AID-induced immune diversification (Betz et al., 1994, 
Goyenechea et al., 1997, Klix et al., 1998, Kothapalli et al., 2011, Yamane et al., 2011). 
Additional factors such as location and chromatin configuration may also play a 
significant role. In vivo, AID equally deaminates both the transcribed (TS) and non-
transcribed (NTS) strands of transcribed target DNA sequences (Rada et al., 2004). 
However, transcription supports deamination of the NTS when AID is expressed in 
Chapter 1. Introduction 
 29 
yeast, in bacteria and when a simplified in vitro system employing T7 polymerase is 
used (Chaudhuri et al., 2003, Dickerson et al., 2003, Gomez-Gonzalez and Aguilera, 
2007, Petersen-Mahrt et al., 2002, Ramiro et al., 2003, Sohail et al., 2003). Furthermore, 
a slight strand bias of the final mutation patterns has been observed, arguing for a 
differential processing of mutations on either strand (Di Noia and Neuberger, 2007, 
Franklin and Blanden, 2008). The mechanism by which AID deaminates the transcribed 
strand (TS) is unknown, although different theories have been proposed. ssDNA on the 
TS could be generated during antisense transcription. Antisense transcripts have been 
detected at low levels in S regions, but it is not known if they participate in 
hypermutation. Antisense transcription can potentially deliver AID to the antisense 
RNA polymerase II machinery, or the required chromatin modifications could be 
deposited. More recently it has been proposed that targeting of the TS may be helped by 
the exosome complex (Basu et al., 2011). 
The sequence of the target gene per se does not influence SHM, as V region 
replacements and artificial constructs can be substrates for SHM (Betz et al., 1994, 
Klotz et al., 1998, Peters and Storb, 1996, Yelamos et al., 1995). This is contrary to 
VDJ recombination, where specific sequence motifs play a major role. Although cis 
regulatory elements such as enhancers are needed to establish transcription, it is debated 
if they can regulate AID by direct recruitment. A definitive proof for sequence 
requirement has been lacking (Betz et al., 1994, Blagodatski et al., 2009, Inlay et al., 
2006, Kim and Tian, 2009). E box transcriptional motifs have been suggested but may 
only act on the transcription levels (Conlon and Meyer, 2006, Michael et al., 2003, 
Staudt and Lenardo, 1991, Tanaka et al., 2010). Secondary structural motifs such as R-
loops (Huang et al., 2007, Yu et al., 2003), G quadruplex structures (Duquette et al., 
2004) or stem loops (Tashiro et al., 2001) have been suggested to play a role in CSR 
regulation, either to allow for AID targeting, substrate availability, or lesion resolution 
(Chaudhuri and Alt, 2004, Odegard and Schatz, 2006). In the V region for SHM, no 
such structures exist, although they have been postulated. 
1.3.3 Resolution of the AID lesion 
Initially, it had been assumed that AID’s activity on the Ig loci is the key step in 
achieving the high specificity of SHM. Subsequent analysis identified that the way in 
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which the dU lesion is resolved contributes significantly to the overall outcome of 
SHM. Although AID seems to be targeted preferentially to the Ig locus, other loci also 
undergo AID dependent mutation. Importantly, once BER and MMR is removed from 
the system, those targets have a different mutation outcome and additional, normally 
repaired targets are revealed (Liu et al., 2008, Liu and Schatz, 2009). Moreover, excess 
levels of AID do not alter the much elevated level of targeting of the Ig locus compared 
to other loci (Robbiani et al., 2009). This indicates that not all loci are treated equally in 
terms of DNA repair fidelity. Therefore, the repair of deaminated dC generated by 
spontaneous DNA deamination versus those that are dependent on AID presence can 
differ considerably. AID itself may have a role in co-ordinating lesion resolution (Peled 
et al., 2008, Reynaud et al., 2003). This form of regulation is evident when comparing 
CSR versus SHM for specific AID cofactor association, which can trigger different 
response pathways. For instance, the AID associated protein KAP1, a chromatin 
regulator, is relevant for CSR but dispensable for SHM (Jeevan-Raj et al., 2011). Also, 
the C-terminal domain of AID itself is required for CSR but not for SHM, as described 
above.  
1.3.3.1 DNA damage and DNA damage response pathways 
The repair of DNA damage is essential for the survival of an organism. It has been 
estimated that daily, each cell experiences 20,000 to 30,000 DNA lesions of various 
types, with DNA repair efficiently processing all of them (Lindahl, 1993). 
DNA damage encompasses a large variety of chemical and physical alterations of DNA 
and chromatin. Generated either by exogenous or endogenous (including AID) sources, 
these lesions include alkylations, oxidations, deaminations, depurinations, single 
stranded nicks, double strand breaks, as well as intra- and inter-strand crosslinks 
(reviewed in Lindahl, 1993). AID-induced lesions can initiate various DNA repair 
pathways, depending on the cellular context as well as the location of the lesion, 
however, the choice of which DNA repair pathway is used, is still poorly understood. 
Moreover, it is not understood how at AID targeted loci, DNA repair differs from 
conventional DNA repair in order to generate mutagenic outcomes. Below, pathways 
that play a role in the resolution of AID initiated dU lesions are described in their 
physiological function. 
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1.3.3.2 Pathways and proteins involved in dU lesion resolution 
1.3.3.2.1 Base excision repair (BER) 
BER recognises, excises, and accurately replaces specific forms of base modifications 
(reviewed in (Barnes and Lindahl, 2004). The first step of BER is based on the 
recognition of an inappropriate base, such as uracil, 3-methyladenine, 8-oxoguanine, or 
formamidopyrimidines. Each particular lesion is recognised by at least one specific 
DNA glycosylase (Lindahl and Wood, 1999) that has the ability to excise the altered 
base. The majority of these enzymes catalyse hydrolysis of the N-glycosylic bond, 
resulting in an abasic site with an intact DNA phosphodiester backbone. This is a 
substrate for apurinic endonuclease 1 (APE1), which both incises immediately 5′ to an 
abasic site and removes 3′-obstructive termini (Demple and Sung, 2005, Wilson and 
Barsky, 2001). In short-patch BER, DNA polymerase β (Polβ) replaces the excised 
nucleotide and removes the 5′-terminal abasic fragment left behind by APE1 incision 
(Bennett et al., 1997; Mol et al., 2000). In long-patch BER, polymerases δ and ε (Polδ 
and Polε) re-sythesise multiple nucleotides to replace the faulty stretch of DNA, and the 
displaced 5’ flap is cleaved by the FEN1 flap endonuclease. The remaining nick is 
sealed by either a XRCC1-DNA ligase III heterodimer, or DNA ligase 1 (LIG1) 
(McKinnon and Caldecott, 2007).  
1.3.3.2.2 Mismatch repair (MMR) 
MMR is designed to remove erroneous DNA structures such as mismatches and other 
bulky DNA lesions from newly synthesised DNA (reviewed in Jiricny, 2006). This 
process is based on the ability of mismatch-recognition components: the MSH2/MSH6 
heterodimer, which will recognise mismatches, and the MSH2/MSH3 heterodimer, 
which will act on loop lesions (Jiricny, 2006). Repair is then activated by the 
recognition and binding of the mismatch complex by the MLH1-PMS2 heterodimer, as 
well as other DNA repair proteins, including the polymerase cofactor and sliding clamp 
PCNA and exonucleases. The machinery is thought to recognise and excise the newly 
synthesised strand utilising the presence of nicks (Iams et al., 2002). These boundary 
elements serve as a starting point for the degradation of several hundred basepairs of the 
error-containing strand by exonucleases (EXO1) and associated factors. After the 
mismatch has been removed, resynthesis of the degraded region by DNA polymerase, 
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followed by sealing of the remaining nick by DNA ligase, completes the repair process 
(Kunkel and Erie, 2005). 
In AID dependent Ig diversification, a central role has been assigned to MSH2 and 
MSH6 as well as EXO1, but ablation of MSH3, MLH1 or PMS2 has only minor effects 
on the process. This suggests that MMR proteins may be co-opted into a related but 
mutagenic pathway at Ig loci (Bardwell et al., 2004, Cascalho et al., 1998, Ehrenstein et 
al., 2001, Frey et al., 1998, Martomo et al., 2004, Phung et al., 1999, Phung et al., 1998, 
Rada et al., 1998, Wiesendanger et al., 2000). 
1.3.3.2.3 DNA polymerases and DNA sliding clamps 
Mammals have four replicative DNA polymerases (Polα, Polγ, Polδ and Polε), whereas 
there is also a collection of other polymerases that perform non-replicative tasks (Weill 
and Reynaud, 2008). These functions involve the removal and repair of damaged bases 
(for instance, Polβ in BER) or the bypass of DNA lesions that block the progression of 
replication forks. The latter, also known as translesion synthesis (TLS) (Jansen et al., 
2007), is performed amongst others by the Y family polymerases. These polymerases 
achieve replication directly across damaged DNA templates by means of a catalytic 
domain that can accommodate aberrant basepairs. Although this allows the polymerase 
to synthesise directly across DNA lesions, the inherent lack of proofreading activity 
renders TLS polymerases error-prone, even in the presence of an intact template. Of the 
several known TLS polymerases, only Y family polymerases Polη (which preferably 
misreads A/T bases) and Rev1 (a deoxycytidyl transferase) have been demonstrated to 
be involved in somatic hypermutation (Reynaud et al., 2009). 
In vitro, most DNA polymerases are weakly processive without cofactors (Garg and 
Burgers, 2005, Hubscher et al., 2002). Auxiliary factors, such as the trimeric sliding 
clamp PCNA, are tethered to the DNA and used to reduce the dissociation of the 
polymerase from the template. Interaction between PCNA and the DNA polymerases 
increases the processivity of the polymerase by many orders of magnitude (Waga and 
Stillman, 1998b). Association of TLS polymerases with PCNA is dependent on 
monoubiquitination of lysine 164 (K164) of PCNA by the DNA damage-inducible 
Rad6 E3 ubiquitin ligase. The interaction between the PCNA and the TLS polymerase 
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is enhanced via the polymerases ubiquitin binging domain (Bienko et al., 2005, Guo et 
al., 2008, Guo et al., 2006, Kannouche et al., 2004). 
A PCNA related trimeric DNA clamp is the 9-1-1 clamp, a heterotrimer consisting of 
RAD9, HUS1 and RAD1 (Eichinger and Jentsch, 2011). This complex serves 
predominantly as a DNA damage response and checkpoint protein. 9-1-1, too, can carry 
post-translational modifications and bind cofactors that are part of the DNA damage 
response. Notably, the 9-1-1 clamp has been examined for a role in AID dependent Ig 
diversification. In DT40, presence of 9-1-1 is required for iGC, but not for TLS (Saberi 
et al., 2008). This finding was confirmed by a mouse mutant of residue K185 in RAD1, 
a functionally homologous residue to PCNA K164, that showed no defect in TLS in Ig 
genes (Wit et al., 2011). 
1.3.3.2.4 DNA damage tolerance pathway  
DNA damage tolerance (DDT, also known as post-replication repair) is a mechanism 
for the bypass of DNA lesions without repair, and it is carried out by a set of either 
error-prone or error-free processes (Chang and Cimprich, 2009). DDT enables DNA 
replication to be continued even when DNA damage is present, by overcoming damage 
induced replication fork stalling. Thus, DDT is an essential component of the overall 
cellular response in surviving genotoxic stress. The error prone branch is based on TLS, 
and the error-free branch involves template switching. The pathways were initially 
identified as the Rad6 epistasis group, as they depend on the E2 ubiquitin conjugating 
enzyme Rad6 and the E3 ubiquitin ligase Rad18 (Hoege et al., 2002, Stelter and Ulrich, 
2003). They are also dependent on PCNA, which fulfils a co-ordinative role in DDT 
(Moldovan et al., 2007). DNA damage induced monoubiquitination of K164 by RAD6 
acts as a switch from the replicative to a TLS polymerase (Hoege et al., 2002, Bienko et 
al., 2005). Further K63-linked polyubiquitination of K164 PCNA stimulates template 
switching, enabling stalled replicative polymerases to bypass the lesion by switching 
transiently to the intact template strand of the sister chromatid (Chang and Cimprich, 
2009). 
1.3.4 AID and cancer 
As AID is designed to introduce genomic instability into the cellular DNA, 
misregulation can easily lead to mutagenic and carcinogenic outcomes. This can occur 
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while AID is carrying out its natural function, leading to B cell malignancies, or when 
AID is activated out of context.  
AID has been directly implicated in tumourigenesis of lymphocytes as well as cells 
outside of the immune system. Many B cell malignancies bear chromosomal 
translocations that join Ig loci and portions of proto-oncogenes as a result of aberrant 
CSR (Chiarle et al., 2011, Klein et al., 2011, Kuppers and Dalla-Favera, 2001, Ramiro 
et al., 2004, Robbiani et al., 2009). The c-myc oncogene frequently fuses to the Ig 
promoter at switch region breakage points in Burkitt’s lymphoma (Pasqualucci et al., 
2001, Rabbitts et al., 1984). This translocation may also be facilitated by the common 
nuclear localisation of Ig and c-myc in transcription factories (Osborne et al., 2007). 
Moreover, additional translocation partners of Ig and c-myc in lymphocytes tend to be 
actively transcribed genes (Chiarle et al., 2011, Klein et al., 2011). Mistargeted SHM 
has been reported in normal B cells as a by-product of AID activity as mentioned above, 
but has also been found to contribute to cancer development (Kuppers and Dalla-
Favera, 2001, Muschen et al., 2000, Pasqualucci et al., 1998, Pasqualucci et al., 2001, 
Shen et al., 1998). Frequently, oncogenes such as Bcl-6, Fas, c-myc, Pim1 are targeted. 
Apart from Burkitt’s lymphoma, AID may also be required for tumour progression in 
other leukaemias such as chronic myeloid leukaemia (Klemm et al., 2009), where AID 
promotes clinical progression as well as drug resistance. Aside from AID mistargeting, 
AID overexpression may also contribute to oncogenesis. Systemic overexpression of 
AID clearly leads to tumour susceptibility in mice (Okazaki et al., 2003). Interestingly, 
B cells were less affected by tumour development, as they may have a natural 
protection against AID-induced lesions by expressing a specific DNA repair protein 
repertoire (Klemm et al., 2009). Indeed, in overexpression experiments, AID causes 
mutation in genes that are not usually mutated in normal B cells (Martin et al., 2002, 
Okazaki et al., 2003, Yoshikawa et al., 2002). As described above, AID can be activated 
via NF-κB. Apart from physiologically controlling AID expression, this pathway can 
also be tumourigenic (reviewed in Ben-Neriah and Karin, 2011). In Helicobacter pylori 
infections, AID is continuously activated via NF-κB and may contribute to gastric 
cancer (Matsumoto et al., 2007). Similarly, the PAX5 transcription factor has 
importance as an AID regulator (Gonda et al., 2003) but is also implicated in 
lymphomagenesis (Busslinger et al., 1996, Iida et al., 1996, Morrison et al., 1998, 
Chapter 1. Introduction 
 35 
Pasqualucci et al., 2001). Notably, PAX5 is also a target for aberrant somatic 
hypermutation by AID (Pasqualucci et al., 2001). Hormones, specifically oestrogen, 
have long been known to be cancer causing agents (reviewed in Petersen-Mahrt et al., 
2009). The finding that oestrogen directly activates AID (Pauklin et al., 2009) provides 
the most direct link between hormones and DNA mutagenesis to date. 
Chapter 1. Introduction 
 36 
1.4 Aims of the Study 
There are important open questions in AID biology: How is AID targeted to induce 
DNA alterations at specific loci, and restricted from others? More specifically, which 
role does transcriptional targeting and differential lesion resolution play?  
As co-factors of AID are likely to be important to regulate targeting, activity and lesion 
resolution, I used two approaches to gain insight into the AID interaction network: 
 
Aim I: Characterising the AID interaction with transcription elongation factors  
In order to understand complexes that AID associates with on chromatin, an unbiased 
biochemical approach was used to isolate AID and associated factors with a focus on 
the emerging connection between AID and the transcription machinery. 
 
Aim II: Characterising the AID interaction with PCNA 
To understand how AID can influence the DNA repair pathway downstream of lesion 
generation, the connection between AID and PCNA was examined. 
Chapter 1. Introduction 
 37 
 
1.4.1 Introduction for Aim I – transcription related mechanisms 
1.4.1.1 The RNAPII transcriptional cycle 
RNA polymerase II (RNAPII) transcription of mRNA is known to undergo five distinct 
phases, initiation, promoter escape, promoter-proximal pausing, elongation and 
termination (reviewed in Saunders et al., 2006). During each phase, phosphorylation of 
the heptamer repeats in the C-terminal domain (CTD) tail of the largest RNAPII subunit 
is of regulatory importance (reviewed in Buratowski, 2009). Phosphorylation can occur 
at serine 2 (S2) and serine 5 (S5) of the CTD, which allows for key proteins to associate 
and dissociate with the holocomplex (Buratowski, 2009). The transition from initiation 
to elongation takes place between the transcription start site (TSS) and 50 - 150 bp 
downstream. Processive elongation correlates with increasing phosphorylation of S2 of 
the CTD, while the earlier stages are associated with S5 phosphorylation. The CTD is 
fully S2 phosphorylated after approximately 1,000 bases downstream of the promoter of 
coding genes (Mayer et al., 2010). 
1.4.1.2 Promoter-proximal pausing 
Promoter proximal pausing of RNAPII can be defined as a state where the enzyme is 
recruited to a promoter, forms an initiation complex and clears the promoter to engage 
in transcription, but pauses proximal to the transcriptional start site. Upon gene-specific 
activation, RNAPII can be quickly activated to elongate and transcribe the gene. 
Promoter-proximal pausing represents a checkpoint before committing to productive 
elongation that is highly regulated (Saunders et al., 2006). 
RNAPII pausing is well defined on heat shock genes in Drosophila, where it was shown 
for the first time at promoters of genes encoding heat shock proteins (Lis and Wu, 1993, 
Saunders et al., 2006). Other genes were also shown to be controlled downstream of 
RNAPII recruitment, such as junb, c-myc and Igκ (Aida et al., 2006, Krumm et al., 
1992, Raschke et al., 1999, Strobl and Eick, 1992). The mechanism has now been 
recognised as a genome wide method of transcriptional control, for instance in 
development (Zeitlinger et al., 2007). In humans, stalled polymerase could also be 
detected genome-wide on genes (Kim et al., 2005), and was revealed to control 
oestrogen receptor regulated genes in human breast tissue (Aiyar et al., 2004). 
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Furthermore, in embryonic stem cells (Rahl et al., 2010) and activated B cells (Yamane 
et al., 2011), the vast majority of genes accumulate stalled RNAPII.  
1.4.1.3 Transcription elongation control, elongation factors and 
transcriptional chromatin marks 
Apart from transcription initiation complex assembly, processive elongation can be a 
rate limiting step in mRNA biogenesis, with numerous auxiliary factors being required 
(reviewed in Selth et al., 2010). Basal elongation factors are essential for elongation in 
vitro, and chromatin elongation factors help RNAPII transcribe through nucleosome 
templates.  
Elongation barriers such as repetitive sequences, competition with other DNA 
metabolism processes or programmed pausing sites can induce RNAPII pausing, 
frequently in the promoter-proximal region as described (Gilmour and Fan, 2009, Lis, 
2007). Regulated pausing requires specific factors, such as the 5,6-dichloro-1-β-D-
ribofuranosylbenzimidazole (DRB) sensitivity-inducing factor (DSIF) (Figure 5 A) 
(Swanson et al., 1991, Wada et al., 1998, Yamaguchi et al., 1999b) and the multisubunit 
negative elongation factor (NELF) (Yamaguchi et al., 1999a). DSIF is a heterodimer 
composed of Suppressor of Ty homologue 4 and 5 (SUPT4H and SUPT5H). Stalled 
RNAPII can be reactivated by the pTEFb kinase (Figure 5 A) (Fujinaga et al., 2004, 
Yamada et al., 2006), which phosphorylates SUPT5H and RNAPII, releasing the 
transcription complex. SUPT5H stays associated with RNAPII throughout the 
elongation stage, contacting additional elongation factors such as the PAF complex. The 
roles of the PAF complex are to communicate with transcriptional activators, the 
recruitment and activation of histone modification factors, and the recruitment of 
cleavage and polyadenylation factors to RNAPII (reviewed in Jaehning, 2010), but it is 
also a direct transcription elongation activator (Chen et al., 2009). This complex 
consists in humans of the subunits PAF1, CTR9, LEO1, CDC73, SKI8 and RTF1 
(Figure 5 A). The PAF complex recognises phosphorylation of the CTD and of 
SUPT5H, and then initiates a cascade of histone modifications. The starting point of 
this cascade is Histone H2B ubiquitination, a mark set by the PAF complex by tethering 
the Histone H2 ubiquitination machinery (RAD6/BRE1) to the RNAPII machinery, 
promoting cotranscriptional chromatin remodelling (Kim et al., 2009). Another 
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Figure 5. Transcription elongation and elongation promoting factors. 
 
A, Elongating RNAPII proximal to the TSS is serine 5 phosphorylated at the CTD. The 
factors associated at this stage are indicated as ellipses. H2B monoubiquitination-
dependent H3K4 trimethylation is the predominant chromatin mark. On the right hand 
side, the subunits of various elongation complexes are indicated. The RTF1 subunit is 
not as stably associated to the PAF complex as the other five subunits (Jaehning, 2010). 
B, RNAPII in later elongation stages is phosphorylated at serine 2 of the CTD, and the 
predominant chromatin mark is H3K36 trimethylation. 
 
chromatin elongation factor, SUPT6H, is a histone chaperone and aids transcription 
through nucleosomes. The FACT complex (comprised of subunits SSRP1 and 
SUPT16H), also travels with the polymerase and has an ability to facilitate transcription 
by destabilising histone nucleosomes and by enhancing co-transcriptional chromatin 
marks (Pavri et al., 2006). The H3K4 trimethylation is a mark promoted by the FACT 
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complex and set by the PAF complex (Kim et al., 2009), which can also tether the 
enzyme complex SET1 to RNA polymerase. This mark is in general restricted to the 
start of a gene, and replaced by another co-transcriptional mark, H3K36 trimethylation, 
further towards the 3’ end of the gene. The role of the PAF complex in H3K36 
trimethylation is unknown in mammals (reviewed in Newey et al., 2009), but a 
dependency of this mark on the PAF complex and H2B monoubiquitination has been 
found in yeast (Krogan et al., 2003) and plants (Xu et al., 2001). There are numerous 
other cotranscriptional chromatin marks such as Histone H3 acetylation, which is 
strongly associated with active and accessible chromatin. 
1.4.1.4 Links between AID dependant mutagenesis and transcription 
1.4.1.4.1 Known connections to elongation factors 
While the connection between AID targeting and transcription have been recognised for 
almost two decades, the molecular details of this connection are now emerging. Recent 
findings support the importance of transcription elongation and associated processes for 
AID targeting, as various RNAPII associated factors have been identified as cofactors 
for AID. These transcription elongation factors comprise basal elongation factors such 
as SUPT5H (Pavri et al., 2010) and exosome components [a nascent mRNA processing 
and degradation complex (Basu et al., 2011)], while elongation factors needed to 
transcribe through chromatin (chromatin elongation factors) such as SUPT6H (Okazaki 
et al., 2011) and the FACT complex (Stanlie et al., 2010) have also been implicated. 
SUPT5H was identified by a shRNA screen for factors reducing CSR in B cells (Pavri 
et al., 2010), and was subsequently found to interact, although weakly, with AID. ChIP 
experiments showed the co-localisation of SUPT5H with AID on Ig genes and other 
potential AID targets, while confirming the connection between SUPT5H and stalled 
RNAPII. Finding stalled polymerase on Ig genes was in line with previous reports that 
document RNAPII pausing on Igκ  (Raschke et al., 1999), on Sµ switch regions 
(Rajagopal et al., 2009) and other S core domains (Wang et al., 2009, Yamane et al., 
2011). These data led to the conclusion that stalled RNAPII could be necessary to 
recruit AID, whereas it was not clear weather this would happen through a promoter-
proximal pausing step or through extended pausing throughout the gene. Interestingly, 
SUPT5H was mapped throughout the Ig loci chromatin, even extending well into c 
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regions where AID-induced mutation/recombination is excluded (Pavri et al., 2010). 
Therefore, apart from simple RNAPII pausing, additional signals for AID recruitment, 
exclusion or activation are likely to occur. 
1.4.1.4.2 Chromatin modifications on the Ig locus 
Chromatin marks are another factor that is thought to influence AID targeting, activity 
and lesion resolution, either directly or indirectly (e.g. through transcription). In line 
with this, the histone chaperone SUPT6H has been shown to interact with AID, and its 
knock-down to have an adverse effect on CSR (Okazaki et al., 2011). Similarly, the 
FACT complex has been shown to be required for CSR, possibly by promoting the 
histone modification cascade that leads to H3K4 trimethylation of the Ig gene in B cells 
(Stanlie et al., 2010). This mark has been shown to be important for CSR in B cells and 
is enriched at the Ig locus (Wang et al., 2009). Knock-down of the enzyme complex that 
is able to transfer this mark to histones (SET1) has shown (Stanlie et al., 2010) a 
reduction both in H3K4 trimethylation at switch regions and in CSR. Both the H3K4 
and the H3K36 co-transcriptional trimethylation marks are induced upon transcriptional 
activation of S-regions (Wang et al., 2009), whereby the H3K4 trimethylation domain 
overlaps better with the AID targeted region (Wang et al., 2009). 
Other histone marks that have been correlated temporally and spatially to CSR and/or 
SHM include H2B phosphorylation on serine 14 (Odegard et al., 2005) and H4K20 
methylation (Schotta et al., 2008), both DNA damage related marks; H3 acetylation 
(Kuang et al., 2009, Nambu et al., 2003, Wang et al., 2009), a hallmark of active 
chromatin; and H3K9 trimethylation, a mark generally associated with silenced genes 
(Chowdhury et al., 2008, Jeevan-Raj et al., 2011, Kuang et al., 2009, Wang et al., 2006, 
Wang et al., 2009). 
1.4.2 Introduction for Aim II – biology of PCNA 
1.4.2.1 PCNA is a major player in DNA replication, repair and damage 
response 
As described above, processive DNA polymerases require cofactors like the sliding 
clamp PCNA, a trimeric ring protein that is loaded via the RFC clamp loader onto DNA 
at junction regions of ssDNA and dsDNA (Majka and Burgers, 2004) with the DNA 
threading through the ring (Figure 6 A) (Krishna et al., 1994). 
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Figure 6. PCNA, its modifications and the pathways they trigger. 
 
A, PCNA is a ring shaped trimer loaded on DNA to function as a sliding clamp, 
processivity factor and docking protein for DNA metabolism processes. DNA damage 
is depicted as a yellow star. B, PCNA can be sumoylated (red sphere), 
monoubiquitinated (green sphere) or polyubiquitinated (green chain). These 
modifications trigger a block of homologous recombination, translesion synthesis or 
template switching. Sumoylation may have additional unknown functions. 
 
Outside DNA replication, PCNA plays an important role in DNA repair (Jonsson and 
Hubscher, 1997). All repair pathways that confer replacement of damaged DNA by 
DNA polymerases, including MMR, DDT, TLS, HR, long patch BER as well as 
nucleotide excision repair (NER) require PCNA as a cofactor. For instance, upon UV 
irradiation, PCNA immobilises on chromatin in the nucleus, enabling the repair of 
damaged DNA by contributing to chromatin bound repair complex formation (Bouayadi 
et al., 1997, Miura et al., 1992). A myriad of proteins involved in replication and the 
maintenance of DNA interact directly or indirectly with PCNA (Moldovan et al., 2007), 
making it a docking platform for a wide variety of pathways. Examples of interacting 
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proteins that are relevant for AID dependant processes are BER protein UNG, MMR 
protein MSH2, nucleases EXO1 and FEN1, and chromatin factors such as DNA 
methylase DNMT1. 
1.4.2.2 PCNA modification and DDT  
Proteins competing for PCNA binding can influence repair pathway choice, therefore 
this choice can be altered by modifications of PCNA. When PCNA is loaded onto the 
DNA near DNA damage, the modification of PCNA at K164, monoubiquitination, 
polyubiquitination or sumoylation can influence replication and DDT (Figure 6 B) 
(Moldovan et al., 2007, Ulrich, 2009). For instance, in yeast, PCNA is 
monoubiquitinated upon replication fork stalling or single strand gap exposure, caused 
by DNA lesions (reviewed in Ulrich, 2009), enabling TLS by recruiting error-prone 
translesion polymerases (Hoege et al., 2002, Bienko et al., 2005). Of note, in higher 
eukaryotes, TLS or polymerase switch can occur independent of PCNA K164 
monoubiquitination (Edmunds et al., 2008, Hendel et al., 2011, Mirchandani et al., 
2008). The DDT pathway has mostly been studied in yeast (Branzei et al., 2008), but 
the factors defining the modification state of PCNA and the responses that are triggered 
are more complex in vertebrates (Ulrich, 2009). 
Monoubiquitination of PCNA seems to fulfil a similar role in higher eukaryotes as in 
yeast, activating TLS. However, in vertebrates not all PCNA monoubiquitination is 
Rad18-dependenent, and other E3 ligases can provide a residual pool of 
monoubiquitinated PCNA (Simpson et al., 2006, Terai et al., 2010, Arakawa et al., 
2006).  
In yeast and vertebrates, polyubiquitination of PCNA is a subpathway of the DDT 
pathway dependent on another set of ubiquitin conjugating enzymes (Mms2-Ubc13-
Rad5 in yeast), which have more diversified human homologues (Motegi et al., 2008, 
Motegi et al., 2006, Oh et al., 1994, Xiao et al., 1998). This pathway is not well studied, 
but represents an error-free damage bypass pathway relying on template switching. The 
molecular mechanisms are still debated (Branzei et al., 2008, Broomfield et al., 2001), 
but the modification initiates a template switch using the intact sister chromatid and 
seems to proceed via a HR-related mechanism (Lehmann and Fuchs, 2006, Torres-
Ramos et al., 2002, Vanoli et al., 2010).  
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In yeast, sumoylation of PCNA at K164 is damage-independent and has been shown to 
recruit the antirecombinogenic helicase Srs2 (Papouli et al., 2005, Pfander et al., 2005), 
possibly to protect cells in S-phase from toxic recombination intermediates. It has also 
been proposed to be an early step in the polyubiquitin-dependant HR DDT pathway 
(Branzei et al., 2008). An Srs2 homologue that would bind to sumoylated PCNA does 
not exist in vertebrates. Therefore, although sumoylation of PCNA could be proven in 
the DT40 system (Arakawa et al., 2006) and Xenopus laevis egg extract (Leach and 
Michael, 2005) the exact role of PCNA sumoylation in vertebrates is yet unknown. 
1.4.2.3 PCNA K164 has a phenotype in AID dependent DNA 
rearrangements - The K164 mutants 
Several studies have addressed the role of PCNA in AID dependent Ig rearrangement 
mechanisms (Arakawa et al., 2006, Langerak et al., 2007, Roa et al., 2008). As PCNA 
knock-out cells are not viable, these studies use a PCNA mutant (K164R) defective in 
modification, to observe the effects of disturbing various DNA repair and DDT 
pathways.  
Studies in DT40 cells (Arakawa et al., 2006) and mice (Langerak et al., 2007, Roa et al., 
2008) showed defects in AID-dependent Ig hypermutation in PCNA K164R mutants. In 
the mouse studies, where a classical phase II of SHM can be observed, K164R mutation 
leads to omission of mutations at A and T (corresponding to phase II mutations), while 
the overall mutation load was not (Roa et al., 2008) or little (Langerak et al., 2007) 
altered. This was interpreted as an effect of the disruption of PCNA’s ability to interact 
with DNA Polη, the polymerase responsible for the bulk of phase II SHM. In DT40, the 
PCNA K164R mutation disrupts a G/C focused, rudimentary form of SHM. In contrast 
to the mouse models, in the DT40 mutant there was also a large overall drop in 
hypermutation activity (Arakawa et al., 2002). 
On the effect of PCNA mutation in CSR, conflicting conclusions were made: While 
(Langerak et al., 2007) did not observe an effect on CSR, in (Roa et al., 2008) the 
K164R allele altered CSR.  
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Chapter 2.  Materials and Methods 
2.1 Materials 
Note: 
All chemicals were obtained from Sigma except where indicated. 
All media or buffers marked with “*” were prepared by CRUK media kitchen. 
2.1.1 Blocking solution for streptavidin plates 
3% BSA, 1x Roche blocking reagent in 40 mM HEPES and 120 mM NaCl. 
2.1.2 Buffer 2 (AID extraction buffer) 
20 mM MES (pH 6.0), 100 mM NaCl, 50 mM KCl, 5 mM β­‐mercaptoethanol, 1.6 mM 
CHAPS, 300 mM L­‐arginine HCl, filtered and adjusted to pH 6.  
2.1.3 Buffer A (PCNA loading buffer) 
40 mM HEPES, 8mM MgCl2, 0.1mg/ml BSA, 1mM DTT, 120 mM NaCl 
2.1.4 Buffer C (HTNCre purification) 
600 mM NaCl, 20 mM HEPES (pH 7.4)  
2.1.5 Buffer D (HTNCre purification) 
50% glycerol, 500 mM NaCl, 20 mM HEPES (pH 7.4) 
2.1.6 Buffer R for AID activity assay 
5 x Buffer R: 250 mM NaCl, 200 mM KCl, 15 mM MgCl2, 200 mM Tris-HCl (pH 8), 5 
mM DTT, 50% Glycerol (filtered and stored at 4 °C). 
2.1.7 Coupling buffer  
0.1 M NaHCO3 (pH 8.3), 0.5 M NaCl. 
2.1.8 DT40 lysis buffer  
50 mM TrisHCl (pH 7.5), 100 mM NaCl, 50 mM KCl, 2 mM MgCl2, 1mM EDTA, 
10% Glycerol, 1 tablet of Complete Protease Inhibitors (Roche, UK) per 50 ml, 1 
PhosStop phosphatase Inhibitor Cocktail tablet (Roche, UK) per 10 ml.  
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2.1.9 DT40 lysis buffer+T  
DT40 lysis buffer + 0.3% Triton X-100. 
2.1.10 DT40 lysis buffer+TB  
DT40 lysis buffer+T + 150 U/ml Benzonase (25 U/µl, Novagen). 
2.1.11 DT40 wash buffer  
50 mM TrisHCl (pH 7.5), 200 mM NaCl, 100 mM KCl, 2 mM MgCl2, 1mM EDTA, 
10% Glycerol, 1 tablet of Complete Protease Inhibitors (Roche, UK) per 50 ml, 1 µg/ml 
1 x FLAG peptide (CRUK peptide synthesis service) 
2.1.12 E. coli lysis buffer 
50 mM NaH2PO4, 500 mM NaCl, pH 8.0 
2.1.13 Elution buffer  
DT40 Lysis Buffer + 400 µg/ml 3xFLAG peptide (CRUK peptide synthesis service) 
2.1.14 Freezing media  
10% DMSO, 20% FCS in cell culture media 
2.1.15 Fuscin formamide 
0.1% fuscin dye (Sigma), 10 mM Tris HCl (pH 8), in formamide 
2.1.16 Hypotonic lysis buffer  
10 mM TrisHCl (pH 7.5), 2 mM MgCl2, 3 mM CaCl2, and 0.32 M sucrose 
supplemented with 1 Complete EDTA free Protease Inhibitor Cocktail tablet (Roche) 
per 50 ml and PhosStop phosphatase inhibitor cocktail (Roche Applied Sciences, UK). 
2.1.17 IF blocking solution 
PBSTS + 1% BSA +2% FCS, filtered. 
2.1.18 20x KN  
1M KCl, 2M NaCl 
2.1.19 293 lysis buffer 
20 mM Tris pH 8, 150 mM NaCl, 0.04 % SDS, 1 % NP40, PhosStop tablet (Roche), 
EDTA-free Protease inhibitor tablet (Roche) 
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2.1.20 PBS buffer*  
3.3 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 136 mM NaCl (pH 7.2) 
2.1.21 PBSTS 
PBS + 0.1% Tween 20 + 0.02% sodium dodecyl sulphate 
2.1.22 PCNA lysis buffer 
50 mM NaH2PO4, (pH 8.0), 10 mM NaHSO3 (pH 7.0), 500 mM NaCl, 5 mM β-
Mercaptoethanol, 0.01% NP40, 10 mM imidazol, 5% Glycerol, Complete EDTA free 
Protease Inhibitor Cocktail tablet (Roche) 
2.1.23 PCNA elution buffer 
150 mM imidazol, 25 mM Tris-HCl (pH7.5), 1 mM β-Mercaptoethanol, 0.02% NP40, 
5% Glycerol, 25 mM NaCl, Complete EDTA free Protease Inhibitor Cocktail tablet 
(Roche) 
2.1.24 PTB buffer 
50 mM Na2HPO4, 5mM Tris (pH 7.8)  
2.1.25 PTB(A) buffer 
50 mM Na2HPO4, 5mM Tris (pH 7.8), 500 mM NaCl, 15 mM imidazole 
2.1.26 PTB(B) buffer 
50 mM Na2HPO4, 5mM Tris (pH 7.8), 500 mM NaCl, 250 mM imidazole 
2.1.27 PTB-Ta buffer 
50 mM Na2HPO4, 5mM Tris (pH 7.8), 500 mM NaCl, 20 mM imidazole, 2M L-Tartaric 
acid 
2.1.28 ph 4 wash solution 
0.1 M acetic acid/sodium acetate, (pH 4), 0.5 M NaCl 
2.1.29 ph 8 wash solution 
0.1 M Tris-HCl, (pH 8), 0.5 M NaCl 
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2.1.30 5 x SDS sample buffer  
10% SDS, 50% glycerol, 0.1% bromophenol blue, 50 mM DTT, 150 mM Tris-HCl (pH 
6.8) 
2.1.31 Southern blot denaturing buffer  
0.5 M NaOH, 1.5 M NaCl 
2.1.32 Southern blot hybridisation solution 
200 mM NaPO4  pH7.2, 1 µM EDTA, 1% BSA, 7% SDS, 15% Formamide 
2.1.33 Southern blot SSC wash buffer  
0.1x SSC + 0.1% SDS. 
2.1.34 Southern blot transfer buffer  
20x SSC stock*: 3 M NaCl, 0.3 M N3citrate*2H2O. pH adjusted to 7.0 (with 1 M HCl). 
2.1.35 SYPRO fix solution  
50% methanol, 7% acetic acid 
2.1.36 SYPRO wash solution  
10% methanol, 7% acetic acid 
2.1.37 TBE electrophoresis buffer  
10x TBE stock: 109 g of Tris base, 55 g Boric acid and 4.65 g EDTA was diluted in 1 
litre dH2O and pH was adjusted to 8.3 with HCl. The final concentration of TBE buffer 
was 89 mM Tris, 89 mM boric acid, 1.25 mM EDTA (pH 8.3). 
2.1.38 TBS buffer  
10x stock*: 1.54 M NaCl, 250 mM Tris-HCl, (pH 7.4). 
2.1.39 TBS-T buffer  
154 mM NaCl, 25 mM Tris-HCl (pH 7.4), 0.05% Tween-20 (pH 7.4). 
2.1.40 TBS-Tri for IP 
1x TBS*, 1% Triton X-100 
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2.1.41 TE buffer*  
1 mM EDTA, 10 mM Tris-HCl (pH 7.5). 
2.1.42 TEN buffer for AID activity assay*  
1M NaCl, 10 mM EDTA, 50 mM Tris-HCl pH7.5 
2.1.43 TNT Bead washing buffer  
25 mM Tris (pH 8), 125 mM NaCl, 25 mM KCl, 2.5 mM MgCl2, 0.5 % NP40, and 
Complete Protease Inhibitors (Roche, UK). 
2.1.44 2xTY*  
16 g/l Bacto-tryptone (Difco, UK), 10 g/l Bacto-yeast extract (Difco, UK), 5 g/l NaCl. 
Autoclaved. 
2.1.45 Tris-glycine Transfer Buffer for western blot  
40 ml of 25x transfer buffer stock [12 mM Tris-base, 96 mM Glycine (pH 8.3)] + 200 
ml methanol + 760 ml H2O. 
2.1.46 Txn 11 buffer 
40 mM KCl, 20mM Tris-HCl (pH 7.9), 7 mM MgCl2 20µM ZnCl2, 5mM DTT 
2.1.47 Txn 12 buffer 
40 mM KCl, 20mM Tris-HCl (pH 7.9), 0.2 mM MgCl2 20µM ZnCl2, 5mM DTT 
2.1.48 Western blot blocking solution  
5% milk powder in TBS + 0.05% Tween 20 
2.2 Methods 
2.2.1 Biochemistry methods 
2.2.1.1 Subcellular fractionation of DT40 cells 
Large quantities of DT40 and DT40 AID-3FM were grown by CRUK cell service 
facilities using 5 litre spin paddle containers. Cells (1 - 4 x 1010) were collected by 
centrifugation at 1,200 rpm in 1L bottles at 4 ˚C for 10 minutes and cell pellet was 
washed twice with 50 ml ice-cold 1 x PBS.  
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Cytoplasmic lysis: 5 times packed cell volume (PCV) (approx. 1 µl PCV = 106 cells) of 
Hypotonic Lysis Buffer was added to the cell pellet, resuspended gently and incubated 
for 12 min on ice. To the swollen cells, 10 % Triton X-100 was added to a final 
concentration of 0.3 %. The suspension was mixed and incubated for 3 min on ice, 
centrifuged for 5 min at 1,000 x g at 4 ˚C, and the supernatants were collected as 
cytoplasmic fraction. The nuclear pellets were washed once in hypotonic lysis buffer + 
0.3 % Triton X-100, resuspended in 2 x PCV of DT40 Lysis Buffer + T and dounce 
homogenised with 30 strokes. The samples were incubated with gentle agitation for 30 
min at 4 ˚C and ultracentrifuged at 33,000 x g for 30 min at 4 ˚C in a Beckmann 
ultracentrifuge (Ti45 or Ti70 rotor). The supernatants were collected as nucleoplasmic 
fraction. To extract chromatin, the pellets were resuspended in 2 x PCV of DT40 Lysis 
Buffer +TB containing Benzonase nuclease and dounce homogenized until resistance 
was lost. The samples were incubated at RT for 30 min and cleared by 
ultracentrifugation at 33,000 x g for 30 min at 4 ˚C in a Beckmann ultracentrifuge (Ti45 
or Ti70 rotor). The supernatants were collected as chromatin fraction. 
2.2.1.2 FLAG immunopurification of AID complex from chromatin 
10-400 mg of a chromatin fraction obtained from DT40 cells as described above were 
pre-cleared with agarose beads for 1 hour at 4 °C. For analysis of association of AID 
with the PAF complex, salt concentrations in the chromatin fractions were adjusted to 
200 mM NaCl and 100 mM KCl prior to IP by adding specific volumes of 20x KN. 
Concentration of Triton-X 100 was adjusted to 0.5 %. Anti-FLAG M2 affinity beads 
(Sigma, UK) were washed and equilibrated in DT40 Lysis Buffer + T. 1 µl of M2 beads 
(50 % slurry in DT40 Lysis Buffer + T) per 5 x 107 DT40 cells were incubated with 
chromatin fractions, for 3 - 4 hours at 4˚C on a rotator and collected for 3 min at 300 x g 
at 4 ºC. Beads were washed 5 times in 25 x bead volume of DT40 Wash Buffer 
(containing 1 µg/ml 1 x FLAG peptide N-DYDDDDK-C) and once with DT40 Lysis 
Buffer, each washing step was performed for 10 min at 4 ºC. M2 coupled protein 
complexes were eluted from M2 beads by two elution steps in 4 x bead volume of 
Elution Buffer (containing 400 µg/ml 3 x FLAG peptide, sequence N-
MDYKDHDGDYKDHDIDYKDDDDK-C); the first elution for 1 hour at RT, the 
second over night at 4˚C. 
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2.2.1.3 Size exclusion chromatography of DT40 chromatin extract 
One millilitre of DT40 chromatin extract was loaded onto a Superdex 200 - 10/300 GL 
column, which had been equilibrated in DT40 lysis buffer and calibrated with standard 
proteins using Äkta Explorer (GE Healthcare, UK). Fractions were collected at 1 ml 
volume steps using a 0.5 ml flow-rate, concentrated using StrataClean protein 
concentration resin (Stratagene), and analysed by western blot. 
2.2.1.4 Mass spectrometry analysis 
Samples were prepared by running proteins on 4-12% Bis-Tris NuPAGE Gels 
(Invitrogen). Gels were stained with SYPRO-Ruby (Invitrogen) using equipment that 
was pre-washed with methanol, under very clean and dust-free conditions. Gels were 
imaged, then bands were visualised using a UV transilluminator and bands of interest 
were cut out in small portions slices (1 - 2 mm). Samples were stored in ultrapure water 
until analysis. All mass spectrometry analysis was carried out at the CRUK central 
Protein Analysis and Proteomics Laboratory according to the below summarised 
protocol.  
Polyacrylamide gel were prepared for mass spectrometric analysis using the Janus 
liquid handling system (PerkinElmer, UK) by alkylation and trypsin digestion, followed 
by extraction in formic acid and acetonitrile. Samples were analyzed by nano-scale 
capillary LC-MS/MS using a nanoAcquity UPLC (Waters, UK) coupled to a linear 
quadrupole ion trap mass spectrometer (LTQ XL/ETD, ThermoScientific, USA). LC-
MS/MS data were searched against a protein database (UniProt Knowledge Base) using 
the Mascot search engine (Matrix Science, UK) (Perkins et al., 1999), and validated 
using the Scaffold program (Proteome Software Inc., USA) (Keller et al., 2002).  
2.2.1.5 Preparation of human PCNA protein from E. coli 
E. coli BL21-CODONPLUS(DE3)-RIL strain (Stratagene, USA) were transformed with 
pSPM588 (plasmid containing a C­‐terminal his­‐tagged human PCNA cDNA, 
expressed under the control of a T7 promoter, and a kanamycin resistance) . Bacteria 
were transformed according to the manufacturer’s instructions and plated onto an 
appropriate selective LB plate. One fresh colony was picked and incubated over night at 
37 °C in 10 ml LB with 50 µg/ml kanamycin. The next day, 1L of the same medium 
was inoculated with the over night culture and shaken at 37 °C until OD600 was 0.5. 
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Protein expression was induced by adding 1mM IPTG, and cultures incubated for 4 
hours at 37 °C. Bacteria suspensions were centrifuged at 3500 g for 15 minutes at 4 °C. 
The cell pellet was resuspend in 50 ml of PCNA Lysis Buffer. Keeping the cells on ice, 
the suspension was sonicated for 12 minutes in total with a broad tip, amplitude 50%, 
and a duty cycle of 15 seconds on, 15 seconds off. Lysates were centrifuged at 35,000 
rpm for 30 min at 4 °C in a 70 Ti rotor in a Beckman ultracentrifuge. The cleared lysate 
was incubated with 1 ml of prewashed Talon Metal affinity resin (Clontech) to bind the 
his-tagged PCNA for 90 min at 4 °C. The resin was washed with 50 ml of lysis buffer, 
then with 25 ml of elution buffer and the protein was eluted with 3 ml of elution buffer 
containing 150 mM imidazol. Eluted protein was dialysed against elution buffer and 
concentrated with a Millipore Amicon-15 (UFC 901024) concentrator by centrifugation 
at 3000rpm at 4 °C. The protein was loaded onto a Superdex 200 size exclusion column, 
which was equilibrated with the same buffer. The collected fractions containing PCNA 
trimer were pooled, snap-frozen, and stored at -80 °C. Aliquots were analysed on a 12% 
NuPAGE Bis-Tris gel (Invitrogen). To determine the protein concentration the gel was 
stained with SYPRO-Ruby (Invitrogen), scanned with a Typhoon Trio (GE Healthcare), 
and quantified using a range of BSA concentration as reference. 
2.2.1.6 Preparation of human AID from E. coli 
Human AID protein was prepared based on (Coker et al., 2006) with slight 
modifications. E. coli of the C41(DE3) strain (Miroux and Walker, 1996) were 
transformed with pSPM75 (a plasmid containing a C­‐terminal his­‐tagged human AID 
cDNA under the control of a T7 promoter with kanamycin resistance). Cells were plated 
onto an appropriate selective LB plate and incubated over night. One colony was picked 
and resuspended thoroughly in 1 ml selection-free 2x TY media. This was used to 
further inoculate 30 ml selection-free 2x TY, which is then grown, shaking at 37 °C 
until reaching an OD600 of 0.4. At this stage, 10 ml of the culture was used to inoculate 
each of three 2­‐liter flasks, each containing 1 litre of selection-free 2x TY, which was 
then grown, shaking at 37 °C, until reaching an OD600 of between 1.0 and 1.5. After 
immersion in iced H2O for 15 minutes the culture was induced with a final 
concentration of 0.4 mM IPTG and in the presence of 10 µM ZnCl2. Holes were made 
in the foil lids of the flasks to ensure that sufficient air exchange will take place during 
protein production. The cultures were incubated, shaking at 250 rpm at 16°C for 16 h. 
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The 3 L of bacteria were harvested by centrifugation at 3500 g, 10 min at 4 °C, the 
supernatant was removed, and the pellets were resuspended and combined in ice­‐cold 
H2O. Bacteria were again centrifuged at 3500 g, for 10 min at 4 °C, before the 
supernatant was immediately removed and the pellet resuspended in 100 ml of buffer 2 
along with six complete EDTA­‐free protease inhibitor cocktail tablets (Roche) and 150 
mg RNaseA (Sigma), which had been heated previously to 80 °C for 10 min in buffer 2. 
Keeping the cells on ice, the suspension was sonicated with a broad tip, amplitude 50%, 
12 minutes total, duty cycle 15 seconds on, 15 seconds off. The sonicated lysates were 
cleared by centrifugation at 100,000 g, for 30 min, at 4 °C in a Beckmann 
ultracentrifuge (Ti45 rotor). The supernatant was filtered using a pre-chilled 0.22?µm 
Millipore filter. The extract was then incubated with 2 ml of prewashed Ni­‐NTA beads 
(Qiagen) at 4 °C, rotating for 90 min. The beads were loaded in suspension onto a 
prewashed Poly­‐Prep chromatography column (Bio­‐Rad) and washed at 4 °C with 10 
ml of 30 mM imidazole. The protein was eluted at 4 °C with 10 ml of 150 mM 
imidazole. The eluate was concentrated to approximately 150 µl using a centrifugal 
concentrator (Vivaspin) with a molecular weight cut-off of 10,000 d according to the 
manufacturer’s instructions. The concentrated protein was snap­‐frozen in small aliquots 
and stored in liquid nitrogen for use within 10 months. Aliquots of the eluated proteins 
were analysed on a 12% NuPAGE Bis-Tris gel (Invitrogen). To determine the protein 
concentration the gel was stained with SYPRO-Ruby (Invitrogen), scanned with a 
Typhoon Trio (GE Healthcare), and quantified using a range of BSA concentrations on 
the gel as reference 
2.2.1.7 Preparation of human APOBEC2 from E. coli 
APOBEC2 protein was prepare in an analogous way to AID protein based on (Coker et 
al., 2006) with slight modifications. 
2.2.1.8 Preparation of cell soluble Cre recombinase from E. coli 
E. coli Tuner (DE3) pLysS strain (Novagen) were transformed according to the 
manufacturer’s instructions with pTriEx-HTNCre [plasmid containing a His-TAT-NLS 
tagged Cre-protein cDNA, and an ampicillin resistance, (Peitz et al., 2002)], plated on 
ampicillin plates and incubated over night at 37 °C. A 50 ml starter culture (LB + 50 
µg/ml carbenicillin + 34 µg/ml chloramphenicol + 1% glucose) was inoculated and 
Chapter 2. Materials and Methods 
 54 
grown over night at 37 °C. On the next day, 2 litres LB + 100 µg/ml carbenicillin + 34 
µg/ml chloramphenicol was inoculated with the starter culture and allowed to grow until 
OD600 was 1.5, then induced for 1 hour at 37 °C with 0.5 mM IPTG. Cells were 
harvested by centrifugation for 30 minutes at 3500 g at 4°C. The pellets were washed in 
ice-cold PTB and snap-frozen in a dry ice/ethanol bath for storage at -20 °C. On the day 
of purification, cells were thawn on ice and resuspended in 10 ml PTB containing 1 
protease inhibitor tablet (Roche), 10 mg lysozyme and 20 µl Benzonase (25 U/µl, 
Novagen), followed by sonication in an ice cold glass beaker at 40% amplitude for 2 
minutes total, duty cycle of 0.5 seconds on, 0.5 seconds off. After incubating the lysates 
on ice for 5 minutes, 10 ml PTB-Ta was added dropwise while stirring the lysate on ice, 
followed by a second 5 minute incubation on ice. After spinning for 30 minutes in a 
Beckmann ultracentrifuge at 30,000 g (Ti45 rotor) at 4 °C, the supernatant was gently 
mixed with 1.5 ml Nickel-NTA beads (Quiagen) for 1 hour. The suspension was 
transferred into a Poly Prep (BioRad) gravity flow column and washed with 2 x 5 bed 
volumes of PTB(A). HTN-Cre containing fractions were eluted with 3 bed volumes of 
PTB(B). The imidazol was removed from the eluates by dialysis against buffer C (2x 
for 30 minutes in 500 ml beaker at 4 °C) and further concentrated by dialysis against 
buffer D (2x for 30 minutes in 500 ml beaker at 4 °C). The resulting glycerol stock was 
aliquoted, snap frozen and stored at - 20 °C. The concentration was determined by 
PAGE and staining as described. 
2.2.1.9 SYPRO Ruby staining 
Protein gels were stained using the SYPRO Ruby system from Invitrogen according to 
the manufacturer’s instructions. After electrophoresis, polyacrylamide gels were 
immersed in SYPRO fix solution for 30 minutes, the solution was changed and the 
incubation repeated. The gel was immersed in SYPRO Ruby stain and left agitating 
over night, followed by a 30-minutes wash in SYPRO wash solution. Before imaging, 
the gel was briefly washed in ultrapure H2O. 
2.2.1.10 Oligonucleotide deamination assay (AID activity assay) 
2.2.1.10.1 Deamination reaction 
1x Buffer R, 10 µg RNase A (Sigma) [heated previously to 80 °C for 10 min in 0.1 M 
Tris-HCl (pH 8)], 2.5 mM oligonucleotide SPM163 (5’biotin-
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ATTATTATTATTAGCTATTTATTTATTTATTTATTTATTT-3’FITC) in 10 µl total 
volume were heated to 90 °C to denature the oligonucleotide, followed by quenching on 
ice and a pulse-spin. Purified deaminase was thawn on ice and the appropriate (as 
determined for each preparation by titration) amount was added to the ice­‐cold reaction 
mix for each sample in 0.5­‐ml tubes. The volume of deaminase added was generally 
between 0.05 and 0.5µl. The reaction was incubated at 37 °C for 15 min for optimal 
activity. Each reaction was terminated by adding 100 µl of H2O and then heating at 90 
°C for 4 min before placing on ice. 
The oligonucleotides were then purified using streptavidin-magnetic beads: 8 µl of 
resuspended streptavidin­‐magnetic bead slurry (Dynal Invitrogen) per reaction was 
washed twice in TEN buffer before resuspension in 800 µl TEN buffer. Bead 
suspensions were added to the reactions, mixed by rotating at RT for 15 min, followed 
by applying the tubes to the magnet supplied by the bead manufacturer. After carefully 
removing the supernatant, the procedure was repeated twice, each time washing with 
750 µl TEN pre-heated to 70 °C. The final wash was with 100 µl TE, followed by 
resuspension of the beads in a UDG reaction mix (1µl 10x UDG buffer (NEB), 1 µl 
UDG (NEB), 8 µl H2O). The mix was incubated at 37 °C for 1 hour, after which the 
reaction was stopped by adding 20 µl fuscin formamide. After heating to 90 °C for 3 
min, the sample was subjected to analysis by Urea-PAGE. 
2.2.1.10.2 Urea-PAGE 
Gel preparation: For a 17.5 % TBE-urea gel, a mixture of 4.7 g urea, 1 ml 10X 
TBE,1.27 ml H20 and 4.38 ml 40% acrylamide was mixed on a shaker. 20 µl 25% APS 
and 7 µl TEMED were added and a minigel was poured. After polymerisation (about 1 
hour) the gel was pre-run for 10 min at 200 V, then the samples were loaded and 
electrophoresis was carried out for 70 min at 200 V (e.g. for SPM 163, electrophoresis 
conditions  depended on the length of the oligonucleotide and products). The 
fluorescent signal was detected using the FLA­‐5000 fluorescent scanner (Fuji). 
2.2.1.11 Extended oligonucleotide deamination assay (AID activity 
assay on a PCNA coated substrate) 
The assay was developed to combine the standard oligonucleotide deamination assay 
for AID with a PCNA loading assay [J. Parker and H. Ulrich, CRUK; (Parker et al., 
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2008, Waga and Stillman, 1998a)]. The oligonucleotide KW5022 (5’BIO-
TGAATTATTAGCTATTTAGATTTTTCATTTGCTGCTGTCAGCGTGGCACTGTT
-DIG-C-3’FITC) was hybridised to its complement KW5023 (5’-
AGTGCCACGCTGACAGCAGCAAATGA-3’) by heating a mixture of both 
oligonucleotides at a 1:2 molar ratio (KW5022 to KW5023) to 95 °C and slowly 
cooling it in a PCR machine using the following program: 95 °C – 3 minutes; 80 °C – 
15 minutes; 70 °C – 15 minutes; 65 °C – 15 minutes; 55 °C – 15 minutes; 40 °C – 10 
minutes. Streptavidin plates (cat. No. 15120, Thermo Scientific) were allowed to reach 
room temperature and hydrated for 5 min with 200 µl 154 mM NaCl per well. Wells 
were blocked for 20 minutes at RT with 200 µl blocking solution followed by a wash 
with 250 µl buffer A. 2.5 pmol hybridised oligonucleotide was diluted in 90 µl buffer A 
and loaded into the wells. Plates were incubated for 1 hour at 4 °C to coat the plate with 
DNA. After 3 washes with 250 µl buffer A the first reaction mix (1 mM ATP, 0.5 µg 
anti-Digoxygenin Fab fragments (Roche), 50 pmol PCNA, 1 pmol RFC) in a total of 50 
µl buffer A was applied to the wells. The reactions were incubated for 30 minutes at RT 
with occasional tapping, followed by one wash with 200 µl buffer A + 0.2 mM ATP at 
RT followed by one wash with 200 µl buffer A + 0.2mM ATP at 37 °C. The same 
loading mixture was re-applied, incubated and washed away 2 times as described 
followed by 2 additional washes with 200 µl buffer R + 0.2mM ATP. 
Samples that were used for western analysis were stopped at this step by adding 100 µl 
1.5x SDS buffer and 5 µl subject to PAGE followed by western blotting.  
To the rest of the wells, a second reaction mix is applied consisting of 0.001% Triton, 
0.3 µl AID (DEL99) and 20 µg RNAse A in a total of 20 µl buffer R. Wells were 
covered with parafilm and incubated in a humidified chamber for 1 hour at 37 °C. Next, 
200 µl of TEN buffer heated to 70 °C was added to each well to stop the reaction. Wells 
were washed 2-times with TEN (pre-warmed to 70 °C) and once with TE buffer. After 
aspiration of all liquid the following UDG reaction mix was applied to each well: 
0.001% Triton, 2.2 µl 10x UDG buffer (NEB), 2.2 µl UDG (NEB) in a total volume of 
22 µl. Wells were covered and incubated in a humidified chamber for 1 hour at 37 °C, 
followed by addition of 30 µl of fuscin formamide and heating to 90 °C. The samples 
were analysed on a 12% TBE-Urea gel. Electrophoresis was  for 60-70 minutes at 200 
V (see section 2.2.1.10.2). 
Chapter 2. Materials and Methods 
 57 
2.2.1.12 Reconstitution of a transcription elongation complex and 
NTS deamination by AID 
RNA oligonucleotides were purchased from Dharmacon. DNA 90-mers (TS and NTS) 
were purchased from DNA technologies, Denmark.  Radioisotope labelling of RNA or 
DNA oligonucleotides was performed using T4 polynucleotide kinase (Roche) 
according to the manufacturer’s instruction (37 °C for 30 minutes) using γ−32P-dATP, 
followed by phenol chloroform extraction of nucleic acid by using PhaseLock tubes 
(Eppendorf). After passing through a G25 spin column (GE Healthcare), nucleic acids 
are precipitated with 3x volumes of ethanol and 0.1 volumes of 3 M sodium acetate at -
20 °C, washed twice with 95% ethanol (centrifuged at 15,000 rpm for 30 minutes 
between each wash), and resuspended in TE. After a second pass through a G25 column 
followed by ethanol/sodium acetate precipitation, the labelled nucleic acid is dissolved 
in TE pH 7.5.  
Reconstitution reactions were carried out in the presence of 400-1000 counts per second 
labelled nucleic acid. 1 pmol of the 90 nucleotide long oligonucleotide (TS) was 
hybridised to 2 pmol complementary RNA by cooling the mixture from 65 ˚C to 25 ˚C. 
3 pmol purified yeast RNAPII (gift from D. Hobson, CRUK) was added at 25 ˚C in 
Txn12 buffer followed by 6 pmol of the complementary 90-mer strand (NTS). The 
assembled complex was purified via a biotin label on the TS to remove unbound 
components using magnetic streptavidin beads according to the manufacturer’s 
instructions (Promega, UK). The obtained complex on biotin beads was exposed to 
0.12, 1.2 and 12 pmol of active AID before and after the addition of NTP’s (0.58 mM or 
0.29 mM) in Txn 11 buffer + 1mg/ml BSA. After phenol chloroform extraction and 
precipitation of the nucleic acids, a UDG reaction mix was applied analogous to ODA. 
Products were dissolved in a 90% formamide gel loading buffer and separated on a 8 % 
Polyacrylamide-TBE gel containing 8.3 M Urea using a BioRad 50 cm sequencing gel 
cell. The gel was dried, exposed to phosphoimager and scanned using a Typhoon Trio 
scanner (GE Healthcare). 
2.2.1.13 In vitro PCNA ubiquitination  
In vitro ubiquitination reactions were performed in 100 µl reaction volumes using the 
Biomol ubiquitination kit (UW9920-0001, Enzo life sciences, UK). A reaction had 10 
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µl 10 x Ubiquitination buffer, 2 µl 50 mM DTT, 5 µl Mg-ATP, 3 µl 20 x E1 
conjugating enzyme, 3 µl E2 conjugating enzyme, 5 µl 20x Biotin-Ubiquitin, PCNA 
protein and water to 100 µl. 10 - 20 pmol AID, 10 - 20 pmol Apo2, 5 pmol PCNA and 5 
pmol PCNA K164A of proteins were used in the assay. Proteins were purified as 
described above. Reactions were incubated at 37˚ C for 90 minutes before stopping with 
4x SDS sample buffer and boiling for 3 minutes. Samples were analysed by Western 
blotting.  
2.2.1.14 PCNA sumoylation assay 
BL21-Gold (DE3) bacteria (Stratagene, UK) were transformed with vectors expressing 
his-tagged PCNA, the activating (E1) and conjugating (E2) enzymes, SUMO-I, and 
either an empty vector or a vector encoding for AID. Protein expression was induced by 
the addition of 1 mM IPTG. The cells (100 µl of culture) were centrifuged and 
resuspended in 250 µl of E. coli lysis buffer and diluted in SDS loading buffer. Proteins 
were separated on a 12 % NuPAGE Bis-Tris gel (Invitrogen), transferred on membrane 
and analysed by western blot. 
2.2.1.15 Cross-linking antibodies to CNBr-activated Sepharose 4B 
The cross-linking of antibodies was carried out using CNBr-activated Sepharose 4B 
(GE Healthcare, UK) according to the manufacturer instructions, using monoclonal 
anti-myc 9E10 control antibody (CRUK antibody services), monoclonal anti-AID 
hAnp52-1 (CRUK antibody services), monoclonal anti-PCNA PC10 (CRUK antibody 
services), and irrelevant mouse IgG2a control antibody (Serotec, USA). 300 µg 
sepharose powder was resuspended in 1 mM HCl yielding 1000 µl medium and washed 
for 15 minutes with abundant 1 mM HCl on a porous filter. The medium is briefly 
washed in coupling buffer, instantly activating the reactive groups therefore 
immediately transferring the medium to a tube containing the antibody in coupling 
buffer (5 mg Ab per ml medium). The mixture is rotated for one hour at RT or over 
night at 4 °C. Excess Ab is washed away with 5 medium volumes of coupling buffer. 
Any remaining active groups are blocked with 0.1 M Tris-HCl, pH 8, incubating for 
two hours. The medium is washed with at least three cycles of alternating pH (washing 
volume is 5x medium volume), using pH 4 wash solution and pH 8 wash solution. 
Finally, the medium is washed once in PBS and resuspended at a 50% slurry in PBS for 
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storage at 4 °C. 1ml of medium is treated in the same way but without antibody to use 
as preclearing material or control for IP. 
2.2.1.16 Co-immunoprecipitation of AID expressed in E. coli 
A pETDuet-1 derived vector for expressing human AID in E.coli was generated by 
using NcoI/HindIII restriction sites for cloning. Using this construct as a base, AID 
interacting proteins were cloned into the second multiple cloning site of the vector at the 
NdeI/XhoI restriction sites. The two proteins were co-expressed in BL21-
CODONPLUS(DE3)-RIL cells (Stratagene, USA). Bacteria were transformed 
according to the manufacturer’s instructions. One colony per construct was picked and 
dissolved in 2 ml 2x TY + 100 µg/ml Carbenicillin + 0.2% Glucose and incubated at 
37°C for 1 hour. A 30 ml LB culture with 100 µg/ml Carbenicillin and 0.2% Glucose  
was inoculated with the started culture and protein expression was induced with IPTG 
(1 mM) in the presence of 0.1 mM ZnCl2 when OD600 was 0.6, for 3 h at 18°C. Cells 
were lysed by sonication in TBS-Tri for a total of 2 x 25 seconds on ice, 1 second on, 1 
second off, 20% amplitude in a 2 ml tube. Debris was pelleted at 19,000 g and 
supernatant collected. For Paf1 interaction analysis, NaCl concentration was adjusted to 
300 mM at this point. The lysate was pre-cleared with sepharose beads for 1 hour 
followed by over night incubation with sepharose-coupled monoclonal antibodies anti-
AID hAnp52-1, anti-PCNA PC10 or control anti-myc 9E10. After 5 washes with TBS-
Tri the immunoprecipitates were analysed by western blot using polyclonal anti-PCNA 
and monoclonal anti-AID, followed by Odyssey LICOR secondary antibodies. LICOR 
analysis of the blots was performed as recommended by the manufacturer. 
2.2.1.17 Co-immunoprecipitation of AID expressed in TnT rabbit 
reticulocyte lysate 
2.2.1.17.1 Paf1 interaction analysis 
35S labelled Paf1 was expressed using the TnT T7 Coupled Reticulocyte Lysate System 
(IVT) according to the manufacturer’s instructions (Promega, USA), as follows.  Paf1 
was expressed from a PCR fragment harbouring the Paf1 cDNA and a T7 promoter. Per 
sample 500 ng of DNA template was combined with 1 µl of TnT retic buffer, 1 µl of 35S 
labelled methionin, 0.5 µl of 1mM amino acid mixture (minus methionin), 0.5 µl 
RNaseOut (Invitrogen), 0.5 µl T7 polymerase, 12.5 µl TnT retic lysate, and topped up to 
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25 µl with water in the presence of 1mM ZnCl2. The reaction was incubated at 30°C for 
90 minutes followed by incubation with RNase A at 10 µg/ml for 15 minutes at 37°C. 
The labelled protein mixture was incubated with 100 ng of AID or 300 ng of APOBEC2 
protein for 1 h at RT and 30 min at 4 ˚C. Proteins were isolated by prewashed and TBS-
Tri + 2 % BSA blocked anti-AID hAnp52-1 or anti-myc (9E10) beads coupled to 
sepharose. After bead incubation for one hour at 4 ˚C, beads were washed 5 times in 
TBS-Tri + 2 % BSA, resuspended in SDS PAGE loading buffer, and separated on 12 % 
Bis-Tris polyacrylamide gels (Invitrogen, USA). Gels were dried, exposed to Fuji 
Imaging Plates, and visualized with a Fuji FLA-3000 scanner. 
2.2.1.17.2 PCNA interaction analysis 
35S labelled AID (pSPM270) and control protein (Luciferase) were expressed from 
plasmids harbouring a T7 promoter using the TnT T7 Coupled Reticulocyte Lysate 
System (IVT) according to the manufactures protocol (Promega, USA) as described 
above. RecD purified protein was a gift from D. Wigley, CRUK. After in vitro 
translation, protein mixtures were added to 100 ng of PCNA or RecD protein for 1hour 
at RT, followed by 30 min at 4˚ C. Anti-PCNA (PC10 - Santa Cruz, USA) or control 
immunoglobulin was added for 30 min at 4˚ C. Mixtures were added to 20 µl Protein 
A/G Sepharose beads (Santa Cruz, USA) and further incubated for 30 min at 4˚ C. Bead 
complexes were washed 5 times in TnT bead washing buffer. Beads were resuspended 
in SDS gel loading buffer and analysed as above. 
2.2.1.18 Western blotting 
5 x SDS lysis buffer was added to 1 x to protein samples and denatured at 90 ºC for 5 
minutes. Samples were loaded to 12% or 4-12% NuPAGE Bis-Tris gels (Invitrogen). 7 
µl of Spectra Multicolour Broad Range Ladder (Fermentas) was electrophoresed 
simultaneously with the protein samples using MOPS SDS Running Buffer (Invitrogen, 
UK) at 200 V for 50-70 minutes at RT. The separated proteins were transferred onto 
Immobilon-P polyvinylidene fluoride (PVDF) membrane (Millipore, UK) in transfer 
buffer in a Novex MiniGel transfer apparatus (Invitrogen, UK) at 30 V for 150 minutes 
or 25 V for 240 minutes on ice. Membranes were blocked with 5% milk in TBS-T 
(blocking solution) for 30 minutes at RT, probed with primary antibody (in blocking 
solution) for 1hour at RT or 4 °C over night followed by washing the membrane with  
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Antibody Manufacturer Concentration/dilution 
Monoclonal anti-FLAG M2 F3165, Sigma, UK 1/3000 
Monoclonal anti-FLAG M2 coupled to HRP A8592, Sigma, UK 1/2000 
Monoclonal anti-AID clone 4.26.1 CRUK antibody production service 1/1000 
Monoclonal anti-AID clone hAnp52-1 
(Conticello et al., 2008) CRUK antibody production service 1/1000] 
Rabbit polyclonal anti-beta Tubulin ab6046, Abcam, UK 1/1000 
Monoclonal anti-GFP clones 7.1 and 13.1 11814460001, Roche 0.4 µg/ml 
Monoclonal anti-His sc-8036, Santa Cruz, USA 1:1000 
Monoclonal anti-beta-Actin ab8226, Abcam, UK 1:2000 
Monoclonal anti-Histone H3 ab10799, Abcam, UK 1:1000 
Rabbit polyclonal anti-SUPT5H ab26259, Abcam, UK 1/1000 
rabbit polyclonal anti-PAF1 ab20662, Abcam, UK 1/1000 
rabbit polyclonal anti-PAF1 A300-172A, Bethyl laboratories, USA 1/3000 
rabbit polyclonal anti-SUPT6H A300-801A, Bethyl laboratories, USA 1/2000 
rabbit polyclonal anti-CDC73 sc-48770, Santa Cruz, USA 1/1000 
mouse polyclonal anti-CDC73 ab43256, Abcam, UK 1/1000 
rabbit polyclonal anti-CTR9 A301-395A, Bethyl laboratories, USA 1/3000 
rabbit polyclonal anti-LEO1 ab70630, Abcam, UK 1/1000 
Monoclonal anti-PCNA clone PC10 CRUK antibody production service 1 µg/ml 
Rabbit polyclonal anti-PCNA ab2426, Abcam, UK 1/1000 
Goat anti-mouse Ig-HRP conjugate P0449, DakoCytomation, UK 1/10,000 
Goat anti-rabbit Ig-HRP conjugate P0448, DakoCytomation, UK 1/10,000 
Goat anti-mouse IR Dye 680 926-32220, LI-COR Biosciences 1/10,000 
Donkey anti-rabbit IR Dye 800 926-32213, LI-COR Biosciences 1/10,000 
 
Table 1. Antibodies used for western blotting. 
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TBS-T two times for 5 minutes at RT. The membrane was then incubated with HRP-
conjugated secondary antibody in blocking solution for 1 hour at RT, washed three 
times with TBS-T for 7 minutes at RT, and bands detected with ECL Plus Western 
Blotting Detection System (GE Healthcare, UK) according to manufacturer’s 
instructions. Primary and secondary antibodies used for western blotting are listed in 
Table 1. 
Quantitative western blot was carried out using the LI-COR system, according to 
manufacturer’s instructions. Secondary antibodies were coupled to IR Dye 680 or IR 
dye 800 and analysed with LI-COR Odyssey Infrared Reader. 
2.2.2 Mammalian or chicken cell methods 
2.2.2.1 Thawing cells 
A cryotube with cells was thawed quickly at 37 °C by hand warming and adding warm 
media. Cells were immediately transferred to a 15 ml falcon tube with 10 ml warm 
culture medium in it and centrifuged at 1,200 rpm for 5 min followed by aspiration of 
the supernatant, leaving 100 µl of media on the pellet. The cells were resuspended by 
tapping the tube gently and transferred to a small sized flask with 6 ml culture medium. 
2.2.2.2 Freezing cells 
Cells were grown to approximately 106 cells / ml. 5-50 x 106 cells were centrifuged at 
1000 rpm for 5-7 minutes and the supernatant aspirated. Cells were gently resuspended 
in 0.5-1 ml ice cold freezing medium and transferred into an ice cold cryotube. The 
cells were placed into a NALGENE Cryo Freezing Container containing isopropanol, 
and stored at -80 ºC for 72 hours before transferring the vials into liquid nitrogen. 
2.2.2.3 293 cells 
293 cells were maintained in DMEM + 10% heat inactivated fetal calf serum (30 min at 
55 ºC). For splitting adherent cells, the culture media was aspirated, cells were rinsed 
with PBS and detached from the surface by trypsin treatment. Cells were then counted 
by haematocytometer and transferred to a new flask with fresh culture medium, splitting 
approximately 1:5 every 3 days. 
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2.2.2.4 CH12 cells 
Murine B cell line CH12F3 (Nakamura et al., 1996) was a gift from B. Reina-san-
martin. Cells were maintained at 37ºC at 5% CO2 in RPMI (Invitrogen), 20 mM Hepes, 
10% heat inactivated fetal calf serum (30 min at 55 ºC), 1mM Sodium Pyruvate, 50 µM 
beta-Mercaptoethanol freshly added. CH12 are split between 1:5 and 1:10 every 3-4 
days. 
2.2.2.5 Chicken DT40 cells 
Chicken bursal derived DT40 cell line was cultured at 37 ºC with 5% CO2. Cells were 
monitored on a daily basis. The requirement for feeding was estimated according to cell 
density, cell morphology and culture medium colour. Cells were counted by using a 
haematocytometer or a cell counter. Cells were maintained at a density of 5 x 105 and 2 
x 106 cells / ml in RPMI 1640 +Glutamax media with 10% heat inactivated fetal calf 
serum (30 min at 55 ºC), 1% heat inactivated chicken serum (30 min at 55 ºC), 50 µM 
β-mercapthoethanol (Sigma, UK) and 10 U penicillin / streptomycin. Culture media was 
warmed up at 37 ºC prior to adding it to the cells.  
Large volumes of DT40 cells were cultivated by CRUK cell services in spin paddle 
flasks of 2-5 litres volume in a 37 ºC room, using high bicarbonate E4 media (DMEM, 
3g/l bicarbonate)+ 10% heat inactivated fetal calf serum (30 min at 55 ºC), 3% heat 
inactivated chicken serum (30 min at 55 ºC), 50 µM β-mercapthoethanol (Sigma, UK), 
and 10 U penicillin / streptomycin. 
2.2.2.6 Retrovirus production and retroviral transduction of shRNA 
constructs into CH12 
29mer shRNAs were cloned in the Origene HuSH pGFP-V-RS retroviral vectors 
(OriGene, USA, Table 2) and used together with pCL-Amphotropic helper vector 
(suitable for CH12 retroviral transduction) to produce infective virus from 293 host 
cells. Host cells in log phase were prepared for transfection by plating 150,000 cells in 2 
ml DMEM media per well in a 6-well tissue culture plate. The next day, 293 cells were 
transfected at 60-70% confluency. The DNA (very clean) was diluted to 1 µg/µl 
solution. Per construct and well a transfection mix is prepared using FuGene 6 reagent 
(Roche) at a 6 to 1 ratio: 94 µl OptiMEM medium + 6 µl FuGene 6 + 1 µl retroviral 
shRNA construct + 1 µl pCL-Ampho. The mixture was vortexed and pulse-spun,  
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Target  
gene 
sequence Retroviral vector 
aid 5'-ACCAGTCGCCATTATAATGCAA-3’ pLMP (B. Reina-San-Martin 
Laboratory, France) 
leo1 5'-GTGGCAGTGACAATCACTCTGAACGGTCA-3’ HuSH pGFP-V-RS  
(GI529047, OriGene, USA) 
supt5h 5'-GCTTGGCTACTGGAACCAGCAGATGGTGC-3’ HuSH pGFP-V-RS  
(GI336016, OriGene, USA) 
cdc73 5'- GACGTGCTCAGCGTCCTGCGACAGTACAA-3’ HuSH pGFP-V-RS  
(GI561719, OriGene, USA) 
paf1 5'-GGTGACGGAGTTTACTACAATGAGCTGGA-3’ HuSH pGFP-V-RS  
(GI518753, OriGene, USA) 
ctr9 5'-GATGAGGATTCCGACAGTGACCAGCCGTC -3’ HuSH pGFP-V-RS  
(GI528588, OriGene, USA) 
Untargeted 
control 
shRNA 
5'- GCACTACCAGAGCTAACTCAGATAGTACT -3 HuSH pGFP-V-RS  
(TR30007, OriGene, USA) 
 
Table 2. shRNA sequences used for knock-down in CH12. 
 
followed by a 15-minute incubation at RT. The 100 µl mix was added carefully and 
dropwise to the 293 cells and the plate shaken gently. Cells were returned to an 
incubator designated for virus work and left over night. After 24 hours, virus production 
starts. GFP expression was confirmed under the microscope and transfection efficiency 
estimated. CH12 cells were split for next day. At 48 hours post transfection, 1x106 
CH12 cells per construct/well were infected using the viral supernatant from the 293 
host cells. To this end, 1x106 CH12 cells were placed in a 15 ml tube and spun down. 
The supernatant was aspirated shortly before virus is added. Viral supernatants were 
harvested after 48 hours using a sterile syringe fitted with a 0.45 µm filter, to remove 
debris and host cells, into 15 ml tubes. Hepes (Invitrogen) was added to a 20 mM final 
concentration and polybrene to 10 µg/ml. The mixture was topped up to 2 ml and CH12 
cells were resuspended in the virus mixture, followed by transferring the cell suspension 
to 6-well tissue culture plates. Plates were centrifuged for 1.5 hours at 1150 g at RT 
without brake, then transferred to an incubator designated for viral work. At this stage 
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host cells could be trypsinised or scraped to accurately determine the transfection rate 
using FACS. 
After 24 hours post infection viral supernatants were disposed of appropriately and 
CH12 cells washed 1x with media, followed by resuspension in puromycin-containing 
culture media (0.5 µg/ml). Half of the cells were saved and plated into non-selective 
media to compare death rates. In the case of the pLMP control retroviral vector, 
transduction efficiency could be analysed by monitoring GFP expression pre-selection 
and post-selection by FACS. 
2.2.2.7 Stimulation of class switch recombination in CH12 
Assays are carried out in 6-well tissue culture plates. 200,000 CH12 cells growing in 
log phase are used per well. CH12 are diluted to 200,000 cells/ml in media and 1 ml 
aliquoted into each well. Cytokines are diluted into media at a 2x concentration. Final 
concentrations should be: 5 ng/ml Interleukin 4 (recombinant murine IL-4 Peprotech 
214-14), 200 ng/ml anti-CD40 (functional grade purified anti mouse CD40 clone 
HM40-3, eBIOSCIENCES 16-0402-85), 0.3 ng/ml TGF-β (R&D systems Europe 240-
B-002). 1 ml of cytokine solution is added to each well containing cells and shaken 
gently before incubating for 24 hours at which point a first flow cytometric analysis for 
IgA positive cells should be carried out, followed by a second one at 72 hours post 
stimulation. 
2.2.2.8 Flow cytometry (FACS) 
Sample preparation: Where cells were antibody stained prior to flow cytometry (as in 
switching analysis), a 96-well round bottom plate was used for the procedure. 
Depending on cell density, 200-1000 µl of CH12 suspension was taken for each sample. 
The cells were washed in ice-cold PBS and spun at 1200 rpm at 4 ºC followed by 
another wash in PBS + 1% FCS. After vortexing the plate briefly to dissolve the pellet, 
50 µl of antibody mix was added and cells resuspended. The antibody used for anti-IgA 
staining was: goat anti-mouse IgA-PE (Southern Biotech 104009), 1:1000 in PBS + 1% 
FCS. The antibody used for anti-IgM staining was: Rat Anti-Mouse IgM-FITC (BD 
Biosciences 553437), 1:1000 in PBS + 1% FCS. Cells were stained for 10 min at RT in 
the dark. After washing 2x with PBS + 1% FCS, cells were resuspended in 500-300 µl 
in PBS + 1% FCS and transferred to FACS tubes. For GFP analysis, cells were washed 
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and then resuspended in 500-300 µl PBS + 1% FCS. TOPRO DNA dye (Invitrogen) 
was added to all samples at 30 nM final concentration. 
For IgA switching analysis, a non-stimulated and a non-stained control was included, 
whereas for GFP expression analysis, a non-GFP expressing control line was included.  
Flow cytometry was carried out on a BD FACSCalibur with 4-colour option. Live cell 
population was selected by using FSC-H and TOPRO (FL4-H), excluding TOPRO-
positive cells. Live cells were analysed for PE signal (FL2-H) or GFP/FITC signal 
(FL1-H). Data were acquired using BD CellQuest Pro software, and analysed using 
FlowJo 9.2 software. 
2.2.2.9 Isolation of RNA 
1 x 106 cells were spun down in a 1.5 ml tube, the supernatant discarded and cell pellet 
immediately resuspended in 500 µl Trizol Reagent (Invitrogen), pipetting up and down 
to break up cells. The samples were incubated for five minutes at RT to facilitate lysis. 
100 µl chloroform was added, followed by vortexing for 15 seconds and incubating at 
RT for five minutes. Samples were spun at 12,000 g for 15 minutes at 4 °C to separate 
phases. The upper aqueous phase was transferred to a new tube, and 250 µl isopropanol 
was added and the tube mixed, followed by a 10-minute incubation at RT. Next, the 
samples were spun at 12,000g for 30 minutes at 4 °C. The resulting pellet was washed 
with 1ml of 70% ethanol in nuclease-free water, followed by another spin at 12,000g for 
five minutes at 4 °C. The supernatant was removed and pellet was dried in the air. RNA 
was resuspended in 20 µl nuclease-free water and stored at -80 °C. 
2.2.2.10 cDNA synthesis 
First-strand cDNA synthesis was carried out using SuperScript II reverse transcriptase 
(Invitrogen) according to the manufacturer’s instructions. 1 µl (300ng) random hexamer 
primers were combine with1 µg total RNA and 1 µl 10 mM (each) dNTP mix, topped 
up to 12 µl with sterile nuclease-free water and heated to 65 °C for five minutes 
followed by chilling the mixture on ice. After brief centrifugation 4 µl 5x first strand 
buffer, 2 µl 0.1 M DTT and 1 µl RNasin RNase inhibitor (Promega) were mixed and 
incubated at 25 °C for two minutes. Next, 1 µl of SuperScript II enzyme was added and 
mixed, followed by an incubation at 25 °C for 10 minutes and an incubation at 42 °C 
for 50 minutes. A control sample omitting the addition of the reverse transcriptase was  
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Target Primer sequence PCR program 
cd79b 5'-CCACACTGGTGCTGTCTTCC-3’  
5'-GGGCTTCCTTGGAAATTCAG-3’ 
 
50 cycles: 
94 °C 10 seconds 
60 °C 20 seconds 
72 °C 30 seconds 
hprt 5'-GTTGGATACAGGCCAGACTTTGTTG-3’  
5'-GATTCAACTTGCGCTCATCTTAGGC-3’ 
50 cycles: 
95 °C 15 seconds 
60 °C 30 seconds 
72 °C 30 seconds 
Germ line transcript  
GLTα 
5'-CAAGAAGGAGAAGGTGATTCAG-3’  
5'-GAGCTGGTGGGAGTGTCAGTG-3’ 
50 cycles: 
94 °C 10 seconds 
61 °C 30 seconds 
72 °C 20 seconds 
Germ line transcript 
GLTµ 
5'-ACCTGGGAATGTATGGTTGTGGCTT-3’  
5'-TCTGAACCTTCAAGGATGCTCTTG-3’ 
50 cycles: 
94 °C 10 seconds 
60 °C 20 seconds 
72 °C 30 seconds 
aid 5'-GAAAGTCACGCTGGAGCCG-3’ 
5'-TCTCATGCCGTCCCTTGG-3’ 
50 cycles: 
94 °C 7 seconds 
61 °C 30 seconds 
72 °C 10 seconds 
leo1 5'- GAGGAGCAAGACCAGAAGTCAG -3’ 
5'-TGTCGCTGTCTGCTTCGGAATC-3’ 
50 cycles: 
94 °C 10 seconds 
60 °C 20 seconds 
72 °C 20 seconds 
supt5h 5'- TGCACTGCAAGAAGCTGGTGGA -3’ 
5'-GCTCATAGGAGTGAAGCCACCA-3’ 
50 cycles: 
94 °C 10 seconds 
61 °C 20 seconds 
72 °C 30 seconds 
cdc73 5'- GAGAGAGTGTGGAGGACAAGAAC -3’  
5'-GCACGACCTTCTTCTCTGGCTT-3’ 
50 cycles: 
94 °C 10 seconds 
61 °C 20 seconds 
72 °C 30 seconds 
paf1 5'- GGAGGAAGAGATGGAGGCTGAA -3’ 
5'- CACTTGCCTCATCTCTGTCACC -3’ 
50 cycles: 
94 °C 10 seconds 
60 °C 20 seconds 
72 °C 30 seconds 
ctr9 5'- GTGACACCTACTCTATGCTGGC -3’  
5'- TGGCAGCATACAGGTTCTTGGC -3’ 
50 cycles: 
94 °C 10 seconds 
60 °C 20 seconds 
72 °C 30 seconds 
 
Table 3. Primers and programs used for qRT-PCR. 
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included and processed in an identical way to control for amplification from 
contaminating DNA in PCR. 
The reaction was inactivated at 70 °C for 15 minutes, topped up with TE to 100 µl and 
the cDNA stored at -20 °C.  
2.2.2.11 Quantitative real time PCR (qRT-PCR)  
The real-time PCR reaction were set up in triplicates as follows: 2 µl cDNA template, 5 
µl SYBR Green JumpStart Taq ReadyMix (Sigma), 1 µl 5µM primers and 2 µl H2O 
were mixed in wells of a 96-well qRT-PCR plate and subject to PCR according to Table 
3. cDNA template was used at a 1/125 dilution. Standard curves were prepared by 
making serial dilutions of control cDNA from cells expressing scrambled shRNA. 
Transcript quantities were calculated relative to standard curves and normalised to 
CD79b or HPRT mRNA. Data were acquired and analysed in a LightCycler 480 qRT-
PCR machine (Roche) and corresponding software. 
2.2.2.12 Isolation of genomic DNA 
Genomic DNA was isolated from cells using PUREGENE products Genomic DNA 
Isolation (Gentra Systems, USA) according to manufacturer’s recommendations. 50 µl 
of TE (pH 8.0) were added to DNA pellets and left to rehydrate over night at RT. 
Samples were stored at -20 ºC. 
2.2.2.13 Southern blotting 
The southern blotting probe was prepared by PCR amplifying a part of the AID gene 
using Pfu Turbo DNA polymerase and PCR parameters: primer annealing 57ºC, 30 
seconds, polymerization 72ºC. 60 seconds, 35 cycles. Primers used were: 5’-
CTTATGACTGTGCCCGACATG-3’ and 5’-CTGCTCCAGAGAGGACAC-3’. 
Radioactive probe was generated using α-32P dCTP together with the PrimeIt labelling 
kit (Stratagene, USA,) according to the manufacturer’s instruction. The probe was 
purified using a 50 G nick column (GE Healthcare). Genomic DNA was digested with 
KpnI and subject to gel electrophoresis on a 0.7% agarose gel at 4ºC. The gel was 
immersed for 45 minutes in 0.5 M NaOH and 1.5 M NaCl to denature the DNA, 
followed by immersion into 20 x SSC. Capillary transfer blotting was performed using 
hybond N+ membrane (Amersham, UK). After transfer, the membrane was fixed by 
placement on 3MM paper soaked in 0.4M NaOH for 20 minutes. After washing the 
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membrane in 2X SSC it was transferred to a rotating hybridisation bottle together with 
prewarmed hybridisation solution for pre-hybridisation (1 hour). The radioactive probe 
was incubated with the membrane in fresh hybridisation solution at 65ºC over night. 
After washing at least four times with southern blot washing buffer, the membrane was 
exposed to a Fuji IP plate and readout by a Fuji FLA-5000 scanner.  
2.2.2.14 Midi-preparation of plasmid DNA for transfection into cells. 
Plasmids were transformed into the bacterial subcloning strain XL1-Blue. A single 
bacterial colony was inoculated into 50 ml LB medium containing antibiotics  and 
incubated for 14-16 hours at 37 ºC with shaking (225 rpm). 
Isolation of plasmid DNA was then carried out using PureYield Plasmid Midiprep 
System, containing a washing step to eliminate endotoxins, (Promega, UK) according to 
the manufacturer’s instructions. The DNA was eluted with 600 µl of nuclease-free 
water. Plasmid DNA was stored at -20 ºC. 
2.2.2.15 Generation of recombinant DT40 lines 
pKW5001-5005 were generated as derivatives of the plasmid described in (Pauklin et 
al., 2009). Briefly, a 3’ fragment of the chicken AID gene lacking the last 33 
nucleotides, containing PshAI and a SpeI restriction sites was generated by PCR using 
Pfu turbo polymerase, primers used were 5’- AGAGACCAGTGTCCTCTCTGGA – 3’ 
and 5’- NNNACTAGTATCATCTACTTCATACAGTGG – 3’, and cloned via the 
PshAI and a SpeI restriction sites into pSPM509-5014, plasmids based on (Pauklin et 
al., 2009), Appendix Figure 29, encoding an AID targeting vector carrying Renilla 
luciferase (RL), GFP, 3 x FLAG (3F), 3 x FLAG 2 x TEV 3 x MYC (3FM) or 3 x MYC 
(3M) tagged AID. 
1 x 107 DT40 cells were spun down at 90 g for 5-10 minutes, resuspended in RPMI 
growth medium to give a 500 µL final volume. 25-50 µg of Not I linearised targeting 
construct was added to the culture solution and transferred to a 4 mm electrode gap 
Gene Pulser Cuvette. The cuvette was placed on ice for 10 minutes and electroporated 
using the following parameters: voltage = 550 V, capacitance (FD) = 25 µF, resistance 
= ∞, followed by placing the culture on ice for five minutes. The cells were transferred 
to a flask, containing 10 ml filter-sterilized culture medium followed by two hour 
incubation, whereafter 10 more ml media was added and the culture incubated over 
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night. The next day, the culture was pelleted and resuspended in 10 ml puromycin 
containing media (1 µg/ml) and dispersed into 96 well flat bottom plates for single cell 
cloning (200 µl cell suspension per well). After 5-10 days, surviving clones appeared as 
colonies. Clones were fed or split every day until reaching high density. Construct 
integration was monitored by southern blotting and appropriate clones were expanded, 
for performing selection marker excision. To this end, 3 x 105 cells for each 
recombinant line were washed in RPMI growth medium and resuspended in 300 µl 
RPMI growth medium containing 6 µM purified HTN-Cre protein, followed by 
incubation for 3 hours. 300 µl RPMI growth media and 30 µl FCS containing 10% 
chicken serum was added to the cells and they were incubated further over night. The 
next day, cells were diluted 1:8300 in RPMI growth media and plated at 100 µl cell 
suspension per well in a 96 well flat bottom plates. Colonies were grown and expanded 
as describes and subject to southern blot analysis to determine successful recombinants. 
2.2.2.16 Lipofectamine transfection of 293 cells 
Transfection of 293 cells with Lipofectamine 2000 (Invitrogen, UK) was performed as 
suggested by the manufacturer. The day before transfection, cells were plated in a 
density so that the next day, cells would have a confluency of 90-95%. The media used 
for Lipofection was Opti-MEM Reduced Serum Medium (Invitrogen). Cells were 
grown in Opti-MEM supplemented with 10% FBS. Approximately 5 hours before 
transfection, fresh media with FCS but without antibiotics was added to the cells. 
Lipofectamine was diluted in Opti-MEM medium without serum and incubated for 5 
min at RT. Plasmid DNA was diluted in Opti-MEM medium without serum and 
combined with Lipofectamine, followed by incubation at RT for 20 min. The medium 
in plates was substituted with serum free medium and the DNA-Lipofectamine 
complexes were added to the wells. The cells were incubated for 6 hour at 37 ºC and the 
medium was once again substituted with medium containing 10% FCS. After 
incubation for 24 hours, fresh media with serum and antibiotics were added to the cells. 
2.2.2.17 Luciferase Interaction Assay 
Renilla luciferase - AID fusion proteins (full length and N-terminal as well as C-
terminal truncations) were generated by cloning the human AID ORF/peptides 
downstream of the Renilla luciferase gene. 10 cm plates of 293T cells were transfected 
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with the indicated DNA using Lipofectamine 2000 (Invitrogen) according to the 
manufacturers instructions. 48 hr later, cells were lysed in 293 Lysis buffer, centrifuged 
and supernatants harvested. Lysate volumes were adjusted to equivalent luciferase 
counts based on the total lysate counts as determined by a Glomax luminometer 
(Promega, USA). Lysates were incubated with rotation over night at 4˚ C in the 
presence of antibody: PC10 antibody for endogenous PCNA (CRUK antibody service), 
M2-FLAG antibody (Sigma) for transfected FLAG-tagged PCNA, or an IgG2a 
antibody as a control (Serotec, USA). Protein A/G sepharose beads (Santa Cruz, USA) 
were added for 1 hr at 4˚ C, beads washed and resuspended in 30 µl 293 Lysis buffer. 
20 µl were added to 20 µl of 1x Renilla Luciferase Assay Buffer (Promega, USA), 
followed by addition of 75 µl luciferase substrate and luciferase reading in the Glomax 
luminometer. Per cent binding was determined from counts from each sample as a 
proportion of the total lysate counts.  
2.2.2.18 AID/APOBEC chimera GFP-IP 
Chimera GFP-fusion plasmids were a gift from M. S. Neuberger and S. Conticello 
(Conticello et al., 2008). 293T cells were transfected with the indicated DNA using 
Lipofectamine 2000 (Invitrogen) according to the manufacturers instructions.  Cells 
were lysed in 293 lysis buffer. Chimera protein expression levels in total lysates were 
checked by Western blotting and adjusted to equivalent levels with mock lysate. 
Lysates were incubated with control or FLAG-PCNA lysates and a polyclonal anti-GFP 
antibody (Abcam, ab290), rotating over night at 4˚ C. Subsequently, protein A agarose 
beads were added and rotated a further 1 hr at 4˚ C. Following 3 x washes, proteins 
bound to the beads were analysed by Western blotting. Chimera proteins were detected 
using a monoclonal anti-GFP antibody, while PCNA was detected using M2-anti FLAG 
antibody. 
2.2.2.19 Microscopy 
Immunofluorescence studies of DT40 cells were carried out based on (Szuts and Sale, 
2006). Irradiation of DT40 cells was performed by spinning down 2 ml of DT40 culture 
at 400 g onto poly-l-lysine covered coverslips in 24-well tissue culture dishes, dipping 
them in PBS, blotting the edges and immediately placing them under a UV lamp with a 
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measured flow rate to receive a dose of 10 J/m2. Afterwards they were placed back in 
warm DT40 media for a 40-minute recovery before spinning once more. 
After treatment, coverslips were washed in PBS and incubated in 0.2% Triton in PBS 
for 5 minutes to extract soluble proteins. After another wash in PBS, 4% 
paraformaldehyde is added for 5 minutes to fix cells, followed by a wash in PBS. IF 
blocking solution was added for 10 minutes and primary antibody diluted in IF blocking 
solution was applied to the coverslip.  
Fixed cells were stained using mouse monoclonal anti-PCNA PC10 (CRUK antibody 
services) 1:1000 and rabbit polyclonal anti-GFP (abcam ab290) 1:2000, and coverslips 
incubated for 1.5 hours at 37 °C in a humidified box in the dark. After a 10-minute 
immersion in PBST to wash, a 1:1000 staining mix of secondary antibodies (goat anti-
mouse coupled to Alexa Fluor 594; goat anti-rabbit coupled to Alexa Fluor 488, 
Invitrogen) was applied and coverslips incubated for 1 hour at 37 °C in a humidified 
box in the dark. After another 10-minute wash in PBSTS coverslips were mounted 
upside down on mounting medium containing DAPI (ProLong Gold, Invitrogen) and 
sealed with nail varnish. 
Images were acquired on a Zeiss Axio Imager M1 microscope using a Plan Apochromat 
100×/1.4 oil objective lens (Zeiss) equipped with an ORCA-ER camera (Hamamatsu) 
and controlled by Volocity 4.3.2 software (Improvision). 
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Chapter 3. Analysis of AID cofactors on chromatin 
3.1 Results 
3.1.1 Biochemical identification of proteins associating with AID on 
chromatin of B cells 
The purpose of this part of the thesis was to identify and characterise novel interacting 
partners of AID, as well as to pursue the connection between AID and the transcription 
machinery in more detail. To isolate proteins that interact with AID on chromatin, 
where AID activity takes place, two conditions were required to be fulfilled: First, AID 
had to be purified from a source that naturally expresses AID and undergoes AID 
dependent Ig diversification. Second, the purification had to be enriched for chromatin 
bound AID. An initial mass spectrometric analysis of the protein complexes that 
associate with AID on chromatin was performed by S. Pauklin and S. Petersen-Mahrt, 
CRUK, and is the starting point of this aspect of my thesis work. 
Cell lines suitable for this analysis had been engineered in the lab (Pauklin et al., 2009), 
using the DT40 B cell line as a parent. Briefly, in these lines, one allele of endogenous 
AID was tagged at the C-terminus with various peptide tags, either 3xFLAG peptides 
(3F) or the combination of 3xFLAG peptide - 2xTEV cleavage sites - 3xMyc peptides 
(3FM). This yielded cells expressing tagged AID protein at endogenous amounts 
(DT40-3F and DT40-3FM). Even though it is known that the C-terminus of AID plays 
an important role in sub-cellular localisation, the introduction of the mono-allelic C-
terminal tags did not change AID’s subcellular localisation or immune diversification 
activity (data not shown).  
To characterise proteins that associate with chromatin bound AID, a subcellular 
fractionation protocol for DT40 adapted from a recently developed method for isolation 
of chromatin bound protein-complexes (Aygun et al., 2008) was used. As mentioned 
above, in diversifying B cells AID is usually sequestered in the cytoplasm, thus to 
overcome this problem, it was required to grow large amount of cells (1 - 2 x 1010). Cell 
lysates were sub-fractionated into cytoplasm, nucleoplasm and chromatin fraction and 
the fractions were subject to FLAG peptide immunoprecipitation (IP) of AID followed  
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Figure 7. Subcellular fractionation of DT40. 
 
Analysis of DT40 subcellular fractions. 15 µg of each fraction was loaded (not 
representative of the total protein amount in each fraction, total chromatin bound 
protein is approx. 2% of total protein in all fractions) A, Lysates of the wild type 
(DT40) and the recombinant strain (DT40 AID-3FM) are probed for FLAG expression 
in all 3 fractions, as well as probed for markers of B, cytoplasm (beta-Actin) and C, 
chromatin (Histone H3).  
 
by one-dimension SDS-PAGE and mass spectrometry identification. A representative 
fractionation experiment can be seen in Figure 7. AID was present in each fraction, and 
chromatin AID was estimated to be less than 2 % of total AID-3FM.  
Data obtained from large scale mass spectrometric analysis of AID-3F chromatin 
fraction comprised 151 peptide hits corresponding to 52 proteins (Figure 8 A). Non-
tagged control cells were used to generate a control IP dataset, which was used to filter 
peptide hits as unspecific associations. By this method, hits were reduced to 75 specific 
peptide hits corresponding to 25 proteins. An extended list of mass spectrometry 
identified proteins can be viewed in Appendix Table 4. The majority of the AID 
associated proteins on chromatin were part of mRNA processing (Figure 8 B). 15% of 
peptides could be assigned to RNA polymerase alone. More than 80 % of all isolated 
peptides were interconnected in a functional and physical interacting network (as 
classified using Ingenuity Systems Pathway Analysis software, data not shown),  
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Figure 8. Summary of a mass spectrometric analysis of AID isolated from B cell 
chromatin. 
 
A, Schematic of complex isolation and analysis. DT40 cells expressing tagged AID 
(red) and untagged AID (blue - control) were fractionated into cytoplasm, nucleoplasm 
and chromatin. Each fraction was then subjected to anti-FLAG bead IP and mass 
spectrometry analysis. 151 peptides  corresponding to 52 proteins were identified from 
the chromatin fraction only. The equivalent Mass Spec data set from control cells was 
used as a filter to remove false positives (yellow lines/boxes), leaving 75 peptides (25 
proteins). B, Analysis of filtered peptide hits of the chromatin fraction. The most 
abundant peptides identified were functionally grouped and groups are displayed in a 
pie chart as percent of total peptides (75) that could be assigned to each complex. The 
right 54% of the pie chart comprises proteins directly involved in RNAPII elongation.  
 
(in collaboration with Siim Pauklin) 
 
clustering around RNAPII. They include RNAPII elongation factors (SUPT5H, PAF 
complex components - PAF1, CTR9, LEO1), chromatin modifiers (SUPT6H, DNA 
topoisomerase I, FACT complex components - SSRP1 and SUPT16H), exosome 
components (SUPT6H), and RNAPII pausing and re-initiation factors (PAF complex, 
SUPT5H, and SUPT6H) (Figure 8 B); with some proteins serving multiple functions. 
Furthermore, another 20 peptides comprised proteins involved in RNA metabolism 
(splicing associated factors and RNA helicases). The high percentage (54 %) of 
peptides that co-isolate with AID and are part of the same biological process (RNAPII 
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elongation) indicate that this isolation and analysis procedure had identified key AID 
interacting proteins from chromatin of immune diversifying cells.  
In line with these findings, recent work from other laboratories has identified SUPT6H, 
SUPT5H and the exosome to interact directly or indirectly with AID and be involved in 
CSR (Pavri et al., 2010,  Basu et al., 2011, Okazaki et al., 2011), while the identification 
of the FACT complex in the mass spectrometry data supports the discovery that SSRP1 
and SUPT16H are essential for CSR (Stanlie et al., 2010). In our analysis, the PAF 
complex especially caught our attention as several subunits of this complex (CTR9, 
PAF1 and LEO1) were identified. This could indicate that a functional form of the 
complex, in conjunction with AID, could carry out an important role in B cell 
diversification, and provide the missing link between SUPT5H function and the FACT 
complex activity.  
Taken together, these data prompted me to reproduce the initial mass spectrometry 
results, confirm AID interaction with the found RNAPII associated proteins, and 
elucidate the role of RNAPII pausing and elongation factors for AID function.  
To validate the interactions, the AID-3FM DT40 line was subjected to the described 
fractionation protocol, and FLAG immunoprecipitates analysed by replica mass 
spectrometry (data not shown) and by western blot. The association of AID with PAF1 
could be validated by using two different antibodies (Figure 9 A), as well as the 
association with another subunit of the PAF complex, LEO1 (Figure 9 B). Although not 
identified in the original mass spectrometry analysis, CDC73 showed significant 
association with AID on chromatin (Figure 9 C). Importantly, interaction of AID with 
the aforementioned SUPT5H (Figure 9 D) and SUPT6H (Figure 9 E) could also be 
confirmed. It is important to note that the chicken genome is not fully characterised, and 
its annotation is incomplete. Therefore, the number of proteins identified may be 
underestimated. Furthermore, there are only a limited number of characterised 
antibodies that recognise the chicken homologues of candidate proteins – as seen by the 
seemingly weak interaction between SUPT5H and AID. This is most likely due to the 
poor cross-reactivity of the SUPT5H-specific antibody between species. Nevertheless, 
this interaction was confirmed by multiple mass spectrometry analysis (3 out of 5). 
Taken together, this work has for the first time identified and verified AID-associated  
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Figure 9. Western blot analysis of interaction candidates of chromatin-bound AID. 
 
Co-IP of RNAPII associated proteins with AID-3FM purified from DT40 chromatin. 
AID-3FM was immunoprecipitated from chromatin fractions prepared as in Figure 7, 
and eluted proteins were probed by Western-blotting. Input chromatin lysate from 
DT40-3FM and DT40 control cell lines prior to FLAG-IP are shown on the left. A, anti-
PAF1 (using two alternative polyclonal antibodies); B, anti-LEO1; C, anti-CDC73; D, 
anti-SUPT5H; E, anti-SUPT6H; F, AID expression and IP. AID is detected by an anti-
FLAG antibody and an anti-AID antibody. Anti-AID antibody was unable to detect 
chicken AID at physiological levels in DT40 lysates. 
 
complexes on chromatin in diversifying B cells. Furthermore, it highlights the 
connection between AID and RNAPII transcription elongation. 
3.1.2 AID is found in a high molecular complex in chromatin of B cells 
To further characterise chromatin-AID in its physiological conformation, we 
determined the possible size of the AID associated complex. The DT40 AID-3FM 
chromatin fraction was separated using a Superdex 200 column for size exclusion  
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Figure 10. Size exclusion chromatography profile of DT40 chromatin bound 
fraction. 
 
The chromatin fraction from DT40 AID-3FM cells was loaded onto a Superdex 200 
column. A, The elution profile of standard proteins is plotted in the graph. Red circle: 
Theoretical elution volume of AID-3FM (29 kD). Green circle: Peak fraction of AID-
3FM (200 kDa). Eluted fractions (elution volume indicated) were analysed by western 
blot probing for the presence of AID-3FM B, Western blot analysis of the fractions as in 
A probing for PAF1, LEO1, CTR9, and CDC73. 
 
(in collaboration with Gopinath Rangam) 
 
chromatography (SEC). The eluted fractions were collected and analysed by western 
blot for the presence of AID. The obtained profiles could be compared to the elution 
profile of standard proteins to assign molecular sizes to fractions. AID was identified as 
part of a 200 kD protein complex (120 kD to 300 kD - based on standard proteins), 
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while only a minor fraction of AID eluted at its theoretical monomeric size of 27 kD 
(Figure 10 A). This is the first demonstration that chromatin bound AID resides in a 
large heteromeric complex. Earlier observations of AID as a component of a 
significantly larger complex by Jeevan-Raj et al., 2011 and others were not chromatin 
specific and were based on cell extracts in which AID was overexpressed as a transgene 
rather than expressed at endogenous AID levels. 
Although the peak of AID elution is fairly sharp, it remains to be determined whether 
AID resides in one or more species of complex, and how stable the associations with its 
direct interacting partners are. Certainly, AID does not form one highly stable complex 
with all partners identified by co-IP, or with one fully identified partner complex. For 
instance, the human PAF complex is larger than 400 kDa (Kim et al., 2010). To see 
what type of an overlap with the AID complex we could identify, we analysed the SEC 
profile of the PAF complex in DT40 chromatin extract. Western blot analysis of the 
chromatin SEC fractions (Figure 10 B) demonstrated that PAF1, LEO1, and CTR9 co-
migrate in a large (>400 kD) complex (elution ml 9.7-11.7), only with the peak trailing 
fractions overlapping with the AID peak (elution ml 13.7, lane 5). The DT40 PAF 
complex's migration through SEC is almost identical to that of the PAF complex 
isolated from HeLa cells (Kim et al., 2010), indicating that the overall complex 
configuration is conserved in Ig diversifying cells. Although CDC73 is known to be part 
of the PAF complex, it had a slightly different elution profile, with its peak fraction 
more closely matching that of the AID peak fraction (lane 5). 
Taken together, an overlap of a small subset of the AID and PAF protein complexes 
would be consistent with the data, alternatively, subunits of the PAF complex could 
overlap with AID and form a complex (e.g. CDC73).  
3.1.3 A direct interaction of PAF1 with AID? 
Considering the data from our SEC experiment, it was possible that AID interacted with 
transcription elongation complexes via binding of one subunit. Therefore, interaction of 
individual candidate proteins with AID was tested using an E. coli in vitro IP system. 
Here, both proteins were co-expressed from the same plasmid in bacteria, one of them 
immunoprecipitated, and co-immunoprecipitates detected by western blot. The cloned 
human candidate cDNAs were C-terminally FLAG tagged while human AID was  
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Figure 11. Transcription elongation factors as candidates to interact with AID in 
vitro. 
 
A Candidate RNAPII associated proteins for direct AID interaction were expressed with 
a FLAG tag in E. coli together with AID (CDC73, SUPT5H and SSRP1 as indicated on 
the left). Lysates were used for IP with anti-FLAG antibody (lanes 1 -  2), anti-AID 
antibody (lanes 3 -  4) or anti-myc control antibody (lanes 5 -  6) and lysates containing 
PAF1-FLAG only served as controls. Precipitates were analysed by western blotting 
using anti-FLAG. B, AID expression was confirmed for each experiment in the lysates, 
shown in a separate blot. 
 
untagged. After protein immunopurification, the co-IP’s were analysed by anti-FLAG 
western blot (Figure 11). The first proteins that were tested were SUPT5H [a protein for 
which indication of interaction existed (Pavri et al., 2010)], a subunit of the FACT 
complex (SSRP1) and a subunit of the PAF complex that had co-eluted with AID in the 
SEC experiment (CDC73). The presence of FLAG-tagged protein could be confirmed 
by FLAG IP (Figure 11 A, lanes 1 and 2), and AID interaction would be indicated by 
detection of co-IP of FLAG-tagged protein (Figure 11 A, lanes 3 and 4). In the case of 
SUPT5H, interaction could not be shown above a background signal (lane 3 versus lane 
4 and Figure 11 B, lane 7 versus lane 8). SSRP1 and CDC73 showed no co-IP signal 
(lane 4). Of all the proteins tested, only FLAG-PAF1 was co-isolated with AID (Figure 
12 A). This association was dependent on AID (lanes 4 – 6, lanes 11-13) and did not 
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Figure 12. AID and PAF1 interact directly in vitro. 
 
A, B; AID and PAF1 were expressed from the same plasmid in E.coli. PAF1 fragment 
is ~50 kDA.  
A, PAF1 co-immunoprecipitates with anti-AID. IP was performed as in Figure 11. 
Lysates for expression of both proteins were made in duplicates, and lysates containing 
PAF1-FLAG only served as controls. AID expression in the lysates was confirmed, as 
before. B, AID co-immunoprecipitates with PAF1. Reciprocal IP was performed using 
anti-FLAG beads and E.coli lysates as in A. (Top panels) Western blot of IP (lane 1 - 3) 
and lysates (4 - 6) using anti-FLAG. (Bottom panels) The same IP and lysate as on top 
probed with anti-AID. Lysate with AID only (lane 1 and 4), with PAF1-FLAG (lane 2 
and 5), and with AID and PAF1-FLAG (lane 3 and 6). C, AID and PAF1 are interaction 
partners in a cell free system. Pull down assays were performed with 35S-labelled in 
vitro translated PAF1 and recombinant AID or APOBEC2 (APO2) purified from E.coli. 
Pull down samples were analysed on SDS page followed by autoradiography. Assays 
performed with control antibody (lane 2 & 4) or APO2 protein (lane 3 & 4) served as 
controls. 
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occur in the absence of AID specific antiserum (lanes 7 - 9). Analysis of the FLAG-IP 
of PAF1 indicated that equal amounts of PAF1 could be immunoprecipitated in all E. 
coli samples (lane 1 - 3). Notably, PAF1 is processed as a shortened fragment in 
bacteria, even when rare codon strains are used (data not shown). The observed 
fragment runs near 50 kDa in polyacrylamide gel electrophoresis, while human PAF1 
has a calculated molecular weight of 60 kDa but can migrate near 80 kDa (Rozenblatt-
Rosen et al., 2005). Small amounts of full length PAF1 protein can be seen after AID IP 
in Figure 12 B. Although we could identify full length PAF1 in the FLAG IP, the 50 
kDa C-terminal FLAG tagged fragment was the prominent band in the lysate. All 
indicated PAF1 bands in the blot (full length and C-terminal) were verified to contain 
PAF1 peptides by mass spectrometry. A reciprocal IP experiment was done confirming 
AID interaction with the C-terminal part of PAF1 (Figure 12 B, lane 3). 
The interaction of AID and PAF1 in a system that excludes any other eukaryotic 
proteins supports a direct interaction. However, to confirm the interaction between AID 
and PAF1 in a different system, we performed pull down analysis with in vitro 
produced proteins from rabbit reticulocyte lysate. As shown in Figure 12 C, in vitro 
transcribed and translated radiolabelled PAF1 was pulled down by purified recombinant 
AID protein (lane 1), while APOBEC2 protein (lane 3 and 4) or a control antibody (lane 
2) did not have the same effect. Together, these data indicate that AID directly interacts 
with the PAF complex via the PAF1 protein. 
3.1.4 shRNA knock-down of transcription elongation factors have an 
effect on Class Switch Recombination in B cells 
Because the PAF complex associates with AID in vitro and in vivo, it was determined 
whether depletion of members of the PAF complex could have a biological effect on 
AID dependent recombination processes. As a system, the murine B cell lymphoma line 
CH12 was used for readout of AID function, monitoring AID dependent CSR. The 
CH12 subclone CH12F3 (called CH12 here) expresses the IgM isotype on the cell 
surface and can be induced to switch to the IgA isotype in vitro using the cytokine 
combination IL-4, TGF-β and anti-CD40 (Nakamura et al., 1996). Compared to primary 
B cells, CSR in CH12 occurs at a much higher frequency. In Figure 13 A, FACS  
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Figure 13. Class Switch Recombination assay in the CH12 B cell line.  
 
A, A control wt CH12 population analysed by flow cytometry. Cells were stained with 
ToPro dead cell stain in all cases and either for IgM surface expression or IgA surface 
expression. Live cells were selected in the coloured plot (x-axis: FSC-forward scatter; 
y-axis: ToPro dye signal). The live subpopulation was used for observation of surface Ig 
expression by monitoring levels of antibody (PE) staining (contour plots). The 
percentage of negative or positive staining is indicated in the respective quadrants. B, A 
cytokine stimulated CH12 population analysed by flow cytometry. Cells were stained 
and analysed as in A. 
 
profiles of a representative CH12 population is shown. The live cell population is 
determined by ToPro staining. When IgM as well as IgA staining is applied, the FACS 
plots show that this B cell line is largely IgM+ and IgA-. When culturing the cells with 
cytokines, within 72 hours generally 40-60% of the population undergoes CSR from 
IgM to IgA resulting in surface expression changing from IgM+ to IgA+ (Figure 13 B). 
Depletion of AID and SUPT5H (Pavri et al., 2010) was used as controls. In order to 
deplete PAF complex subunits in CH12 B cells, a retroviral system was used to express 
short hairpin RNA specific for the target mRNA. First, a packaging retroviral vector  
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Figure 14. shRNA knock-down of PAF complex members in CH12 results in 
impaired CSR. 
 
A IgA surface expression was monitored by flow cytometry (FACS) using stimulated 
CH12 cells expressing shRNAs specific for supt5h, members of the PAF complex 
(paf1, leo1, ctr9 and cdc73) or a non-target shRNA negative control (representative 
plots shown). An shRNA specific for aid was used as a positive control. Numbers 
within the FACS plots indicate the percentage of IgA positive cells in the live 
population upon cytokine stimulation (left panels). B, Quantitative RT-PCR of 
transcripts in knock-down cells (black bars) relative to the corresponding non-target 
shRNA controls (white bars). aid, supt5h, paf1, ctr9 and cdc73 mRNAs are analysed in 
each respective knock-down population used for CSR assay. cDNA was generated by 
reverse transcribing mRNA. Transcript Ct values were normalised to cd79b or hprt 
mRNA abundance and are shown relative to the levels in the non-target shRNA 
negative control, set to 1. Error bars: standard deviation. p values, Student's t-test.  
 
(In collaboration with Sara Milosevic) 
 
[pCL-Ampho (Naviaux et al., 1996)] together with a vector carrying a shRNA hairpin 
expression cassette (HuSH pGFP-V-RS, provided by OriGene, USA; or pLMP shRNA 
vector for AID) was transfected into host cells (293T cells). pCL-Ampho expresses 
retroviral proteins, including an amphotropic envelope protein, which are sufficient to 
assemble infective retroviral particles that self-inactivate after the first viral cycle. 
pGFP-V-RS carries a GFP marker for monitoring host cell transfection, a shRNA 
hairpin, a puromycin expression cassette, and flanking long terminal repeats that serve 
as a signal for packaging the interjacent DNA into the viral particles. For AID shRNA 
introduction, a pLMP backbone was used analogous to pGFP-V-RS. Next, viral 
supernatant produced by the host cells was used to infect the target cells (CH12) and 
successful transformants were selected using puromycin resistance. Finally, the capacity 
of transduced B cells to undergo CSR to IgA was determined by flow cytometry in an 
assay analogous to the experiment in Figure 13. Transduced cell populations were 
stimulated to undergo CSR in vitro (Figure 14 A). The efficiency of shRNA dependent 
gene knock-down was determined by quantitative real-time PCR (qRT-PCR) (Figure 14 
B). Consistent with previous reports, it was found that knock-down of aid and supt5h 
resulted in a significant reduction in the efficiency of CSR (Figure 14 A). Remarkably, 
knock-down of paf1, leo1, and ctr9 resulted in a similar reduction in the efficiency of  
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Figure 15. CSR reductions in multiple knock-down experiments. 
 
Average percentage (+ standard deviation) of CSR in knock-down cells (black bars) 
relative to the non-target shRNA control (white bars) from three independent 
experiments. CSR in cells expressing the non-target shRNA control was set to 100 %. 
The % difference in CSR efficiency between non-target and target shRNA knock-down 
is indicated. Error bars: standard deviation. 
 
(In collaboration with Sara Milosevic) 
 
CSR (Figure 14 A). These results could be observed over 3 independent experiments 
with reductions ranging from 27 % to 42 % (Figure 15). As the PAF complex is part of 
the RNAPII transcription machinery, the knock-down of its individual subunits could 
have broader influences on the cell than just altering AID’s function at the IgH locus 
during CSR. In order to minimise the selection pressure of general transcription profile 
alterations that could occur, cells were subject to CSR assay after no more than 5 days 
post infection. Furthermore, the effect of gene knock- down on switch region 
transcription and aid mRNA expression was monitored in samples used for CSR assays 
(Figure 16). As observed in previous studies, in aid and supt5h knock-down cells, 
germline transcription at the µ (donor) (Figure 16A) or α (acceptor) (Figure 16 B)  
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Figure 16. Switch region and AID transcript levels in shRNA knock-down cells 
 
Quantitative RT-PCR of transcripts in knock-down cells (black bars) relative to the 
corresponding non-target shRNA controls (white bars). aid, supt5h, paf1, ctr9 and 
cdc73 knock-down cells used for CSR assay in Figure 14 are analysed. All transcript Ct 
values were normalised to cd79b or hprt mRNA abundance and are presented relative to 
the levels in the non-target shRNA negative control, set as 1. Error bars: standard 
deviation. p values, Student's t-test. NS: not significant. A, Analysis of µ germline 
transcript in knock-down cells as indicated. B, Analysis of α germline transcript in 
knock-down cells as indicated. C, Analysis of aid transcript in knock-down cells as 
indicated. 
 
(In collaboration with Sara Milosevic) 
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switch regions were unaffected. While transcription at the donor switch region was also 
unaffected by the knock-down of any of the PAF complex subunits (Figure 16 A), it 
was found that knock-down of leo1, ctr9 and cdc73 resulted in altered levels of 
germline transcription at the acceptor switch region, with a significant reduction of 
transcription in the ctr9 knock-downs (Figure 16 B). Furthermore, knock-down of paf1, 
ctr9 and cdc73 resulted in a significant reduction in the level of aid mRNA (Figure 16 
C). Importantly however, knock-down of leo1 did not reduce AID mRNA expression 
(Figure 16 C), nor reduce the levels of germline transcripts (Figure 16 A and B), yet 
CSR was significantly reduced (Figure 14 A and Figure 15). This indicates that LEO1, 
as a PAF complex component, can directly influence AID’s activity in CSR, even if the 
knock-down was incomplete. The direct role in CSR of the other members of the PAF 
complex was not possible to delineate, as their effect could also be indirect by altering 
the expression of CSR relevant transcripts.  
In this project, I was able to show that on chromatin AID associates with the PAF 
complex, likely mediated through the direct biding of AID to PAF1, and that this 
complex/interaction plays a significant role during CSR. 
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Chapter 4. Analysis of AID cofactor PCNA 
4.1 Results 
Taking a different approach than in the first part of the study, here, a candidate protein 
was selected for AID association based on previous knowledge on AID function and Ig 
diversification cofactors. Partners of AID will help control AID-induced DNA 
alterations by regulating targeting of AID (addressed in the previous part of the study) 
or by regulating the outcome of the AID-induced lesion. It is well established that AID-
induced lesions can be processed via BER or MMR related processes, including 
employment of specialised polymerases (TLS). BER, MMR and TLS are dependent on 
polymerases and, thus, on a processivity cofactor, the predominant one being the DNA 
sliding clamp PCNA. PCNA has also been shown to have a role in Ig diversification in 
vivo. Moreover, it has the ability to act as a switch between a set of DNA damage 
response pathways through variable modification at its K164 residue, comprising 
monoubiquitination, polyubiquitination and sumoylation. Therefore, I explored PCNA 
as a candidate AID interacting protein. 
4.1.1 The interaction between AID and PCNA 
4.1.1.1 In vitro association of AID and PCNA 
In an initial experiment, AID’s ability to interact with PCNA was tested in a cell-free 
system similar to the system used in 3.1.3 (Figure 17A). For this experiment, AID or a 
control protein (luciferase) was expressed and labelled with 35S radionuclide using a 
TNT rabbit reticulocyte lysate system. The protein mixture was then incubated with 
recombinant PCNA protein or control protein (recD protein, another DNA binding 
protein, used to control for unspecific indirect binding via DNA). After IP with anti-
PCNA or isotype control antibody, a co-precipitation can be observed only in those 
samples where PCNA and anti-PCNA were used. Experiments in our as well as other 
laboratories have shown that AID can unspecifically adsorp to gels and resins such as 
agarose (Metzner et al., 2010), therefore another system (employing a different bead 
product) was used to corroborate the interaction between AID and PCNA. To this end, 
the E. coli co-expression system described before was used. AID and PCNA were co-
expressed from the same plasmid in E. coli followed by co-IP. Western blot analysis of  
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Figure 17. AID interacts with PCNA in vitro.  
 
A, In vitro co-IP. Radiolabelled AID or luciferase control proteins are expressed using 
rabbit reticulocyte lysate and subjected to incubation with either purified recombinant 
his-PCNA, RecD control protein or without protein. IPs are performed using anti-
PCNA antibody or IgG isotype control antibody, and analysed on SDS page followed 
by autoradiography. B, Co-IP in E. coli. AID only or AID and PCNA are 
simultaneously expressed in E. coli, followed by IP of AID or PCNA. Using LICOR 
infrared co-identification in Western-blot, AID protein gives a magenta signal and 
PCNA a green signal in inputs and reciprocal IP’s. 
 
 
 
IP and lysates was performed using the two-colour infrared LICOR Odyssey detection 
system. Here too, a specific PCNA and AID interaction could be identified (see Figure 
17 B). The lysates showed AID (magenta signal) and PCNA (green signal) expression 
(lanes 6 and 7), and were subject to IP using anti-AID as well as anti-PCNA antibodies. 
A PCNA specific band was identified as a co-precipitate in anti-AID samples (lane 3). 
This interaction was also identified with a reciprocal IP, when using an anti-PCNA 
antibody for IP, an AID association was identified (lane 5). 
Together, these data indicate that AID and PCNA interact directly in vitro. 
4.1.1.2 In human cells 
To show the interaction in higher eukaryotes, AID and PCNA expression vectors were 
co-transfected into 293 human embryonic fibroblasts. FLAG-tagged PCNA was used 
together with a Renilla reniformis luciferase-AID fusion (RL-AID). Following anti-
FLAG-IP or anti-PCNA-IP, AID binding was measured by the relative amount of  
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Figure 18. AID and PCNA interaction in 293 fibroblasts using luciferase fusion. 
 
A, Schematic representation of the RL-AID interaction assay. The RL-AID protein is 
expressed in cells that are lysed and incubated with immobilised antibody targeted to 
bind PCNA. After washing and eluting, the luciferase activity of the eluate is detected 
by an enzymatic luciferase assay as a measurement of bound RL-AID. B, 293 
fibroblasts transfected with FLAG-PCNA and Renilla luciferase or RL-AID fusion 
construct are used for IP. After anti-PCNA or anti-FLAG IP, bound luciferase is 
measured by luciferase activity assay. C, 293 fibroblasts transfected with RL-AID 
fusion construct or control constructs only are used for co-precipitation. Control 
constructs comprise Renilla luciferase only, as well as RL fused to the small protein 
NEMO (RL-NEMO). After anti-PCNA and control IP, bound luciferase is measured as 
in B. 
 
(In collaboration with Maria Simon) 
 
bound luminescence (Figure 18 A), whereby the ratio of bound luminescence versus 
luminescence in the input was used to judge enrichment. 
Anti-FLAG-IP or anti-PCNA-IP showed luminescence binding, while controls (RL only 
or control IPs) did not (Figure 18 B). Because the anti-PCNA IP showed AID 
interaction, and because PCNA is an abundant nuclear protein, it was tested if AID 
interacted with endogenous PCNA. To this end, only RL-AID was transfected. As with 
the co-transfection experiments, AID could be identified to interact with PCNA (Figure 
18 C). These data demonstrate that AID can interact with PCNA in vivo. 
4.1.1.3 In B cells 
To confirm the interaction of AID and PCNA in cells where physiological AID function 
can be observed, co-IP experiments were performed using the previously described 
DT40 derivatives, DT40 AID-3FM and DT40 AID-3F. Tagged AID was recovered 
from whole cell lysates using immobilised M2 anti-FLAG antibody, and co-precipitated 
PCNA was detected using western blot (see Figure 19 A). Notably, the quantitative 
difference in PCNA signal parallels the amount of AID-FLAG recovery (Figure 19 A), 
rather than the PCNA expression (Figure 19 B). This data indicates that AID and PCNA 
interact under physiological conditions. 
4.1.1.4 Interacting domains in PCNA 
To identify a domain or stretch of amino acid that would confer AID binding in the 
PCNA protein, a truncation series of FLAG-PCNA (Figure 20 A) was generated. Using  
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Figure 19. Endogenous interaction of PCNA and AID in B cells. 
  
A, FLAG-IP samples from control cells (DT40 parental wt strain), DT40 AID-3FM and 
DT40 AID-3F are run on a western blot and probed with an anti-FLAG or an anti-
PCNA antibody. B, Expression levels of PCNA in the lysates. Western blots probed 
with an anti-PCNA antibody and with an anti-tubulin antibody (loading control). 
 
 
the above described 293 expression and luciferase assay system, a decrease in AID 
binding to PCNA with C terminal truncations near the critical residue K164 in PCNA 
could be identified (Figure 20 A). This suggests a C- terminal AID interacting domain 
on PCNA. Because of the strong structural requirements for PCNA trimerisation and 
function, further truncations may create an artificial situation and are likely to corrupt 
protein structure. This led me to test a small number of PCNA point mutations, located 
within the potential region of interaction (Figure 20 B). Please refer to Appendix Figure 
31 for the localisation of all mutants and residues of interest in a 3 dimensional model 
of human PCNA. 
The point mutant plasmids were constructed using the E. coli co-expression vectors as 
in Figure 17. Mutants were expressed together with AID, then anti-AID IP was 
performed and co-IP monitored. To ensure western blot signals were linear, the LICOR 
Odyssey system based on infrared signal emitting secondary antibodies was used. A 
reduced affinity to AID of the tested PCNA mutants could not be observed when 
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Figure 20. AID interacts with the C-terminal part of PCNA. 
 
A, Summary of luciferase interaction assay data showing the region of PCNA required 
for interaction with AID. FLAG-PCNA full length and truncations and RL-AID were 
transfected into 293 cells. Binding was analysed as in Figure 18. At least 2 experiments 
were used. B, Localisation of the point mutants in PCNA tested for interaction using the 
E. coli assay. Mutations are indicated by amino acid abbreviations. Mutant 66-72 is a 5 
amino acid mutant converting the indicated stretch of the protein into the Xenopus 
laevis homologue sequence. C, Test for loss of interaction between AID and PCNA 
point mutants. An assay as described in Figure 17 was used. The respective wild type 
control is shown for each mutant IP. 
 
compared to the wild type control (Figure 20 C), even when higher stringency (high 
salt) washes were employed (data not shown). These data identify no single amino acid 
to confer PCNA binding to AID, though most likely the interaction domain lies close to 
the site of modification on PCNA (K164) towards the C-terminus. 
4.1.1.5 Interacting domains in AID 
A similar approach was taken to identify PCNA binding domains in AID. The AID 
crystal structure has not been solved, possibly a consequence of the protein’s tendency 
for insolubility and domain instability (SPM lab members, personal communication). 
However, several AID domains have been functionally characterised, and we noticed a 
motif reminiscent of a PIP (PCNA interacting peptide) box near aa 135 (Figure 21 A). 
Therefore, a truncation series of AID was generated and tested for PCNA interaction 
using the RL-AID 293T overexpression system described above.  
The summary of these results can be viewed in Figure 21 B; each truncation was tested 
at least 3 times. Using truncations from the N terminus and C terminus of RL-AID, no 
single stretch of amino acids was identified that conferred PCNA binding, as more than 
one region of AID could mediate residual association. Deletions at the N terminus of 
AID indicated that the PCNA AID interaction could be placed between aa 120-140, 
whereas deletions from the C terminus identified a second binding region throughout 
the N terminus up to aa 80, with a minor loss of binding when deleting aa 80 - 130, 
supporting the C-terminal deletions.  
To investigate binding domains further, a different approach was used in order to 
address the mentioned structural caveats of truncation studies. Previously described 
chimeric GFP tagged AID derived proteins were utilised. These chimeras were  
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Figure 21. AID interacts with PCNA via multiple domains. 
 
A, The putative PIP box in the AID protein. The consensus sequence of a PIP box after 
(Xu et al., 2001) is shown highlighted in red. The reminiscing motif in human AID is 
depicted for comparison. B, Luciferase Interaction Assay data showing AID truncations 
binding to PCNA. The data represents the summary from at least 3 independent 
transfections. RL-AID fusion truncations were transfected as in Figure 18, and 
endogenous PCNA was immunoprecipitated with anti-PCNA antibody (PC10). 
Luciferase activity was determined from the input and the bound fraction, and the ratio 
was used to judge binding efficiency. C, PCNA binding of AID-APOBEC2 chimeras. 
293T cells were transfected with GFP-chimeras 1-4, GFP-AID (wt) and GFP-
APOBEC2, together with FLAG-PCNA. Chimera protein expression levels were 
adjusted to equal levels prior to IP with a rabbit polyclonal anti-GFP antibody. IP’s 
were analysed by western blot, detecting PCNA with an anti-FLAG antibody and GFP 
fusion proteins with a mouse monoclonal anti-GFP antibody. 
 
(In collaboration with Maria Simon and Heather Coker) 
 
comprised of APOBEC2 (a DNA deaminase family protein without DNA deaminase 
activity) portions and AID portions (Conticello et al., 2008). The chimeras have been 
used to characterise other AID interacting proteins (Conticello et al., 2008, Patenaude et 
al., 2009). This system allowed for individual parts of AID to be replaced by the 
corresponding APOBEC2 peptides, potentially without structural loss, and tested for 
interaction (Figure 21 C). The control (full length APOBEC2-GFP) is not able to bind 
PCNA (Figure 21 C). The data show that replacing the N terminus proximal amino 
acids 19-58 (Chimera 1) as well as amino acids 118-150 (Chimera 4) of AID with 
APOBEC2 peptides reduced AID-PCNA interaction, highlighting similar regions for 
interaction as the truncation experiments (Figure 21 C) 
In conclusion, these data establish that AID interacts with PCNA through multiple 
domains, possibly through two linear epitopes or through a specific three-dimensional 
conformation. The cryptic PIP box in AID may contribute to PCNA binding, but is 
certainly not the only region involved in the interaction. A range of PCNA binding 
proteins have been identified that also rely on contacting PCNA additionally via 
peptides outside the PIP box (Bruning and Shamoo, 2004). 
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Figure 22. Influence of the presence of soluble PCNA on AID activity  
 
A, Schematic of the in vitro AID oligonucleotide deamination assay (ODA). A 
biotinylated and fluorescein-conjugated single-stranded oligonucleotide containing an 
AID hotspot motif is incubated with AID and purified using the biotin label. This is 
followed by processing with UDG/endonucleases, with the resulting products visualised 
and quantified on Urea-PAGE. B, Presence of increasing amounts of PCNA does not 
alter AID oligonucleotide conversion. 2.5 pmol DNA were incubated for 15 min with 
~1pmol of active AID yielding between 38% and 31% conversion (lanes 2 and 10). An 
increasing amount of PCNA was added (3, 9, 18, 36, 72, 144 pmols in lanes 3, 4, 5, 6, 
7, 8, 9, respectively). Representative experiment. 
 
4.1.1 Does PCNA influence AID’s catalytic activity? 
Several PCNA interacting enzymes have been shown to be stimulated by PCNA, e.g. 
DNA polymerases (Bambara and Jessee, 1991, Prelich et al., 1987, Tan et al., 1986), 
APE2 (Unk et al., 2002), FEN1 (Li et al., 1995, Wu et al., 1996) and DNMT1 (Iida et 
al., 2002). To test weather the presence of PCNA could influence the enzymatic activity 
of AID, we utilised our in vitro AID activity assay (Coker et al., 2006, Petersen-Mahrt 
and Neuberger, 2003), also known as oligonucleotide deamination assay (ODA). As 
outlined in Figure 22 A, 1 pmol of active AID is incubated with 2.5 pmol of a 
biotinylated and fluorescein-conjugated single-stranded oligonucleotide, which contains 
a cytosine in the context of the preferred AID sequence (AGC) (Beale et al., 2004, 
Morgan et al., 2004). After deamination, the uracil containing oligonucleotide is 
purified using biotin-streptavidin binding to magnetic beads. This is followed by 
incubation of the immobilised oligonucleotide with commercial UDG enzyme, which 
also contains low levels of endonucleases that cleave the abasic sites generated by 
UDG. The resulting products are separated by denaturing Urea-PAGE and visualised 
using a fluorescence scanner. The ratio of cleaved to non-cleaved product is quantified  
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Figure 23. Description of oligonucleotide 5022. 
 
A, Sequence of the oligonucleotide 5022 used for the loaded PCNA assay and its 
features. “BIO” represents a biotin label, “FITC” represents a fluorescein label, “X” 
represents a digoxygenin labelled nucleotide, highlighted in red is the AID hotspot 
motif and highlighted in green is the double stranded portion. B, Schematic of the 
oligonucleotide 5022. C, Testing deamination of the oligonucleotide 5022 in the 
standard ODA. The single stranded form of 5022 is used together with the standard 
oligonucleotide (163) as a control in an assay as described in Figure 22 A. 5022 is heat 
denatured before the AID reaction as in the standard assay in lanes 7 and 8, while this 
step has been omitted in lanes 5 and 6. 
 
and the per cent conversion calculated. Figure 22 B shows the deamination reaction of 
AID without PCNA, and with increasing concentrations of PCNA present at the time of 
deamination. The presence of soluble PCNA does not have a positive, or negative, 
effect on the ability of AID to deaminate cytosines in this ODA (Figure 22 B). This 
result was confirmed with a different batch of purified AID (data not shown), as well as 
with lower AID levels to ensure that a stimulatory effect was not concealed by 
saturation kinetics. It is assumed that most of the PCNA present in the experiment 
shown in Figure 22 is in solution. Although it has been suggested that PCNA can load 
onto linear DNA substrate by diffusion, this process is inefficient and requires high 
concentrations of PCNA (Burgers and Yoder, 1993). The clamp loader RFC actively 
loads PCNA onto DNA in an ATP dependent manner so that the toroid will encircle 
DNA (Tsurimoto and Stillman, 1989, Tsurimoto and Stillman, 1991). Because some  
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Figure 24. Influence of the presence of loaded PCNA on AID activity.  
 
A, Outline of the modified in vitro AID oligonucleotide deamination assay. A 
biotinylated and fluorescein-conjugated oligonucleotide containing an AID hotspot 
motif, dsDNA portion and digoxygenin is bound to a biotinylated plate and subject to 
incubation with PCNA, RFC, ATP, AID and UNG. As before, products can be 
visualised on Urea-PAGE. B, RFC dependent immobilisation of PCNA on assay plates. 
With this method, up to 150 fmol PCNA can be bound to each assay well. Anti-PCNA 
western blot analysing input and assay wells with or without RFC. C, Presence of 
loaded PCNA does not alter AID oligonucleotide conversion. Each well was incubated 
with ~4 pmol of active AID.  
 
enzymes are stimulated specifically when PCNA encircles DNA (Ducoux et al., 2001, 
Gomes and Burgers, 2000, Li et al., 1995, Tom et al., 2000, Tom et al., 2001), I wanted 
to tested if DNA bound PCNA would alter AID activity. To this end, the standard ODA 
was modified to include a digoxygenin label in the oligonucleotide in order to bind a 
bulky anti-digoxygenin antibody to its terminus. This was to ensure that during the 
reaction, loaded PCNA would not slide off the DNA. As RFC loads PCNA preferably 
to boundaries between single stranded and double stranded PCNA (Tsurimoto and 
Stillman, 1990), the oligonucleotide was long enough to accommodate a double 
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stranded portion. The sequence of the used oligonucleotide (5022) can be viewed in 
Figure 23 A, and a schematised depiction in Figure 23 B. The oligonucleotide can be 
deaminated by purified AID using the standard ODA, albeit at a lower efficiency 
(Figure 23 C, lanes 4 versus 7 and 8). This efficiency is further reduced when the 
normal denaturation step preceding the AID reaction is omitted (lanes 5&6 versus 
7&8). This was tested because the hybridised form of the oligonucleotide will not allow 
this step in the modified assay. Streptavidin coated plates were used to immobilise 
PCNA on biotin containing oligonucleotides (Figure 24 A). First, streptavidin plates 
were coated with oligonucleotide 5022. Next, PCNA was immobilised to DNA using 
RFC (Figure 24 B) by applying three consecutive rounds of a loading mix [recombinant 
human PCNA, ATP and recombinant yeast RFC complex (J. Parker, CRUK)] to the 
DNA coated plates. This resulted in a typical yield of 10-150 fmol immobilised PCNA 
per well, showing that the basic steps of the assay are working as well as that yeast RFC 
is able to load human PCNA. The DNA-protein complexes were incubated with AID, 
followed by a UDG reaction. As the results in Figure 24 C show, loaded PCNA 
(dependent on RFC), does not have a stimulatory effect on AID activity. A weak 
inhibitory effect is possible, but could not be shown to a sufficient resolution. Such an 
inhibitory effect can be readily explained with PCNA occupying AID hotspot motifs. 
Limitations of this assay are the level of efficiency of oligonucleotide conversion by the 
end of the procedure that does not resolve small changes well, as well as the small 
amount of loaded PCNA in the reaction (up to 150 fmol PCNA on up to 2.5 pmol DNA 
= 5%). Nevertheless, these preliminary data support that AID activity is not stimulated 
by PCNA in the configuration that was tested. 
4.1.2 AID can interfere with PCNA modification 
As there was no indication that PCNA could influence AID in vitro, we wanted to test if 
the opposite –AID altering PCNA function- was the case, as it is conceivable that AID 
is needed for regulation or recruitment of DNA repair at AID lesions.  
PCNA’s functions in DNA repair are regulated by post-translational modifications. 
AID’s interaction with PCNA lies near K164, the site for ubiquitination and 
sumoylation. Because of this, it was established, initially in vitro, if AID had a 
functional role in influencing these post-translational modifications on PCNA. An in 
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vitro mono-ubiquitination assay was used, based on commercially available purified 
components of the ubiquitination machinery. This allowed the monitoring of PCNA 
ubiquitination via western blotting as a slower migrating band. First, a number of 
provided E2 ubiquitin-conjugating enzymes were tested for their ability to ubiquitinate 
purified human PCNA in vitro, with UBC5B and UBC5C acting on PCNA (Figure 25 
A). Subsequently, AID protein was added at near stochiometric amounts to PCNA in 
the reaction, which contained UBC5B as well as E1 activating enzyme, ATP and free 
ubiquitin. Via western blotting, PCNA modification was monitored by observing a 
higher molecular weight PCNA band (Figure 25 B). Using APOBEC2 as a control 
protein, the data show that recombinant AID represses in vitro ubiquitination of PCNA, 
possibly by directly binding the substrate PCNA.  
To monitor if AID could also inhibit modification of K164 PCNA in a cell-based assay, 
PCNA and AID were co-transfected into an E. coli sumoylation system (Lyst et al., 
2006, Mencia and de Lorenzo, 2004). Here, E1 and E2 enzymes as well as his-tagged 
SUMO I were transfected into a host E. coli together with the PCNA and AID 
expression vectors. Again, western blot analysis showed that PCNA was readily 
sumoylated in the presence of E2 conjugating enzyme in this E. coli system (Figure 25 
C). Monitoring the sumoylation of PCNA over time in the presence or absence of AID 
demonstrated that even in the context of a cell, AID is able to inhibit PCNA K164 
modification (Figure 25 C). 
In conclusion, inhibition of modification of PCNA by AID is likely to be relevant to the 
biological function of the PCNA-AID interaction. 
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Figure 25. AID inhibits modifications of PCNA. 
 
A, In vitro monoubiquitination of PCNA by various E2 conjugating enzymes. Purified 
human PCNA is in vitro ubiquitinated in the presence or absence of 11 different E2 
conjugating enzymes. Reactions were incubated for 90 min at 37 ˚C and higher 
molecular (modified) PCNA was detected via western blotting. B, AID reduces the in 
vitro ubiquitination of PCNA by Ubc5b. Purified PCNA (or PCNA K164A) was subject 
to ubiquitination in the presence of purified APO2 or AID protein. C, AID inhibits 
PCNA sumoylation in an E. Coli expression system. Sumoylation of PCNA was 
induced by co-expressing PCNA, SUMO I and the E1/E2 enzymes in bacteria. The 
effect of AID expression on PCNA sumoylation was assessed by co-transfecting the 
expression vector for AID (pTrc-AID) or the empty vector (pTrc) as a control. Cells 
were induced for the time period indicated. Subsequently the culture was centrifuged, 
resuspended and gel separated. Blots were probed with an anti-AID antibody, an anti-
His-tag-HRP antibody for E2 detection or with an anti-PCNA antibody.  
 
(In collaboration with Maria Simon and Don-Marc Franchini)  
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Chapter 5.  Discussion 
AID and its biological functions has continuously surprised researchers from the 
moment of its discovery. Starting from the early assumption that this small enzyme was 
a simple RNA editing molecule, it was discovered that it actively mutated DNA, that it 
is highly regulated, and that its function is interlinked with many DNA associated 
pathways, and even plays an important role outside the immune system in epigenetic 
reprogramming. Yet one of the most intriguing question remains unanswered: How is 
AID targeted to induce DNA alterations at specific loci, and restricted from others? In 
particular, which role do transcriptional targeting and differential lesion resolution play 
in these varying outcomes? Although progress has been made (Odegard and Schatz, 
2006), additional work is required for the years to come. 
Therefore, to understand AID biology one needs to understand the co-factors of AID 
that will regulate and modulate its targeting, its activity, and its lesion resolution.  
For these reasons, I set out to identify and characterise interacting partners of AID. 
5.1 Aim I  
In Aim I I pursued a currently emerging connection between AID and the transcription 
machinery, by identification and analysis of chromatin associated AID cofactors.  
As highlighted in the introduction, transcription has long been associated with AID-
induced immune diversification. Recent findings support the importance of transcription 
elongation and associated processes for AID targeting. Furthermore, chromatin marks 
seem to be factors that influence AID targeting, activity and lesion resolution, either 
directly or indirectly.  
5.1.1 A novel biochemical study of AID on chromatin 
This study was undertaken in order to analyse chromatin bound AID in an unbiased 
way. Interaction studies in this particular fraction can be seen as a survey of proteins 
that AID associates with on DNA, the place of most interest for studying biological 
AID function. 
This allowed for the first time identification and characterisation of proteins that are 
associated with AID on chromatin in their physiological environment. The method had 
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two key properties: One, the endogenous AID protein was tagged with a FLAG epitope, 
and secondly, we adapted a recently developed method for specific isolation of 
chromatin bound protein-complexes (Aygun et al., 2008).  
The chromatin AID-interactome consisted of RNAPII core and associated proteins, 
splicing factors, RNA helicases, chromatin modifiers and RNAPII elongation 
complexes. Furthermore, the factors/complexes FACT, SUPT5H, PAF and SUPT6H 
were identified, which have been implicated in AID function by us and others. 
The exceptionally high occurrence of factors in our analysis that form part of the same 
interaction network (RNAPII elongation), even from the same complex (PAF complex), 
indicates that biologically meaningful associations have been retrieved. 
This tight concordance of having validated work of others as well as identified a major 
complex, led me to confirm and validated the initial results via biochemical and 
functional assays. I focused on the PAF complex, a novel AID interacting factor that 
has several functional and physical connections to RNAPII and its associated factors (as 
described in the introduction). The PAF complex plays a central role in transcriptional 
control, and serves as a molecular link between early transcription elongation, as 
marked by pausing factor DSIF (SUPT5H and SUPT4H), and downstream extended 
chromatin elongation modifications dependent on FACT (SSRP1 and SUPT16H) and 
SUPT6H. Identification of SUPT6H as an AID associated protein in our study supports 
previous findings (Okazaki et al., 2011), as well as the recent discovery that the 
exosome processing machinery is important for CSR (Basu et al., 2011), because 
SUPT6H has been shown to co-purify with the exosome (Andrulis et al., 2002).  
5.1.1.1 Function-specific AID associations 
The AID complex interactions were isolated from DT40 cells, which undergo iGC but 
do not undergo CSR. Although previous work excluded SUPT6H from a function in 
SHM (Okazaki et al., 2011), the biochemical findings in my study place SUPT6H with 
V region diversification complexes. This difference may be due to AID overexpression 
in the system used in (Okazaki et al., 2011). However, the biochemical association in 
DT40 and the requirement during CSR would argue for a general importance of the 
complex regardless of cellular function. To further test this hypothesis and extend it to 
other elongation factors (especially the PAF complex), respective knock-down or 
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knock-out populations of DT40 and/or other hypermutating cell lines should be assayed 
for AID dependent diversification.  
Another approach to examine CSR versus SHM specific cofactors of AID is to take 
advantage of the C-terminus of AID and its importance for CSR (Barreto et al., 2003, 
Ta et al., 2003). Thus, a C-terminal deletion mutant of AID could be used to identify 
CSR specific interaction partners of AID, as well as identify factors for V region 
diversification, or those that are shared. For these reasons, I generated DT40 cell lines 
that lack the last 10 amino acids of AID (AIDΔC), the region responsible for CSR 
specificity and nuclear export, yet contain the same peptide tags as the described wt 
tagged AID lines (see Appendix 6.1.1). Surprisingly, the AIDΔC mutants shows no 
accumulation of nuclear AID as predicted from similar mutants in fibroblasts (Ito et al., 
2004, McBride et al., 2004), and additionally shows overall reduced AID levels (see 
Appendix Figure 28). Although there is some uncertainty about the unexpected 
phenotype of the truncation mutant in DT40, a novel tool was generated that is bound to 
help to dissect if different subpopulations of AID form different functional complexes. 
5.1.1.2 Biochemical characterisation of AID chromatin associations 
Protein-protein interactions can vary in strength ranging from loose associations to tight 
partners. Although we have been able to identify a specific, direct interaction of AID 
with PAF1 in vitro, the kinetics of the interaction still need to be determined in vivo. 
Our mass spectrometry analysis, as well as indications from other laboratories, have 
identified a large number of possible AID interacting proteins (see Introduction). So far, 
AID seems to prefer weak interactions, and many of the reported interactions could not 
be found in our mass spectrometry analysis, including PCNA. Each of these factors may 
require individual purification conditions. Others have found weak interactions for AID, 
such as in the case of SUPT5H (Pavri et al., 2010). In my hands, this interaction could 
barely be detected in the in vitro E. coli system, although I may have been using a more 
stringent isolation method. Considering the small size of AID and its multiple 
regulatory steps, it is likely that AID will have a number of associated 
proteins/complexes within the cell, possibly some of them serving as adapters for AID 
subpathways, rather than specific tight partner interactions. The 200 kDa complex that 
AID was found to reside in represents the main form of chromatin AID in B cells, but it 
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remains to be determined if this is the active form of chromatin AID, and if this 
complex is one homogenous species. Several subunits of the PAF complex (PAF1, 
CTR9 and CDC73), partially overlap with the 200 kDa AID complex, thus AID 
associating with one or more subunits of the complex would be consistent with the data. 
Most likely PAF1 participates in this complex. However, it is likely that the complex 
has further components that associate directly or indirectly with AID, e.g. from amongst 
our mass spectrometry identified associations. Because AID would engage in several 
processes in the nucleus (sequestering, transport, targeting and recruitment) it would 
have to be able to switch partners easily. By interacting with several partners of a 
specific cellular process (e.g. of the RNAPII machinery), tethering to this process may 
be reinforced and seems to predominate on chromatin. Associations could be mediated 
through AID’s hydrophobic sequence and/or its interaction with RNA (Bransteitter et 
al., 2003, Nonaka et al., 2009).  
The difficulties in purifying AID in a stringent manner as a homogenous population 
with few specific, tight interaction partners may lead to identification of artificial 
interactions if not validation properly. Therefore, my work ensured a specific isolation 
method combined with verification under physiological conditions. 
5.1.2 The PAF complex and its interaction with AID 
The direct interaction with PAF1 and specific effect on CSR by leo1 knockdown, could 
be due to direct as well as indirect effects. The somewhat surprising finding that even 
moderate knock-down of the transcripts of the PAF complex members had a substantial 
effect on CSR could be partially explained by interference with transcription of Ig or 
aid. However, another explanation would be a destabilisation of the PAF complex when 
one subunit is depleted, as it has been observed in HeLa cells when knocking down ctr9 
or ski8 by RNAi. Not only levels of the target protein decreased, but also protein levels 
of other subunits of the PAF complex (Zhu et al., 2005). Another conceivable scenario 
explaining the loss of transcription at Ig, for instance upon paf1 knock-down (3.1.4, 
Figure 16), comprises a direct effect on transcription by AID. One could envision not 
only facilitation of AID deamination by PAF, but also recruitment of efficient 
elongation to Ig via the AID-PAF1 interaction, thus rendering AID a “transcription 
factor” (from discussions with K. Schmitz and S. Petersen-Mahrt, IFOM Milan).  
Chapter 5. Discussion 
 108 
For further experiments using the shRNA system, it would be desirable to improve the 
knock-down efficiency. One way to achieve this would be to select retrovirally infected 
CH12 populations not by puromycin resistance but flow cytometry. Hereby, shRNAs 
should be cloned into a retroviral vector such as pLMP, which carries a co-expressing 
GFP marker. Disadvantages of puromycine selection are the requirement of a selection 
over several days potentially resulting in stressed cells or incomplete selection. This can 
be overcome by selecting highly fluorescent clones early after transduction, likely to 
produce more shRNA molecules. Once these problems are solved, a number of 
questions can be addressed: To examine the specific role of the PAF complex in B cells, 
levels of potentially affected histone modifications in PAF complex knock-down 
populations could be monitored, specifically, it would be interesting to confirm the role 
of the PAF complex in H3K4 trimethylation, [although in mammals there are redundant 
pathways that can set this mark on chromatin (Shilatifard, 2008)]. The role of the PAF 
complex in H3K36 trimethylation could also be addressed, as in mammals, it is still 
unknown if there is a dependency of this mark on the PAF complex and H2B 
monoubiquitination (Newey et al., 2009). Apart from monitoring global changes in 
histone modification patterns in knock-down cells, changes of local histone 
modification and transcription machinery composition could be addressed in more 
detail on single genes, whereby the Ig loci evidently will be of special interest. Firstly, it 
would be important to map a distribution of the PAF complex in relation to AID, 
SUPT5H and RNAPII by ChIP along the Ig loci in normal cells and cells inducing class 
switching. On the other hand, PAF complex knock-down populations could be valuable 
to shed light on further details such as the occupancy of histone modifications 
implicated in AID dependent processes. Apart from this, occupancy of RNAPII, 
associated elongation factors such as FACT, SUPT6H, SUPT5H, and AID can be 
addressed in dependence of the presence of the PAF complex. As a caveat, successful 
AID ChIP experiments in the past have been scarce, possibly due to lack of ChIP grade 
antibody for AID. Difficulties are illustrated by a recent genome wide study (Yamane et 
al., 2011), where background had to be controlled for by including AID knock-out ChIP 
data in the analysis. 
Biochemically, PAF knock-down may alter the size of the AID complex as well as the 
PAF complex, which could be analysed by size exclusion chromatography of chromatin 
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fraction in knock-down cells. However, this experiment may be restricted by the 
number of cells needed. Changes to the complexes analysed in wt DT40 cells (3.1.2 
Figure 10) may be expected upon knock-down, if a substantial amount of the observed 
AID complex contains PAF1 and/or the PAF complex. As for the PAF complex itself, a 
destabilisation when knocking down one subunit is likely (Zhu et al., 2005). 
In summary, this work demonstrates the involvement of the PAF complex in AID 
dependent processes, most likely through a direct interaction between AID and PAF1. 
The data described in this study extends the current model of AID gaining access to 
DNA by stalled RNA polymerase to a more complex model, where AID is intimately 
and specifically linked with RNAPII while pausing, restarting and elongating, requiring 
the correct chromatin environment defined by histone modification cascades.  
The PAF complex has many roles in transcription, including elongation activation, 
chromatin regulation and mRNA biogenesis. In yeast, the PAF complex is nonessential 
and only a subset of genes may be affected by PAF complex absence, whereas in 
vertebrates, the PAF complex is essential (Wang et al., 2008). Mouse mutants of the 
oncogene an tumour suppressor gene cdc73 are embryonic lethal as PAF controls many 
developmental processes in mammals (reviewed in Newey et al., 2009). Therefore, a 
study of a specific effect of PAF complex knock-out on B cells in vivo would require a 
conditional knock-out mouse model. 
5.1.3 RNAPII pausing and elongation to enhance AID activity 
A model for AID recruitment to active transcription requires a landing platform, e.g. 
SUPT5H associated with a paused or stalled RNAPII complex, on which a mutasome 
containing AID and the PAF complex could land. While on the chromatin, the FACT 
complex, SUPT6H and exosome complex associate with AID, modify the local 
chromatin structure, and allow for AID to gain access to ssDNA during RNAPII 
transcription and mRNA biogenesis (Figure 26).  
Mutations at the Ig locus start 50-150 bp after the TSS, and end after 1.5 - 2.0 kb. As 
laid out below, my work provides further insight into the establishment of the AID 
dependent mutation domain (5’ boundary), while the understanding of molecular 
mechanism for the 3’ boundary remains less clear. 
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5.1.3.1 AID recruitment by paused RNAPII and the roles of SUPT5H and 
PAF 
In general, SUPT5H associates with pausing polymerases, while the presence of the 
PAF complex is required for a processively elongating polymerase (usually after restart 
of promoter proximal pausing) (Chen et al., 2009). Although a direct binding of AID to 
PAF1 was shown in this study, it is not clear if this interaction is for targeting AID to 
the paused polymerase or for retention of AID during elongation. There are several 
possibilities of how AID associates with RNAPII: First, loading could occur during 
formation of the initiation complex. This is substantiated, as in higher vertebrates, PAF 
complex has been shown to bind to RNAPII along the entirety of the gene (Kim et al., 
2010, Zhu et al., 2005). AID may only gain access to ssDNA by promoter-proximal 
pausing and elongation, requiring a form of pausing throughout the transcription 
elongation process. Secondly, AID could be loaded at pausing sites and immediately be 
active on its substrate, while staying associated with polymerase throughout the targeted 
region. Finally, AID could associate and dissociate with pausing polymerase throughout 
the Ig gene. Fixation of mutations could be regulated on the level of subsequent steps 
that involve repair proteins (see below). Recent genome wide ChIP data for AID in B 
cells (Yamane et al., 2011) indicates that AID co-localises with polymerase along the Ig 
gene, supporting AID being present throughout transcription from an early stage on. 
Interestingly, recent work identified the PAF complex to have a synergistic function 
with SUPT5H in negatively regulating zebrafish blood developmental genes (Bai et al., 
2010). Here, the PAF complex acts as a negative factor for RNAPII elongation, i.e. PAF 
can be a stalling factor. Furthermore, the Ig genes are rich in associated polymerase 
uniformly, unlike a classical promoter proximal stalled gene (Rahl et al., 2010, 
Zeitlinger et al., 2007), which has a pronounced peak at the TSS accompanied by less 
detectable RNAPII within the transcription unit (Pavri et al., 2010, Yamane et al., 
2011). Although from these profiles one cannot conclude at which rate RNAPII moves 
on Ig, efficient elongation does not seem to take place, as in this case RNAPII detection 
levels would be lower. Instead, impaired elongation and polymerase accumulation 
would fit the current data (Rajagopal et al., 2009, Raschke et al., 1999, Wang et al., 
2009). Taken together, these data indicate, that AID enters the RNAPII complex early 
via the PAF1 complex and exerts its function with the help of constant transcriptional 
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Figure 26. Model of elongation factors associated with AID during Ig gene 
transcription.  
 
A, Promoter-proximal pausing mediated by SUPT5H is attributed to AID targeted 
genes. AID and PAF complex may associate with polymerase at this stage. B, Two 
alternatives of the RNAPII configuration that is potentially required for AID 
recruitment or activation. Scenario 1) stalled elongation;  2) processive elongation.  
 
pausing mediated, amongst others, by SUPT5H (Figure 26 B). Further Ig gene ChIP and 
biochemical studies will elucidate the significance of these relationships. Importantly, it 
is unlikely that the exact molecular mechanisms for AID targeting and efficiency will 
be delineated from studies on genome wide associations. Dissection of a unique protein 
and chromatin composition at the Ig locus will be more informative, and may lead to 
understand how mistargeted genes recapitulate mutation.  
Biochemically, in vitro transcription reconstitution experiments mediating AID 
deamination in the context of a eukaryotic RNAPII transcription bubble could enhance 
our understanding of the molecular mechanisms at AID targets. As can be seen in the 
Appendix (6.1.3) I have made progress towards the setup of such an in vitro system that 
merits further investigation (Appendix Figure 30). Here, RNA elongation competent 
transcription bubbles were reconstituted in vitro using purified DNA, RNA and 
eukaryotic RNAPII components. These complexes can be exposed to AID while 
transcription or transcriptional arrest is taking place to draw biochemical conclusions 
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about co-transcriptional accessibility of cytosines for AID. Subsequently, purified 
transcription elongation factors could be added to the reactions to delineate the optimal 
transcription elongation complex composition for AID. 
5.1.3.2 Chromatin environment 
During transcription coupled AID processes at AID targeted loci, the chromatin 
environment as shaped by the PAF complex, as well as downstream influence of AID 
on the resolution pathways will be of importance. An Ig locus specific RNAPII 
elongation complex (including SUPT5H, AID and the PAF complex) could establish a 
defined set of marks in order to promote mutability at this locus, e.g. by enhancing 
repeated pausing and re-start, thereby providing optimal substrate accessibility for AID. 
As described, during transcription the PAF complex helps set the right co-
transcriptional chromatin marks, serving as docking platform for the H2B ubiquitination 
machinery, as well as for setting the mark H3K4 trimethylation (Jaehning, 2010). As 
described, H3K4 trimethylation serves as an important mark in CSR (Stanlie et al., 
2010, Wang et al., 2009), but is generally restricted to the 5’ end of a gene, and replaced 
by H3K36 trimethylation towards the 3’ end of the gene. In a recent ChIP study 
(Yamane et al., 2011), AID was genome-wide associated with regions marked by H3K4 
trimethylation (as well as other marks for open chromatin), but much less so with 
H3K36 trimethylation marks. Importantly, both these marks are induced upon 
transcriptional activation of S-regions at the Ig locus (Wang et al., 2009), but the H3K4 
trimethylation domain is extended, while onset of the H3K36 trimethylation mark is 
pushed back towards the 3’ end. This correlates roughly with the cease of mutational 
load/AID activity (Wang et al., 2009). If H3K36 is either a prerequisite or an indicator 
of efficient elongation in the body of the gene, it is not surprising that it would be 
excluded from the mutated part of Ig where pausing is predominant. The PAF complex 
could help establish this particular distribution, as its role in H3K4 trimethylation in 
higher eukaryotes is well established and at least in yeast, a connection to H3K36 
trimethylation has been documented. Past work has implicated histone modification 
during SHM, but much less is known about epigenetic requirements for SHM than for 
CSR. However, the isolation of most of the required components for setting the H3K4 
trimethylation mark during transcription from DT40 would imply a similar requirement 
during V region diversification such as SHM.  
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5.1.3.3 The influence of RNAPII pausing on downstream resolution 
pathways 
Furthermore, RNAPII pausing may have a dual function, first for AID loading, and 
second, it may enhance AID’s resident time at the target locus. The extent of RNAPII 
pausing may allow for AID to recruit DNA repair factors outside their normal 
physiological pathway to enhance the mutability at the target locus. Recent observations 
in our lab show that to enhance its effect on DNA alterations, AID needs to recruit 
DNA repair factors to its own lesion (Franchini et al., submitted see discussion for Aim 
II). This could be a means by which the AID-induced uracils become mutagenic, 
considering an excess load of thousands of spontaneous dUs that the genome suffers 
daily (Lindahl, 1993), but that are repaired error-free. Supporting this is the observation 
that some loci, after AID targeting, are more efficiently repaired than others (Liu et al., 
2008). It is therefore possible that there is a link between enhanced RNAPII pausing 
and regulation of AID lesion resolution. Those loci that are deaminated by AID but 
repaired efficiently (Liu et al., 2008) may have AID loaded during elongation but may 
be missing ‘extra’ pausing for DNA repair pathway channelling steps. AID’s universal 
presence near promoters (Pavri et al., 2010, Yamane et al., 2011) may only become 
mutagenic if AID can recruit or alter DNA repair factors. This hypothesis is 
substantiated by this thesis work, showing that AID binds the DNA damage response 
protein PCNA in B cells, potentially altering DNA repair pathway choice upon lesion 
recognition (discussed below, Figure 27). If AID needs to stay close to its lesion in 
order to influence downstream processing, the model of a tight association of AID on 
chromatin during transcription would be supported, as opposed to a continuous 
dissociation and association model.  
5.1.4 Conclusion 
This work has provided biochemical and genetic insight into understanding the 
targeting of AID to the Ig locus. The approach to isolate physiological AID containing 
protein complexes only from chromatin has identified a novel component, the PAF 
complex, as well as verified the significance of previously identified factors (SUPT5H, 
SUPT6H, and FACT) in AID biology. Furthermore, the data described here extends the 
current model of AID gaining access to DNA by stalled RNA polymerase to a more 
complex model, where AID is intimately and specifically linked with RNAPII in the 
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phase of pausing and elongation, requiring the correct chromatin environment defined 
by histone modification cascades. Future work will build on these discoveries to define 
AID targeting further. Interestingly, the finding that AID interacts with PAF1 and the 
RNAPII elongation complex is reminiscent of a model put forth 15 years ago by Storb 
and colleagues, where an unknown mutator (now known to be AID) would bind to 
initiating RNAPII and travel along the machinery during transcription elongation 
(Peters and Storb, 1996). 
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5.2 Aim II 
The approach to study PCNA as a potential interacting partner for AID was based on a 
candidate approach and guided by previous knowledge on AID function and cofactors. 
In this study it was shown that AID interacts with PCNA in several systems, most likely 
in a direct manner. As AID and PCNA were shown to interact in a system that does not 
contain other eukaryotic proteins, it is doubtful that the interaction is mediated through 
RPA, a reported AID interacting protein (Chaudhuri et al., 2004) and a cofactor of 
PCNA (Davies et al., 2008, Moldovan et al., 2007). Moreover, it has been possible to 
narrow down domains of interaction within AID as well as within PCNA.  
Although only preliminary, PCNA does not seem to globally recruit AID or influence 
AID function. In a classical, as well as a newly developed ODA that enables monitoring 
AID activity on a substrate carrying loaded PCNA, AID catalysis was not stimulated by 
PCNA. Using a immunofluorescence approach, PCNA foci also don’t seem to recruit or 
tether AID (supported by preliminary experiments in Appendix Figure 28). Therefore, 
one possibility is that this interaction is of importance after AID has carried out its 
catalytical function. The kinetics of events at an AID lesion may develop in the 
following way: AID is targeted to its site of action by transcription dependent 
mechanisms, followed by recruitment of PCNA for post lesion control of resolution. 
Importantly, an inhibitory effect of AID on the ability of PCNA to be modified at 
residue K164 could be observed in two different systems. 
5.2.1 PCNA and its influence in Ig diversification 
5.2.1.1 PCNA and repair proteins in SHM 
SHM requires a DNA glycosylase for mutation generation outside phase Ia (Transitions 
at dC), as dU can be converted to an abasic site, which becomes a substrate for other 
DNA repair processes. UNG, the principal function of which is to remove dUs from the 
genome after DNA replication, is currently the only uracil dependent DNA glycosyslase 
required for SHM, as over-expression of another uracil glycosylase (SMUG1) cannot 
rescue the SHM phenotype (Di Noia and Neuberger, 2007). UNG is also the only 
glycosylase found to associate with PCNA (Moldovan et al., 2007). Hence it is possible 
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that the interaction of PCNA and AID produce a complex at the site of the lesion, and 
only PCNA interacting BER proteins are able to have access to the lesion. PCNA also 
associates directly with the MMR protein MSH2. Thus, components of both, MMR and 
BER, can be influenced by PCNA (possibly in competition). Cross-talk between both 
pathways exists in the form of nicks or abasic sites, generated by UNG as substrates for 
MMR reactions (Schanz et al., 2009). It is possible, that indirect recruitment of repair 
factors by AID through PCNA as well as repair balance shift can have a direct influence 
on Ig diversification. 
5.2.1.2 The influence of PCNA K164 on SHM 
PCNA has a role in AID dependent Ig diversification, but the details of this mechanism 
have not been fully elucidated. As mentioned in the introduction, mutational shift in Ig 
hypermutation in PCNA K164 mutants had been interpreted as inability of PCNA to 
recruit polymerase for phase II mutations (mainly at A/T). However, looking closely at 
the mutation patterns in the three systems examining the role of PCNA K164 mutations 
(Arakawa et al., 2006, Langerak et al., 2009, Langerak et al., 2007, Roa et al., 2008) 
revealed an effect on phase I of SHM. In the mutant mice, aside from the drop in 
mutations at A/T, overall mutation frequency is not (Roa et al., 2008) or weakly 
(Langerak et al., 2007) altered. Importantly, a compensatory increase of transition 
mutations at C and G bases in the transcribed strand (increased mutations at G) could be 
identified. Furthermore, despite an altered rudimentary form of SHM in DT40 (forced 
by pseudogene removal), PCNA K164 mutants retain this aspect of the phenotype 
(increased transitions at G/C) (Arakawa et al., 2006). In DT40, this is recapitulated in 
RAD18 mutants, the major ubiquitin ligase for PCNA. The knock-out cell line shows a 
similar trend in that transition mutations at C/G are enhanced. However, RAD18 is not 
the only ligase to induce PCNA ubiquitination (Simpson et al., 2006).  
This complex phenotype, including the remarkable shift in mutagenesis favouring phase 
Ia suggests that PCNA has an early role in SHM, making it a potential central protein 
for all classes of SHM mutations. 
On the other hand, TLS polymerases are not exclusively dependent on 
monoubiquitination of K164 to mediate associate with PCNA, as shown for both Rev1 
(Edmunds et al., 2008) and as Polη (Haracska et al., 2006, Nikolaishvili-Feinberg et al., 
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2008). Both in K164 mutation and in Rev1 knock-out in DT40, there is a deleterious 
effect on Rev1 dependent mutations (Rev 1 preferentially catalyses C to G and G to C 
mutations). This indicates that Rev1 may require ubiquitination of PCNA in that system 
(Arakawa et al., 2006), while in mice this dependency could not be seen, as Rev1 
specific mutations did not (Roa et al., 2008) or only slightly (Langerak et al., 2007) 
change in a PCNA K164 background. These discrepancies might be due to the different 
configuration of SHM in the two systems.  
5.2.1.3 PCNA modification and TLS in SHM 
The data in this study indicate that AID could repress PCNA ubiquitination, which 
could prevent TLS DNA polymerase association. As TLS polymerases (e.g. Rev1) also 
play a role in phase Ib of SHM in DT40 (Ross and Sale, 2006), and ubiquitination of 
PCNA enhances TLS polymerase activity (Garg and Burgers, 2005), AID’s ability to 
alter this interaction would allow for a shift in the balance between phase Ia and the 
TLS polymerase dependent phases Ib and II. If K164 modifications are repressed, the 
dU becomes a template for TLS polymerase independent phase Ia more easily. As 
replication across dU would be fixed as a mutation, whereas TLS polymerase dependent 
repair can be error free, the phase Ia pathway may operate at a higher mutagenic 
frequency than pathways relying on any repair proteins. The increase in mutations at 
G/C in the K164 phenotypes described above would support this. 
It will have to be determined in detail if AID is able to exclude specific polymerases 
from accessing dU lesions and if there could be an influence on UNG.  
The influence of AID on PCNA modifications could be investigated further in vivo. It is 
possible that an overexpression of AID could alter the overall pattern of the modified 
PCNA forms, and possibly alter the cell’s sensitivity to DNA damage by blocking 
PCNA modification.  
5.2.1.4 PCNA and SHM in the cell cycle 
The cell cycle can also influence PCNA K164 modification and with it, protein 
association. For instance, Rev1 activity that is independent of monoubiquitination of 
PCNA is thought to have a role during S phase at stalled DNA replication forks via a 
non-catalytic function (Edmunds et al., 2008). During DNA repair in G1, PCNA is 
mono-ubiqutinated at K164 by the RAD6/RAD18 damage response pathway (Hoege et 
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al., 2002). It has also been hypothesised that the different types of mutations occurring 
in SHM arise in different phases of the cell cycle (Franklin and Blanden, 2008, Liu and 
Schatz, 2009, Weill and Reynaud, 2008). UNG activity peaks at S-phase and supports 
that mutations at C/G (BER dependent) are fixed here, while MMR-like processing and 
thus mutations at A/T might be enhanced outside of S-phase (Weill and Reynaud, 
2008), or at least after passage of the replication fork (Sale et al., 2009). In (Faili et al., 
2002) it has been suggested that AID-induced lesions are generated in G1, while the 
final resolution towards mutations of phase II of SHM would occur in S-phase, but this 
hypothesis has not been proven.  
It will be interesting to determine when in the cell cycle the AID-PCNA interaction is 
most prominent. 
5.2.1.5 AID can influence the lesion resolution 
Work in our lab recently detailed the involvement of polymerase-based repair pathways 
in AID lesion resolution (Franchini et al, 2011 submitted). An in vitro system was 
developed that can reveal processing of an AID lesion using a DNA repair competent 
Xenopus laevis oocyte extract (reviewed in Garner and Costanzo, 2009). In this system 
AID is targeted to a supercoiled plasmid to induce lesions in stretches of ssDNA. When 
added to the oocyte extract, repair can be monitored by incorporation of biotinylated 
cytosine. Strikingly, if the system was supplied biotinylated adenosine instead of 
cytosine, a base that cannot be deaminated by AID, base incorporation was still 
detected. Therefore, incorporation of bases away from the original AID lesions could be 
observed (similar to phase II of SHM). This proves patch repair activity during the 
process of AID-induced lesion resolution. 
Another important observation made using this in vitro system is, that AID needs to 
stay associated with its own lesion to efficiently induce repair. If AID is removed from 
the plasmid prior to extract incubation, repair response is impaired, suggesting a repair 
recruitment function or a physical interaction with an effector protein of AID. This 
hypothetical protein has not yet been identified in this system, but may well be part of a 
PCNA complex. 
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5.2.2 AID, PCNA and DNA demethylation 
Through its interaction partners and function as a docking platform on DNA, PCNA is 
well known to also have a role in various epigenetic mechanisms. For instance, through 
interaction with the histone chaperone CAF-1, correct nucleosome placement is ensured 
during replication and NER repair (Mello and Almouzni, 2001). Another epigenetic role 
for PCNA is to maintain DNA methylation patterns. Methylation of DNA is known to 
be performed by DNA methyltransferases 1, 3a and 3b, with DNMT1 designated as a 
“maintenance” methyltransferase that can reinstate methylation status of 
hemimethylated DNA during DNA replication, as well as function in the DNA repair 
response (Chuang et al., 1997, Iida et al., 2002, Ha et al., 2011). On the other hand, 
DNA repair has been implicated to play an important role in CpG DNA demethylation 
(reviewed in Gehring et al., 2009). The molecular mechanisms of this reaction has 
remained elusive, and a variety of mechanisms for active demethylation have been 
proposed (Fritz and Papavasiliou, 2010). Although PCNA had been associated with a 
possible DNA demethylation activity (Vairapandi et al., 2000), no clear mechanistic 
link had been identified between active DNA demethylation and PCNA. As outlined in 
the introduction, recent work has indicated that some DNA demethylation is dependent 
on AID (Bhutani et al., 2010, Morgan et al., 2004, Popp et al., 2010, Rai et al., 2008). 
Interestingly, AID is active on methylated cytosines in vitro and in the oocyte extract 
repair system (Franchini et al., 2011 submitted). Here, methylated DNA substrate also 
required to retain AID in order to recruit efficient repair. Moreover, an in vivo system 
(Franchini et al., 2011 submitted) that recapitulated AID-induced DNA demethylation 
of the H19 gene was established in mice. The data suggested that AID tethered to a 
gene initiates demethylation through a processive polymerase mechanism, which is 
likely to involve PCNA. 
Demonstrating a direct link between AID and PCNA, provides a mechanism for AID-
induced local demethylation. After gaining access to the target, AID would deaminate 
cytosines or methylated cytosines in single stranded DNA. Reformation of the double 
stranded DNA and continuous association of AID with the mismatch lesion would 
allow for PCNA binding and recruitment of PCNA associated factors (e.g. UNG, 
MSH2, or EXO1). Association of other MMR factors could induce demethylation via 
processive polymerisation away from the lesion for 500 - 1500 bp (Jiricny, 2006). It still  
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Figure 27. Model of interplay between AID targeting and AID lesion resolution. 
 
AID may be targeted to RNAPII, followed by deamination and interaction with PCNA 
(blue ring), influencing downstream dU processing.  
 
needs to be determined if during AID-dependent MMR, as in normal MMR, a second 
lesion (Jiricny, 2006, Schanz et al., 2009) is needed to induce the full repair (or 
demethylation).  
5.2.3 Transcriptional pausing and AID resident time: An effect on PCNA? 
Enhanced AID resident time at the site of the lesion could facilitate assembly of a 
mutasome complex containing various DNA repair factors. As described earlier, 
RNAPII transcriptional pausing is likely to achieve this. This work introduces a novel 
player in AID dependent DNA alterations described in Chapter 3, PAF1. Interestingly, 
Rad6, the ubiquitin conjugating enzyme that is stimulated by PAF1, also functions in 
PCNA monoubiquitination.  
RNAPII pausing may have a dual function, first for AID loading, and second it may 
enhance AID’s resident time at the target locus. It is possible that enhanced RNAPII 
pausing could both enhance the ssDNA accessibility for AID (Figure 26) as well as 
cause AID to reside near its own lesion for a prolonged time and induce assembly of a 
mutasome (Figure 27). Hereby, in a yet poorly understood way, AID could influence 
the composition and activity of the mutasome complex through its interaction with 
PCNA in a modification dependent manner. 
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5.2.4 Conclusion 
The immunoglobulin loci seem to have accumulated a large number of different 
targeting mechanisms for AID as well as the correct lesion resolution machinery. 
Perhaps, these loci most efficiently combine properties that attract factors needed for 
programmed mutation, which may explain its outstanding level of targeting by the 
mutasome above all other loci. If components could accumulate dependent on AID and 
on each other, the result would be a self-amplifying system with very efficient and 
specific targeting and lesion resolution. Support for such a model comes from data that 
shows that UNG and MMR components accumulate on Ig dependent on each other and 
AID and data showing RPA accumulation on Ig. Importantly, data from this study 
highlights the importance of AID as the central mutasome protein reaching to 
interacting partners for targeting (transcription machinery) as well as lesion resolution 
(PCNA). These and the other interactions reported for AID would support a self 
accumulating system that can be mistargeted at a lower efficiency and have a slightly 
different compositions for each of the tasks AID encounters.
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Chapter 6. Appendix 
6.1 Work in progress 
6.1.1 Can AID be visualised on chromatin together with immobilised 
nuclear PCNA? 
Some of PCNA functions can be observed by imaging, as local concentrations of PCNA 
in the nucleus and immobilisation on chromatin can be detected during replication and 
upon genotoxic stress (Miura et al., 1992). Certain proteins (e.g. CAF1) that utilise 
PCNA can be visualised to colocalise with PCNA upon UV irradiation (Green and 
Almouzni, 2003). Observing physiological AID under such conditions has proven far 
more challenging, partially due to lower expression levels than PCNA and AID’s mainly 
cytoplasmic localisation. On the other hand, there are reports towards a relocalisation 
effect of DNA damage on AID (Brar et al., 2004).  
This rationale led me to test if our DT40 tagged AID tools could be utilised to probe the 
interaction of AID and PCNA and to possibly identify a function for relocalising AID. To 
this end, DT40 cells were used that carried a GFP-tagged allele of AID, analogous to 
DT40 lines described (S. Pauklin, CRUK). The cells were irradiated with UV light to 
enhance PCNA immobilisation on chromatin. To visualise chromatin bound immobilised 
PCNA (as commonly observed), triton extraction was used (Szuts and Sale, 2006), since 
omitting this step leads to a diffuse nuclear staining of PCNA (Appendix Figure 28 A). 
Without triton extraction, nuclear PCNA was detected in most cells in a non-
synchronised DT40 population, with a slight variation in intensity. The high proportion of 
stained cells could be explained by the fast growth rate of DT40 that makes the 
population rich in S-phase cells that have PCNA upregulated. The AID staining without 
triton extraction confirms AID to be localised predominantly in the cytoplasm (Rada et 
al., 2002). When staining is performed using the detergent step, soluble proteins are 
extracted from the cell structure and only proteins bound to the cell matrix remain. In 
Appendix Figure 28 B, PCNA foci can be detected inside the nucleus (red signal). It 
could not be delineated if these were replicative or damage-related concentrations of 
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Figure 28. AID does not show colocalisation with Triton insoluble PCNA foci in 
DT40. 
 
A, DT40 cells expressing endogenously GFP-tagged AID were UV irradiated and fixed, 
and without detergent extraction, immunofluorescent staining was performed using anti-
GFP and anti-PCNA antibodies. Two representative examples of stainings are shown as 
3-channel overlays (DAPI signal, blue; anti-GFP signal, green; anti-PCNA signal, red), 
together with the singled out channels in monochrome. B, DT40 cells were treated and 
stained as described in A, but with the inclusion of a Triton extraction step in the 
immunofluorescence protocol. 
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PCNA as unirradiated DT40 cells showed similar levels of PCNA foci in my hands. In 
the case of AID, nuclear staining seems to be absent after Triton extraction 
(representative cells shown from different angles), but some residual signal can be 
detected from the cytoplasmic pool of AID. This is not surprising as only an estimate of 
2% of total AID resides in the nucleus (Chapter 3). Interestingly, a cytoplasmic retention 
mechanism for AID has been invoked repeatedly (Patenaude et al., 2009, Wu et al., 
2005), and association of AID with cytoskeletal proteins such as tubulin have been 
suggested by our own and other laboratories’ mass spectrometry studies (S. Pauklin, 
CRUK; Wu et al., 2005). I could not identify significant overlay of PCNA and AID 
accumulations (Appendix Figure 28 B), as there seemed to exist no insoluble AID 
accumulations inside the nucleus under conditions that visualise PCNA foci in this 
compartment. 
In conclusion, these preliminary data show no visible recruitment of AID to PCNA foci 
under the tested conditions, but it cannot be excluded that this could take place in a 
localised manner at an undetected scale or under different stimulating conditions. 
 
Appendix 
 125 
6.1.2 An approach to analyse function-specific AID using AIDΔC mutants 
Another approach to the AID interaction project was in the context of different functions 
of AID. More specifically, during CSR, SHM, iGC or epigenetic reprogramming, the 
targeting of AID as well as the lesion resolution differs, pointing towards a differential 
composition of the respective complex. It is well established that CSR and SHM, 
although related, use different sets of DNA repair proteins in order to exert their function, 
and that the C-terminus of AID is especially important for CSR (Barreto et al., 2003, Ta 
et al., 2003), whereas SHM and enzymatic activity are independent of the C terminus. 
Thus, there may be common subsets of proteins interacting with AID irrespectively of the 
C-terminal domain being present. For these reasons, I generated DT40 cell lines that 
would lack the last 10 amino acids of AID (AIDΔC). AIDΔC would be expected to 
accumulate in the nucleus, providing enrichment in the AID population that will form 
complexes on DNA. Furthermore, comparing the binding partners of full length AID and 
AIDΔC may allow a classification in SHM or CSR relevant factors. Generation of the 
cell lines was analogous to the lines used for the biochemical analysis described in 
Chapter 3 (see Appendix Figure 29). The cloned AID locus was modified resulting in a 
truncated and tagged AID. Subsequently, endogenous AID was targeted in DT40 parental 
cells and recombinant clones selected (Appendix Figure 29 A and B). AID was tagged 
with well-proven peptide tags such as FLAG-tag and MYC tag. For the purpose of in vivo 
observations, I additionally generated GFP-tagged as well as Renilla luciferase tagged 
AID cell lines. Clones of the obtained cell lines were analysed visually and biochemically 
(Appendix Figure 29 C and D). Surprisingly, Figure 29 D shows that AID is not enriched 
in the nuclear fraction of the AIDΔC mutant as expected. Looking at several recombinant 
clones using FACS, immunofluorescence and western blot (Appendix Figure 29 C and 
D), preliminary observations show reduced levels of overall AID protein in the AIDΔC 
mutant. Both of these phenomena were not expected, as similar mutants when 
overexpressed in other cellular systems (fibroblasts), did not show this phenotype (Ito et 
al., 2004, McBride et al., 2004). However, the regulatory layers controlling AID shuttling 
and stability are complex and possibly not fully understood (Patenaude et al., 2009). The 
effect of the AID truncation could also differ with exogenous or endogenous expression 
in B cells. In line with this, a differential reaction has been observed between 
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overexpression and endogenous systems when blocking nuclear export by leptomycin B. 
This treatment can enrich AID in the nucleus, although at a much higher efficiency in 
AID overexpressing cells than in endogenously AID expressing B cells (Patenaude et al., 
2009). Both above observations, lower nuclear and lower overall AID protein levels 
compared to wild type cells, could be explained by a higher nuclear turnover of AID 
protein, which has also been observed before (Aoufouchi et al., 2008, Uchimura et al., 
2011). This would reduce the levels of nuclear, but also cytoplasmic AID, which is a pool 
for nuclear import. 
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Figure 29. Generation and analysis of DT40 cell lines harbouring a endogenously 
tagged AID mutant lacking the C terminus. 
 
A, Schematic of the generation of the five DT40 lines. The genomic AID locus was 
modified to firstly, lack the final 10 amino acids of the protein, and secondly, to carry the 
C-terminal tags Renilla luciferase (RL), GFP, 3 x FLAG (3F), 3 x FLAG 2 x TEV 3 x 
MYC (3FM) or 3 x MYC (3M). The respective constructs were transfected into DT40 
cells for homologous recombination at the AID locus, and puromycine resistant clones 
were selected. Positive clones were treated with cell soluble, purified HTN-CRE protein 
for removal of the puromycine resistance. B, representative southern blot analysis of the 
AID loci in wt, intermediate recombinants and final recombinant cell lines. Southern blot 
results were used for identifying recombinant clones. C, Analysis of the newly generated 
DT40 AIDΔC-GFP cell line in comparison to the DT40 wt, and AID-GFP cell lines (S. 
Pauklin, G. Bachmann, CRUK). Upper panel, flow cytometric analysis of GFP 
fluorescence in 2 recombinant clones (orange and blue profiles) showing a lower GFP 
expression then the DT40 wt AID-GFP cell line (pink profile), with the DT40 wt as a 
control (Lacking GFP, purple profile). Lower panel, immunofluorescent imaging of a 
DT40 AIDΔC-GFP population (left) and an AID-GFP population (right). AID-GFP - 
green, DAPI - blue. D, Fractionation analysis of DT40 AIDΔC-3FM versus DT40 wt and 
AID-3FM cell line (Pauklin et al., 2009). Western blot analysis using anti-FLAG, anti-
beta actin, and anti-Histone H3; DT40 - left, AID-3FM -middle, and AIDΔC-3FM - 
right). Fractions were not loaded representative of the total protein amount in each 
fraction, but 15 µg protein was loaded in all lanes. 
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6.1.3 In vitro transcription assays  
To understand the molecular link between AID and the RNAPII complex, in vitro 
reconstitution studies were used. AID deamination facilitated by transcription has been 
reconstituted in vitro before using phage-coded T7 RNA polymerase (Chaudhuri et al., 
2003) (Basu et al., 2011) or E. coli RNA polymerase (Besmer et al., 2006). Using T7 
polymerase transcription, (Canugovi et al., 2009) could reconstitute AID deamination 
facilitated by transcriptional pausing. However, the RNA polymerases used in these 
studies are much simpler enzymes than the eukaryotic RNAPII and function without the 
eukaryotic cofactors that have now been shown to be crucial to AID function. Therefore, 
these conditions reflect an artificial situation. This is confirmed by a need for an 
overwhelming presence of RPA in these reactions. Therefore, we developed a 
biochemical assay that addresses the mechanistics of transcription coupled DNA 
deamination using eukaryotic enzymes. To this end, I undertook pilot studies based on a 
system described in (Saeki and Svejstrup, 2009) and by D. Hobson, and J. Svejstrup, 
CRUK (personal communication) (Appendix Figure 30 A). Here, NTP dependent RNA 
elongation competent transcription bubbles were reconstituted in vitro (Appendix Figure 
30 B). Two different substrates show RNA elongation by yeast RNAPII after complex 
formation and NTP addition. As shown in Appendix Figure 30 B (lanes 2 and 3), it is 
also possible to arrest transcription by introducing obstacle sequences or nucleotides. 
These complexes can be exposed to AID while transcription or transcriptional arrest is 
taking place (Appendix Figure 30 C). When AID was applied to a transcription complex 
substrate, the NTS is largely protected from degradation (lanes 3, 4, 5 versus 10, 11, 12) 
as opposed to a control single stranded NTS. However a few product bands appear (lanes 
3, 4, 5) in comparison to lane 2 (without AID). Some products are dependent on AID as 
well as UDG (e.g. stars in lane 5, vs lane 6), possibly representing true deamination, 
deglycosylation and cleavage events. Because of multiple dC residues along the 
oligonucleotide, the length of the products cannot be interpreted as an indication towards 
a site of AID deamination. However, digestion of the single stranded substrate (right 
hand side) reveals unspecific nuclease activity in the protein preparations. Lane 13 shows 
a UDG independent degradation of DNA by contamination of AID. Although the UDG 
preparation (commercial) does not degrade the single stranded DNA substrate, it is 
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known to contain endonucleases able to work on abasic and possibly other substrates. 
This leads to the full degradation of the substrate when both preparations are combined. 
For exact delineation of activities responsible for individual products, different protein 
preparations need to be used. In the future, an AID mutant that lacks deamination 
catalysis, E58Q, (Chen et al., 2008, Holden et al., 2008, Ramiro et al., 2003) will be 
included to control for nuclease activities. After substrate oligonucleotides as well as 
protein preparations are optimised, it will be possible to address the co-transcriptional 
accessibility of cytosines for AID and to draw biochemical conclusions. It may be 
possible to induce paused RNAPII and even to mimic traffic by reconstituting 
transcription bubbles with several colliding RNA polymerases (D. Hobson, CRUK) to 
study the effect on AID accessibility to ssDNA. Subsequently, purified transcription 
elongation factors could be added to the reactions to delineate the optimal transcription 
elongation complex composition for AID accessibility to its substrate.  
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Figure 30. In vitro reconstitution of transcription coupled deamination. 
 
A, schematic of the in vitro reconstitution assay based on (Saeki and Svejstrup, 2009). 1 
pmol of a 90 nucleotide long oligonucleotide representing the transcribed strand (TS) is 
hybridised to 2 pmol complementary RNA. 3 pmol purified yeast RNAPII (gift from D. 
Hobson, CRUK) is added followed by 6 pmol of a complementary 90-mer strand 
representing the non-transcribed strand (NTS). The assembled complex was purified via a 
biotin label on the TS. The obtained complex was exposed to AID before and after the 
addition of NTP’s, which results in start of transcription. When using a radiolabelled 
RNA, progression of transcription in the assay can be monitored (as in B), whereas when 
using a radiolabelled NTS, deamination can be monitored if an additional UDG digestion 
step is included (as in C). B, Two different TS-NTS pairs are tested for complex 
formation and RNA elongation. One pairs was designed to contain an AID hotspot motif 
(AGC) in the potentially single stranded region of the transcription bubble (green); the 
other pair was designed to contain an A rich stretch towards the end of the transcribed 
region known to arrest or destabilise the polymerase (barrier) (blue). Radiolabelled RNA 
was used to visualise elongated RNA products, forming after complex formation and 
NTP addition (lanes 1-3). Product in the length of 31 and 32 nucleotides accumulates in 
lanes 2 and 3 at the normal NTP concentration, 0.58mM, (lane 3) as well as at half the 
NTP concentration (lane 2). C, Left part, AID was applied to a transcription complex 
substrate as formed in A; right part, AID was applied under the same conditions to the 
respective single stranded NTS substrate. Radiolabelled NTS was used to visualise 
products. In both conditions, the 90-mer tested in B, carrying a hotspot at the site of the 
transcription bubble, was used (green). Lanes 3, 4, 5 versus 10, 11, 12 show products 
after increasing exposure to AID followed by UDG digestion. Lanes 2 and 9 show 
controls without AID. Lanes 6 and 13 show controls without UDG. Lane 7 shows a 
sample of the untreated complex, and lane 8 shows a sample of the untreated NTS. Stars 
in lane 5 indicate possible specific products. 
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6.2 Additional information  
 
Identified Proteins (232) Name Accession Number kDa N 
C 
N 
A 
C 
C 
C 
A 
Transcription elongation factor 
SPT5 - Gallus gallus (Chicken) 
SPT5 SPT5H_CHICK 120 
kDa 
0 0 0 11 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
SF3A1 Q5ZM84_CHICK 89 
kDa 
0 4 0 8 
U5 small nuclear 
ribonucleoprotein 200 kDa 
helicase - Homo sapiens 
(Human) 
U5-200 helicase U520_HUMAN (+1) 245 
kDa 
2 6 1 7 
Elongation factor 2 - Gallus 
gallus (Chicken) 
EF2 EF2_CHICK 95 
kDa 
2 6 0 6 
RNA polymerase-associated 
protein CTR9 homolog - Homo 
sapiens (Human) 
CTR9 CTR9_HUMAN 
(+5) 
134 
kDa 
0 0 0 6 
DNA-directed RNA polymerase 
II subunit RPB2 - Homo sapiens 
(Human) 
RNA pol II (sub2) RPB2_HUMAN 
(+5) 
134 
kDa 
0 0 0 6 
DNA-directed RNA polymerase 
II subunit RPB1 - Homo sapiens 
(Human) 
RNA pol II (sub1) RPB1_HUMAN 
(+6) 
217 
kDa 
1 0 0 5 
RNA polymerase II-associated 
factor 1 homolog - Bos taurus 
(Bovine) 
PAF1 PAF1_BOVIN (+5) 60 
kDa 
0 0 0 4 
Transcription elongation factor 
SPT6 - Homo sapiens (Human) 
SPT6 SPT6H_HUMAN 
(+2) 
199 
kDa 
0 0 0 4 
Lamin-B2 - Gallus gallus 
(Chicken) 
Lamin B2 LMNB2_CHICK 68 
kDa 
0 0 0 4 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
PolyA BP like with 
4 RRM 
Q5ZL53_CHICK 
(+9) 
71 
kDa 
5 6 0 3 
Splicing factor 3B subunit 1 - 
Homo sapiens (Human) 
SF3B SF3B1_HUMAN 
(+2) 
146 
kDa 
0 4 1 3 
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Putative uncharacterized protein - 
Gallus gallus (Chicken) 
SF RS7 Q5ZMI0_CHICK 26 
kDa 
0 0 2 3 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
DHX15 Q5F3A9_CHICK 
(+1) 
88 
kDa 
1 2 0 3 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
SF RS6 Q5ZJ59_CHICK 
(+10) 
40 
kDa 
0 2 2 2 
DNA-directed RNA polymerases 
I, II, and III subunit RPABC1 - 
Bos taurus (Bovine) 
RNA pol I,II,III 
subunit (25) 
RPAB1_BOVIN 
(+8) 
24 
kDa 
0 0 3 2 
Nucleophosmin - Gallus gallus 
(Chicken) 
Nucleophosmin NPM_CHICK 33 
kDa 
1 1 0 2 
Small nuclear ribonucleoprotein-
associated protein B' - Gallus 
gallus (Chicken) 
snRNP BP RSMB_CHICK (+1) 25 
kDa 
2 0 0 2 
DNA topoisomerase I - Gallus 
gallus (Chicken) 
DNA Topo I P79994_CHICK 91 
kDa 
0 0 0 2 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
DDX3X Q5F491_CHICK 
(+46) 
72 
kDa 
0 1 0 2 
cDNA FLJ77459, highly similar 
to Homo sapiens interleukin 
enhancer binding factor 3, 
90kDa, mRNA - Homo sapiens 
(Human) 
NF-AT 90 IL3F A8K6F2_HUMAN 77 
kDa 
0 1 0 2 
RNA polymerase-associated 
protein LEO1 - Homo sapiens 
(Human) 
LEO LEO1_HUMAN 
(+2) 
75 
kDa 
0 0 0 2 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
MCM5 Q5ZKL0_CHICK 82 
kDa 
0 0 0 2 
WD40 repeat-containing protein 
SMU1 - Gallus gallus (Chicken) 
SMU1 SMU1_CHICK 
(+12) 
57 
kDa 
0 0 0 2 
Nuclease-sensitive element-
binding protein 1 - Gallus gallus 
(Chicken) 
YB1 YBOX1_CHICK 
(+28) 
36 
kDa 
0 1 0 1 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
BUB3 Q5ZHW3_CHICK 37 
kDa 
0 0 1 1 
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Putative uncharacterized protein - 
Gallus gallus (Chicken) 
DEK Q5F422_CHICK 42 
kDa 
0 1 1 1 
U2 small nuclear 
ribonucleoprotein B'' - Homo 
sapiens (Human) 
U2snRNPB2 RU2B_HUMAN 
(+6) 
25 
kDa 
1 0 1 1 
RNA-binding protein HuA - 
Gallus gallus (Chicken) 
HuA Q9PW24_CHICK 
(+13) 
36 
kDa 
1 0 0 1 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
EIF6 Q5ZL92_CHICK 27 
kDa 
1 0 0 1 
Pre-mRNA-processing factor 6 - 
Homo sapiens (Human) 
PRP6 PRP6_HUMAN 
(+12) 
107 
kDa 
0 1 0 1 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
THRAP3 Q5ZMK4_CHICK 72 
kDa 
0 0 0 1 
U4/U6 small nuclear 
ribonucleoprotein Prp4 - Bos 
taurus (Bovine) 
PRP4 PRP4_BOVIN (+12) 58 
kDa 
0 0 0 1 
ACTL6A protein - Bos taurus 
(Bovine) 
ACTL6A A4IFJ8_BOVIN 
(+14) 
47 
kDa 
0 0 0 1 
FACT complex subunit SPT16 - 
Homo sapiens (Human) 
SPT16 SP16H_HUMAN 
(+6) 
120 
kDa 
0 0 0 1 
ATP-dependent RNA helicase 
DDX1 - Gallus gallus (Chicken) 
DDX1 DDX1_CHICK 
(+15) 
82 
kDa 
0 0 0 1 
FACT complex subunit SSRP1 - 
Gallus gallus (Chicken) 
SSRP1 SSRP1_CHICK 
(+13) 
80 
kDa 
0 0 0 1 
Uncharacterized protein 
C17orf85 homolog - Gallus 
gallus (Chicken) 
C17orf85 CQ085_CHICK (+4) 69 
kDa 
0 0 0 1 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
IK Q5ZHM2_CHICK 
(+28) 
65 
kDa 
0 0 0 1 
Lamin-B1 - Gallus gallus 
(Chicken) 
LaminB1 LMNB1_CHICK 67 
kDa 
0 0 0 1 
Nuclear protein matrin 3 - Gallus 
gallus (Chicken) 
Martin3 Q8UWC5_CHICK 101 
kDa 
0 6 0 0 
Splicing factor 3a subunit 2 - 
Gallus gallus (Chicken) 
SF3a2 Q66VY4_CHICK 
(+3) 
35 
kDa 
0 1 2 0 
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116 kDa U5 small nuclear 
ribonucleoprotein component - 
Gallus gallus (Chicken) 
U5snRNPS1 U5S1_CHICK 109 
kDa 
1 2 0 0 
Cohesin complex subunit - 
Gallus gallus (Chicken) 
cohesin Q8AWB8_CHICK 
(+15) 
142 
kDa 
0 3 0 0 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
ABCE1 Q5ZJX6_CHICK 
(+11) 
67 
kDa 
0 3 0 0 
Nuclear cap-binding protein 
subunit 1 - Gallus gallus 
(Chicken) 
NCBP1 NCBP1_CHICK 93 
kDa 
0 3 0 0 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
PDHX Q5F3G9_CHICK 53 
kDa 
1 1 0 0 
DnaJ homolog subfamily C 
member 10 precursor - Xenopus 
laevis (African clawed frog) 
DNAJC10 DJC10_XENLA 91 
kDa 
0 2 0 0 
LOC398542 protein - Xenopus 
laevis (African clawed frog) 
ARS2-b Q6INH5_XENLA 98 
kDa 
0 2 0 0 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
hnRNP M Q5ZL80_CHICK 76 
kDa 
0 2 0 0 
Dynein light chain 2, cytoplasmic 
- Bos taurus (Bovine) 
DyneinLC2 DYL2_BOVIN 
(+12) 
10 
kDa 
0 1 0 0 
Cytoskeleton-associated protein 5 
- Homo sapiens (Human) 
CKAP5 CKAP5_HUMAN 
(+9) 
226 
kDa 
0 1 0 0 
Serine hydroxymethyltransferase, 
cytosolic - Oryctolagus cuniculus 
(Rabbit) 
GLYC GLYC_RABIT 
(+45) 
53 
kDa 
0 1 0 0 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
RiboS26L Q5ZM66_CHICK 
(+66) 
13 
kDa 
0 1 0 0 
NIK- and IKBKB-binding 
protein - Bos taurus (Bovine) 
NIBP NIBP_BOVIN (+6) 127 
kDa 
0 1 0 0 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
DROSHA Q5ZIR3_CHICK 
(+11) 
155 
kDa 
0 1 0 0 
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Eukaryotic translation initiation 
factor 3 subunit C - Homo 
sapiens (Human) 
EIF3C EIF3C_HUMAN 
(+7) 
105 
kDa 
0 1 0 0 
Eukaryotic translation initiation 
factor 3 subunit G - Bos taurus 
(Bovine) 
EIF3G EIF3G_BOVIN 
(+33) 
36 
kDa 
0 1 0 0 
Nuclear calmodulin-binding 
protein - Gallus gallus (Chicken) 
NCBP1 Q9YHD2_CHICK 84 
kDa 
0 1 0 0 
Transport protein particle subunit 
TMEM1 - Homo sapiens 
(Human) 
TMEM1 TMEM1_HUMAN 
(+13) 
142 
kDa 
0 1 0 0 
Staphylococcal nuclease domain-
containing protein 1 - Homo 
sapiens (Human) 
SND1 SND1_HUMAN 
(+20) 
102 
kDa 
0 1 0 0 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
PLK1 Q5ZJ36_CHICK 67 
kDa 
0 1 0 0 
Putative uncharacterized protein - 
Gallus gallus (Chicken) 
GTPBP4 Q5ZM18_CHICK 
(+17) 
74 
kDa 
0 1 0 0 
 
Table 4. Full list of peptides recovered from mass spectrometric analysis of AID 
isolated from B cell chromatin. 
 
Indicated is the description, name and accession number of the identified proteins as well 
as the number of peptide hits in the nucleoplasm control IP sample (NC), the 
nucleoplasm FLAG tagged AID IP sample (NA), the chromatin control sample (CC) and 
the chromatin FLAG tagged AID IP sample (CA). 
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Figure 31. Structure model of the human PCNA trimer. 
 
A transparent surface model as well as an underlying ribbon structure model of the 
PCNA trimeric ring is depicted (2 monomeres depicted in light green, one monomer 
depicted in light grey indicating residues of interest with colours). Residues mutated in 
the experiments described in Figure 20 B are coloured in blue, the crucial residue lysine 
164 is coloured in pink. The C terminus of the PCNA monomer deleted in the 
experiments in Figure 20 A is coloured in orange. The area of PCNA interaction with PIP 
box motives lies at the interdomain connecting loop (ICL) and the groove below and is 
coloured in yellow (including some C terminal residued coloured in orange). The model 
was generated with the MacPyMOL software (DeLano Scientific LLC) using PDB file 
1VYM (native human PCNA). 
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